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ABSTRACT 
The polycystic ovary syndrome (PCOS) is a heterogeneous disorder in women 
characterised by chronic ovulatory failure, hyperandrogenaemia, and insulin resistance. 
Some women are completely asymptomatic and others present with extreme menstrual 
disturbance, severe hirsutism, infertility and recurrent miscarriage. The pathophysiology 
of PCOS is not completely understood, but it is thought that insulin resistance plays a 
central role. 
In normal subjects, non-diabetic obese patients and patients with non-insulin dependent 
diabetes, insulin resistance is associated with elevated plasminogen activator inhibitor- I 
(PAI-l) levels. PAI-l is a glycoprotein, which inhibits the formation of plasmin (a 
proteolytic enzyme). Plasmin aids fibrinolysis and extracellular proteolysis. High PAI-l 
and low plasmin levels increase the risk of thrombosis and impair extracellular proteolysis 
required in ovarian follicle growth, ovulation and embryo implantation. 
This study was designed to determine whether elevated plasminogen activator inhibitor-] 
(PAI-l) was associated with the insulin resistance present in PCOS, investigate its possible 
role in the causation of anovulation and recurrent pregnancy loss in these women and 
ascertain whether it was an additional thrombotic risk factor so that clinicians and patients 
could take appropriate measures to reduce this risk 
In a pilot study, systemic PAI-l activity was significantly elevated in oligomenorrhoiec 
women with PCOS. A larger study supported these findings, but demonstrated that obesity 
was a significant confounding factor, as the increase in PAI-l activity disappeared when 
standardised for weight. Activated Protein-C (APC) resistance was subsequently tested in 
these women because of the unexpected finding of an increased prevalence of a positive 
family history of thrombosis in women with PCOS compared with controls, but there was 
no increase in the prevalence of APC-resistance in PCOS. 
In another project, the cellular distribution of PAl-l protein in human ovaries was 
described for the first time using immunohistochemistry. It was localised to the granulosa 
and theca cell compartments in both polycystic and normal ovaries, however there was no 
significant difference in the intensity of PAI-l staining between both groups on image 
analysis. PAI-l messenger RNA expression was also evaluated in these biopsies by in-
situ hybridisation, but no signal was detected suggesting that there was either a low overall 
RNA preservation in the tissues, or an insufficient sensitivity of the cocktail of 
oligonucleotide probes used. 
This study did not support the hypothesis that elevated PAI-l was a feature of PCOS, 
however the in-situ location of PAI-l protein was demonstrated for the first time in the 
human ovary and consistent with a previously suspected role in ovulation. The results did 
not support a role for PAI-I in anovulation, recurrent miscarriage or increased thrombosis 
in PCOS. 
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CHAPTER I 
INTRODUCTION 
The polycystic ovary syndrome (PCOS) is a heterogeneous disorder of uncertain aetiology 
commonly found in women in the reproductive age group, and the many features of this 
syndrome can be broadly divided into three categories; clinical, endocrine and metabolic. 
The clinical features include anowlatory infertility, menstrual abnormalities, hirsutism, 
acne, alopecia, recurrent miscarriage and the presence of multiple small ovarian follicles on 
histology or ultrasound, while the endocrine features include elevated androgen, luteinizing 
hormone, oestrogen and prolactin levels (Franks 1995). Recently attention has been 
focused on the metabolic aspects of this syndrome, which include insulin resistance (or 
reduced insulin sensitivity) , obesity, lipid abnormalities, an increased risk of non-insulin 
dependent diabetes and the possibility that insulin resistance may provide a unifying 
hypothesis for the hitherto elusive pathophysiology. 
The exact mechanism of insulin resistance and its associated metabolic abnormalities in 
PCOS has not been fully explained. What is certain is that insulin resistance is present in 
obese and non-obese women with PCOS (Chang et a! 1983, Dunaif et al 1989, Mahabeer et 
al 1989, Conway et a! 1990, Dale et a! 1992, Buyalos et a! 1992), correlates positively with 
hyperandrogenaemia (Burghen et al 1980), and when treated with dietary restriction or 
metformin (Anderson et a! 1995, Nestler & Jakubowicz 1996), there appears to be a 
lowering of androgen levels and an improvement in owlation, and pregnancy rates. 
However the exact mechanisms of these inter-relationships are not fully understood. 
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The metabolic consequences of insulin resistance m general have been described as 
constituting an important metabolic syndrome (syndrome X) first described in 1988 
(Reaven 1988). The features of this metabolic syndrome include hypertension, lipid 
abnormalities, an increased risk of coronary artery disease, raised uric acid levels and 
recently (Reaven 1994) the elevation ofplasminogen activator inhibitor- I (PAI-l). 
PAI-l is a glycoprotein whose main role is the regulation of plasmin formation in the 
plasminogen activator system (PAS) by inhibiting the conversion of plasminogen to plasmin 
by tissue plasminogen activator (Francis & Marder 1995). This system is not only involved 
in fibrinolysis, but many extracellular processes including the regulation of follicle growth 
(Peng et al 1993 ), ovulation (Beers 197 5, Beers et al 197 5, Piquette et al 1993) 
implantation (Sappino et al 1989) and tumour metastasis (Saskela 1985). It is therefore 
probable that elevated PAI-l may link insulin resistance with reproductive failure in women 
with PCOS by limiting the plasmin formation required for follicle growth, ovulation and 
implantation of the embryo. 
Unfortunately, the extent to which the metabolic features described as part of the insulin 
resistance in syndrome X overlap with the metabolic features in PCOS is unknown and as 
such whether elevated PAI-l is also a feature of the metabolic aspects of PCOS is 
unknown. The studies in this thesis were therefore primarily designed to answer this 
question, but the other important clinical consideration was whether elevated PAI-l was a 
hitherto unidentified risk factor for thromboembolic disease in women with PCOS. 
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Prior to the first study in this thesis, there were only two published studies on PAl-l in 
women with PCOS. The first study (Dahlgren et a1 1994) was a cross sectional study on 
28 women with PCOS and 56 controls. In this study PCOS had been diagnosed 
histologically on wedge resection of the ovaries taken 25 to 34 years previously and the 
mean age of the participants at the time of the study was about 53 years. The results of the 
study showed that PAI-l levels were not elevated in PCOS, but equally important was the 
fact that the other metabolic variables measured (fasting insulin, triglycerides and body 
mass index (Bl\11)) were not significantly different between the two groups. The authors 
concluded that their negative results might have been explained by the increased age of 
both groups as metabolic variables are increasingly affected by age. In the second paper 
(Anderson et a1 1995), high PAl -1 levels in nine obese patients with PCOS were reduced 
after four weeks on a very low calorie diet. This reduction in PAl-l concentration was 
associated with the return of regular menstruation and successful pregnancy in two women. 
However as there were no controls in this study, it did not answer the question of whether 
elevated PAI-I levels were a unique feature ofPCOS. This study was therefore designed 
with the following aims. 
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AIMS OF THESIS. 
I. To determine whether elevated PAI-l levels were associated with the metabolic aspect 
of PCOS and investigate the overall state of the plasminogen activator system in these 
women .. 
2. To investigate the expression of PAI-l protein and mRNA in the polycystic ovary and 
compare it with normal ovaries. 
3. Based on the above results, to consider whether PAI-l and the PAS contributed to the 
pathophysiology of anovulation and pregnancy failure in women with PCOS, and 
whether they were at increased risk of thromboembolic disease from a prothrombotic 
PAS. 
4. To determine in the light of the results whether altering PAI-l levels in PCOS could 
affect fertility and risk of thromboembolism. 
The nuU hypothesis was that the systemic and local (intra-ovarian) expression of PAI-l in 
women with the PCOS was not different from the expression in normal controls. 
ORGANISATION OF THESIS 
In this thesis, the results of two clinical studies (a pilot and a definitive study) measuring 
systemic PAI-l levels in the PCOS and of two laboratory-based studies on the localisation 
and quantification of PAI-l protein and mRNA in polycystic ovaries, are presented. As a 
result of an unexpected finding of an increased prevalence of a positive family history of 
thrombosis in one of the clinical studies, the results of a further study measuring activated 
protein-C (APC) resistance (the commonest finding in familial thrombophilia) in women 
with PCOS compared with controls, are also presented. A detailed literature review of the 
current understanding of the PCOS can be found in Chapter 2. The overall study design is 
described in Chapter 3, and in chapter 4, a pilot study measuring systemic PAI-l in the 
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PCOS is presented. This is followed by the results of a larger clinical study on systemic 
P AI -I in chapter 5. Chapters 6 and 7 contain the results of the studies on the localisation 
of P AI -1 protein and mRN A and in chapter 8, the results of the study on APC-resistance 
are presented. The conclusions are outlined in chapter 9. 
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CHAPTER TWO 
LITERATURE REVIEW 
OUTLINE 
In this chapter, an overview of the current understanding of the features, pathophysiology 
and management of PCOS are discussed. A general overview of insulin resistance and its 
metabolic consequences are discussed, and the possible role of PAI-l in the 
pathophysiology of PCOS is discussed. 
DEFINITION 
The PCOS has three mam clinical components (anovulation, hyperandrogenism and 
dysmetabolism) and a characteristic morphological appearance on ovarian ultrasound and 
histopathology. However there is still no consensus about which definition (clinical, 
morphological or endocrine) best characterises this syndrome as all these definitions have 
their own limitations because PCOS is multifaceted. Biological evidence of 
hyperandrogenism is generally accepted as a very sensitive marker of PCOS (Hopkinson et 
al 1998). However it is limited by the fact that in PCOS, levels of androstenedione and 
testosterone are modestly and inconstantly elevated in a non-specific manner (Dewailly 
1997) and that the levels are dependent on the weight of the patient, with higher levels in 
more obese individuals 
The use of purely clinical signs of menstrual disturbance or androgen excess (hirsutism, 
acne or alopecia) in the diagnosis of PCOS is limited by the finding of polycystic ovaries 
on ultrasound in up to 20% of "normal" ovulatory women and in up to 50-87% of 
regularly menstruating women with hirsutism. In addition, because the degree of hirsutism 
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or alopecia found in a patient is partly related to varying degrees of end organ sensitivity 
(skin or hair follicle) to circulating androgens, this issue becomes more complicated, 
making it difficult to define clear diagnostic criteria for PCOS. 
Although the first descriptions of the syndrome were based on the morphological 
appearances of the ovary (Stein & Leventhal 1935), this is not thought to be essential for 
the diagnosis. However with the recent development of high-resolution ultrasound, a more 
morphologically based diagnosis (Swan son et al 1981, Parisi et al 1984, Adams et al 1985, 
Yeh et al 1987, Pache et al 1991, Adams et a! 1986) has been adopted and is believed by 
some authors to be a very sensitive marker of PCOS (Balen et al 1995). Unfortunately 
there is still no consensus about its use in the diagnosis of PCOS as the identification and 
quantification of the various parameters depend on the skill and dedication of the 
sonographer. 
A consensus conference in 1990 achieved a definition of PCOS, stipulating that clinical 
symptoms such as anovulation and/or hyperandrogenism should serve as the selection 
criteria, with hormonal results used to exclude conditions that were not PCOS such as 
diseases of the adrenals or pituitary including adult-onset congenital adrenal hyperplasia, 
hyperprolactinaemia and androgen secreting neoplasms (Zawadzki & Dunaif 1992). 
However this definition was empirical, and although simple, economic and safe, it 
compromises clear cut and homogenous results in clinical research. 
HISTORICAL LANDMARKS 
There has always been a recognised correlation between obesity in women and 
amenorrhoea or menstrual irregularity, hirsutism and infertility, but it was only in 1935 
that two American gynaecologists lrving Freiler Stein and Michael Leo Leventhal 
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associated these symptoms with a specific ovarian component (Stein & Leventhal 1935). 
They described seven women with amenorrhoea and bilateral polycystic ovaries at 
laparotomy. They described a tendency to masculinizing changes in some of these women, 
and following the resection of one-half to three quarters of each ovary by wedge resection 
of the cortex containing these cysts, menstruation occurred monthly thereafter in every 
case. They suggested that a mechanical factor was the likely cause of the amenorrhoea and 
sterility, and that it was possible that this factor impeded developing follicles in their 
pathway to the ovarian surface leading to them rupturing into cysts. 
Keettel et al in 1957 were the first to document an endocrine abnormality in PCOS which 
was increased secretion of LH, and Kratochwil et al first described the ultrasound 
appearance of women with PCOS in 1972. The ovaries were defined as having a round 
shape with a symmetrical increase in volume. The association of PCOS with insulin 
resistance was an important landmark in the understanding of this syndrome. In 1976, 
Khan et al reported the finding of acanthosis nigricans and insulin resistance in six women, 
two of whom had polycystic ovaries. Prior to their publication, there had been two case 
reports in the literature linking polycystic ovaries with insulin resistance (Barnes et al 1974 
& Givens et al 1974). In 1978, Cote et al described the spontaneous remission of insulin 
resistance in a patient with PCOS and acanthosis nigricans following the use of an 
oestrogen containing contraceptive and Burghen et al, in 1980, first investigated the 
relationship between plasma insulin levels and plasma testosterone and androstenedione in 
eight obese women with PCO, and six obese controls. They found a significant correlation 
between hyperinsulinism and hyperandrogenism. Although the exact mechanisms of 
insulin resistance in this syndrome are still not clear, recent studies have shown that 
treating it with oral hypoglycaemics such as metformin results in a lowering of androgen 
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levels (Nestler 1996) suggesting that insulin resistance is probably a key player in the 
pathogenesis of this syndrome. 
EPIDEMIOLOGY 
The prevalence of PCOS depends on the population studied, and the criteria used in the 
diagnosis. lrving Stein was only able to collect 90 cases with similar features to his 
originally described syndrome between 1935 and 1964 (Stein 1964). However the post-
mortem studies by Sommers & Wadman in 1956 showed that some women did not have 
the hirsutism or amenorrhoea typically found in the Stein-Leventhal syndrome, and that the 
morphology of polycystic ovaries (PCO) was more common than previously thought. In a 
study of 257 "normal" volunteers who had not complained of any gynaecological 
symptoms, 22 percent were found to have ultrasound features of polycystic ovaries (Poison 
et al 1988). Most of these women had irregular menses compared to women without PCO 
(75% Vs <I%), and objective evidence of hirsutism was present in 45% of women with 
PCO compared with 7% without. Robert Fox however found ultrasound features of PCO 
in 8% of 50 women with normal ovulation and menstrual cycles who were partners of men 
with male infertility (Fox 1992a). In 173 anovulatory women evaluated in a reproductive 
endocrinology clinic, 30% of those with amenorrhoea and 75% of those with 
oligomenorrhoea had ultrasonographic features of PCO (Adams et al 1986). Overall, 57% 
of women with anovulation had ultrasound evidence of PCO. These results were 
consistent with the finding of PCO in 37% of women with amenorrhoea and 90% with 
oligomenorrhoea in a similar study in 1987 (Hull 1987). PCO was the commonest finding 
in women with anovulatory infertility in this study (73%). 
In women with hirsutism and regular menstrual cycles, 50% to 92% have been found to 
have evidence of PCO on ultrasound (Adams et a! 1986, Franks S 1989, O'Driscoll et al 
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1994) and ultrasound evidence of PCO has been demonstrated in 92% of families of 
women with overt PCOS (Hague et at 1988). 
HISTOLOGICAL FEATURES 
Polycystic ovaries are typically enlarged and rounded with a thickened tunica albuginea. 
They contain multiple early forming and atretic cystic follicles usually arranged beneath 
the surface in a characteristic necklace pattern, but the follicles may also be scattered 
throughout an expanded ovarian stroma (White & Turner 1994). These follicles are lined 
by layers of granulosa cells of varying thickness and surrounded by a hyperplastic theca 
cell layer. There is usually little or no evidence of ovulation (corpora lutea or corpora 
albicantia). The numerous follicles lying in the ovarian cortex lead to a loss of the usual 
convolutions on the ovarian surface leaving a blue smooth mottled appearance. These 
findings may occur in only one ovary (Poison et al 1986). 
The number of primordial follicles present in the polycystic ovary is similar to that in 
normal ovaries (Hughesdon 1982). However, the ovaries contain an increased number of 
primary, secondary and tertiary follicles, which rarely develop beyond a diameter of 6mm 
to 8mm (Fauser 1994 ). 
Recent evidence from in-vitro studies suggests that the granulosa cells in PCO are not 
atretic, but viable and healthy. In one study (Aimahbobi et at, 1996) up to 70% of the 
granulosa cells in PCO were found to be healthy and non-apoptotic on flow cytometric 
analysis. This finding was similar to the proportion of viable granulosa cells found in 
normal ovaries. In another study, there was no difference between polycystic and normal 
ovaries in the localisation of a cell cycle related nuclear antigen (Takayama et at 1996). 
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Women with PCO may also have endometrial hyperplasia, and endometrial carcinoma in 
premenopausal women is commonly associated with polycystic ovaries (Sherman & 
Brown 1979). These usually occur as a result of the unopposed high levels of oestrogens 
(as will be later discussed) on the endometrium. 
ENDOCRINE FEATURES. 
The endocrine features of this syndrome may include hyperandrogenaemia, elevated serum 
luteinizing hormone levels (LH), normal or low follicle stimulating hormone (FSH) levels 
resulting in a raised LH/FSH ratio, elevated circulating oestrone, normal oestradiol levels, 
a low sex hormone binding globulin (SHBG) concentration, hyperprolactinaemia, and 
insulin resistance. 
Androgens 
The androgens raised m PCOS include testosterone, dihydrotestosterone, 
dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulphate (DHEAS), and 
androstenedione (Yen 1986). SHBG is a specific binding globulin for testosterone and 
oestradiol, and it is synthesised in the liver. In the globulin bound form, these steroids are 
not available for target tissue action. The free fraction of sex steroids is readily available 
for biologic action, thus the non-SHBG bound testosterone correlates with clinical 
androgenicity. Low SHBG levels in women with PCOS result in the increased 
availability of unbound testosterone which is raised in 59 to 90% of women with PCOS 
(Obhrai et al 1990, Eden et al 1988 & Fox 1992b ), with the higher prevalence found in the 
studies that have only included women with oligomenorrhoea. Raised total testosterone 
concentrations present in 50 to 55% of cases, androstenedione in 45 to 60% of cases 
(Duignan et a! 1975 & Fox 1992b) and DHEAS in 13% to 50% (Hoffman et a! 1984, 
Carmina et al 1986, Fox 1992c). 
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The ovaries and adrenal glands both contribute to hyperandrogenaemia in PCOS. The 
evidence for an ovarian contribution comes from studies showing that elevated DHEA and 
DHEAS levels in hirsutism are readily lowered by dexamethasone in PCOS patients 
whereas the elevated levels of testosterone and androstenedione are not (Yen 1986). Other 
studies show that ovarian suppression by gonadotrophin-releasing hormone analogues 
results in a decline in serum androstenedione and testosterone levels (Chang et al 1983a). 
Studies on ovarian and adrenal vein sampling have shown that the levels of DHEAS are 
higher in the adrenal vein compared to peripheral blood veins, and testosterone and 
androstenedione are higher in the ovarian veins compared to peripheral veins (Kirshner & 
Jacobs 1971 ), reflecting a contribution from both sources. 
Gonadotrophins 
In a paper presented at the 24th annual meeting of the Central Association of Obstetricians 
and Gynaecologists held in New Orleans in 1956, William Keettel, James Bradbury and 
Frederick Stoddard described their observation of hyperaemia and hypertrophy of the theca 
interna of immature rats following injection with extracts of the urine from women with 
Stein-Leventhal Syndrome (Keettel et al 1957). This response was judged to be primarily 
an LH response, based on evidence that LH acted primarily on the theca cells while FSH 
acted on granulosa cells (Gaarenstroom & de Jongh 1946). Subsequent studies have 
supported these findings and described raised LH levels in 48 to I 00% of women with 
PCOS (McArthur et al 1958, Wentz et al 1975, Duignan et al 1975, Aono et al 1977, 
Conway et al 1989, Franks 1989, Obhrai et al 1990). LH secretion is pulsatile, and studies 
relying on single venepuncture assays of LH tend to give results of a lower frequency of 
LH hypersecretion than studies that rely on serial or 24 urinary estimations of LH 
secretion. 
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It is not clear whether this elevation in LH arises from a primary hypothalamo/pituitary 
defect or is a consequence of hyperandrogenism, elevated estrone levels, and or 
hyperinsulinaemia. Evidence for a primary hypothalamo/pituitary defect comes from 
studies showing an increased pulse frequency and amplitude of LH secretion from the 
pituitary (Kazar et at 1987, Waldstreicher et al 1988), and an abnormal forward shift in the 
LH surge in early pubertal girls with PCOS by eight hours (Zumoff et al 1983). On the 
other hand, hyperandrogenic states such as congenital adrenal hyperplasia may also exhibit 
elevated LH levels (Rosenwaks et al 1979), though administration of testosterone to 
eugonadal female-to-male transsexuals actually lowers plasma LH levels (Spinder et al 
1989). To complicate the picture even further, the level of oestrone which is commonly 
raised in the PCOS can enhance the frequency of GnRH pulses (Urban et a! 1991 ), and it 
has been shown that insulin may potentiate the stimulation of LH release by GnRH in 
cultured rat pituitary cells in-vitro (Adashi et all981). However, further in-vivo studies in 
rats have not confirmed these findings (Poretsky et al 1988). 
In contrast to LH, FSH levels in the PCOS are normal or low when compared to controls 
(McArthur et al 1958, Baird et al 1977, Holte et al 1994). The reason for this discrepancy 
in pituitary gonadotrophin levels is not known, but possible explanations that have been 
put forward include a greater inhibitory effect of estrone and oestradiol on FSH than on 
LH, a decreased sensitivity of FSH release to GnRH stimulation, and secretion of follicular 
inhibin from polycystic ovaries resulting in the selective inhibition of FSH (Yen 1986). 
Oestrogens 
Evidence for oestrogenisation in women with PCOS has been adduced from the original 
observation of the return of uterine bleeding in the seven amenorrhoeic women described 
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by Stein and Leventhal in 1935. Subsequent studies have shown that serum oestrone 
levels are either raised or lie within the normal ranges for the early follicular and mid-
follicular phases of the menstrual cycle in the PCOS (Baird et a! 1977 & Poison et al 
1987). 
The serum oestradiol concentrations also appear to lie within the nom1al range for the 
early and mid-follicular phases of the menstrual cycle, but the pattern of secretion is 
different in that there is no mid luteal increase in oestradiol and there is less fluctuation 
than in the normal cycle (Poison et a! 1987). Oestradiol in PCOS is mainly ovarian in 
origin, and although Short and London in 1961 found that ovarian cyst fluid contained no 
oestrone or oestradiol when compared with normal ovaries, on selective catetherisation of 
the ovarian veins, Wajchenburg et al in 1988 found that a large amount of oestradiol was 
generated suggesting that in combination, the numerous follicles in PCO produce a large 
amount of gonadal steroid. 
There is no correlation between oestrone and oestradiol level in PCOS, which suggests a 
different mechanism of production. Evidence of a correlation between oestrone and 
androgens, is consistent with the peripheral conversion of androgens to oestrone in adipose 
tissue especially in obese women (Edman & MacDonald 1978). Oestrogen levels fluctuate 
widely within individuals (Backstrom et al 1982, Venturoli et al 1988), and it is not 
surprising that the ranges in oestradiol and oestrone concentrations in PCOS overlap too 
widely for oestrogens to be of clinical value in the diagnosis (Hull et al 1979). However, 
biological assessments of oestrogen states, such as the progesterone challenge test, appear 
to be better predictors of PCOS (Fox 1992d), and it is thought that these tests integrate the 
active and inactive components of the oestrogen pool. 
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Prolactin 
Elevated prolactin levels are found in 4 to 30% of women with PCOS (Franks et al 1985, 
Conway et al 1989, Luciano et a1 1984, Futterweit 1984), but their importance is unclear. 
Bromocriptine has been successfully used to treat anovulation in some women with PCOS 
( el Tabbakh et al 1988). However, the endocrine changes were otherwise similar in 
women with either normal or raised prolactin levels, which suggests that bromocriptine 
acted through a mechanism other than its effect on the dopamine pathway. 
The observed wide variation in the prevalence of hyperprolactinaemia in PCOS may arise 
because of the failure of some studies to take into account the skewed distribution of 
prolactin with a long upper tail to at least 800mu!L (Jeffcoate, 1978) and it may well be 
that hyperprolactinaemia and PCOS co-exist in most cases by chance. On the other hand, 
ultrasound evidence of polycystic ovaries has been found in up to 50% of women with 
hyperprolactinaemic amenorrhoea (Abdel Gadir et al 1992), and polycystic ovaries may be 
found in women with prolactin secreting tumours and acromegaly (Futterweit & Kreiger 
1979). 
Sex Hormone Binding Globulin 
SHBG has a molecular weight of 80,000 to 90,000. Its levels are influenced by sex 
steroids, obesity and insulin. Androgens inhibit SHBG, while oestrogens and obesity 
increase SHBG levels (Anderson 1974). In the PCOS, SHBG levels are lower than in 
controls (Plymate et a! 1981, Suikkari et a! 1989). Traditionally, sex steroids were 
thought to be the main regulators of SHBG in PCOS. However, recent evidence suggests 
that insulin is a more important regulator of SHBG in PCOS (Buyalos et at 1993, 
Hamilton-Fairley et al 1995). Hepatic production of SHBG is inhibited by insulin (Singh 
et al 1990, Plymate et al 1988, Conover & Lee 1990), and an improvement in hirsutism is 
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associated with calorie restriction and a corresponding increase in SHBG with decrease in 
insulin levels (Kiddy et al 1992). 
INSULIN RESISTANCE & METABOLIC FEATURES 
Overview of the functions, secretion, synthesis and mode of action of insulin 
Insulin is a hormone with a variety of biologic functions, the most important of which is 
the regulation of glucose transport across the cell membrane. Other important functions of 
insulin include the stimulation of glycogen synthesis and lipogenesis and the inhibition of 
lipolysis, glycogenolysis and gluconeogenesis (Madison 1969). Insulin stimulates glucose 
uptake into muscle and adipose tissue through specific insulin sensitive glucose 
transporters (James et al 1989) but it has very little effect on hepatic glucose uptake, which 
is more dependent on glucose concentration in the portal vein. 
Insulin is secreted by the beta cells in the pancreas in response to glucose, glyceraldehyde, 
amino-acids and certain hormones. Glucose is the main physiological secretagogue, and 
the insulin response to glucose is biphasic. A rapid first phase insulin response occurs 
between 5 to 10 minutes and is followed by a continuous second phase which is sustained 
for the duration of the glucose stimulus (Ho well and Bird 1989). Insulin is synthesised in 
the pancreatic P- cells as pre-proinsulin, a larger precursor hormone which is encoded on 
the short arm of chromosome 11 (Howell and Bird 1989). Pre-proinsulin is cleaved to 
form pro-insulin, which is subsequently processed by two endopeptidases to form insulin, 
C-peptide and intermediary fragments of proinsulin. In a mature pancreatic p-cell, more 
than 95% of the hormone released is insulin, and less than 5% proinsulin. 
Insulin initiates its metabolic actions by binding to a specific trans-membrane glycoprotein 
receptor (Khan 1985, Haring 1991 ), which results in a chain of intracellular events leading 
28 
to the biological effects attributed to it. This receptor has two extracellular oc-subunits and 
two P-subunits that transverse the cell membrane (Jacobs and Cuatrecasas 1981, Ullrich et 
a! 1985). The oc-subunits initially bind the insulin to the receptor and the two P-subunits 
are insulin sensitive protein kinases that are activated following insulin binding. 
Activation of tyrosine kinase leads to the autophosphorylation of the receptor itself. The 
phosphorylation cascade generates one or more second messengers which mediate many of 
the actions of insulin. 
General aspects of insulin resistance 
Insulin resistance is defined as a subnormal biologic response to a given concentration of 
insulin and it is often used to signifY a reduced response of glucose transport to a given 
concentration of insulin. It is related to physiological states such as pregnancy and 
puberty (Amiel et al 1986, Buchanan et al 1990), central adiposity, level of physical 
conditioning and skeletal muscle mass. The mechanism of the association between central 
obesity and insulin resistance is unknown, but proposed mechanisms include a release of 
non-esterified fatty acids from intra-abdominal fat cells into the portal circulation affecting 
hepatic insulin metabolism and peripheral glucose uptake (Randle et al 1963, Kissebah et 
a! 1982), an impairment in the physiological haemodynamic response following glucose 
ingestion with a reduction in muscle blood flow instead of the usual increase (Baron et al 
1990), down regulation of the insulin receptor (Seely & Olefsky 1993) and recently 
alterations in sensitivity to leptin (Segal et a! 1996, Sorensen et al 1996). 
Insulin resistance also features in many aetiologically diverse pathological conditions by a 
variety of mechanisms. These include mutations of the insulin receptor gene (M oiler et a! 
1991, Krook et a! 1996), raised concentrations of circulating hormones which antagonise 
the metabolic actions of insulin (glucagon, cortisol, catecholamines and growth hormone), 
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drug treatment, a defect in the function of an insulin sensitive glucose transporter protein 
(GLUT 4), abnormal endogenous insulin pulsatility (Bell 1996) and anti-insulin receptor 
antibodies. Ethnic differences in insulin sensitivity have also been observed; Mexican-
Americans, Pima Indians and people from the Indian subcontinent are relatively more 
hyperinsulinaemic and less insulin sensitive than Caucasians (Haffuer et al 1986, Lillioja et 
all987, Ferrannini et all991, McKeigue et al1991). 
Insulin sensitivity can be assessed in-vivo by any of the following tests; insulin /glucose 
ratios, the oral glucose tolerance test, insulin suppression test, glucose clamp, intravenous 
glucose tolerance test or the insulin tolerance test. These methods all rely on the 
measurement of insulin except the insulin tolerance test. They all have limitations, and none 
is suitable for routine clinical use. 
In most cases of insulin resistance there is a compensatory hyperinsulinaemia secondary to 
insulin resistance. Glucose tolerance and fasting glucose may therefore be normal. 
Impaired glucose tolerance and diabetes develops only when compensatory insulin 
secretion fails to meet the degree of resistance. 
Metabolic Features Of Insulin Resistance 
In 1988, Gerald Reaven of Stanford University suggested that a combination of insulin 
resistance and compensatory hyperinsulinaemia predisposed individuals to develop a high 
plasma triglyceride (TG) and low high-density lipoprotein (HDL) cholesterol concentration, 
high blood pressure, and coronary heart disease. He suggested that this cluster of 
abnormalities constituted an important clinical syndrome which he designated syndrome X 
(Reaven 1988). Subsequently, several other metabolic abnormalities such as abnormalities 
offibrinolysis {specifically raised plasminogen activator inhibitor- I (PAI-l 
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1)} and elevated uric acid levels have been identified as belonging to this syndrome. 
These features can develop independently of obesity, are not dependent on a sedentary life 
style (Reaven 1994) but are all related to insulin resistance. 
The exact role of insulin resistance in the aetiology of these metabolic and clinical features 
has not been well established. Hyperinsulinaemia has been shown to enhance renal 
sodium retention and to increase sympathetic nervous system activity, events which would 
certainly tend to increase blood pressure (Smith, 1993). However acute hyperinsulinaemia 
in humans leads to vasodilatation and blood pressure does not increase (Anderson et al, 
1993). 
Hypertriglyceridaemia and low HDL are risk factors for coronary heart disease (Manninen, 
et al 1992; Assmann et al, 1992) and insulin stimulates proliferation of smooth muscle 
cells and augments lipid synthesis in vascular smooth muscle cells, which may cause 
atheroclerosis. 
PAI-l is a glycoprotein present in plasma, platelets, endothelial cells and in the 
extracellular matrix where it may inhibit local proteolysis (Salonen et al, 1989, Schieef et 
al, 1990). It inhibits the activation of plasminogen to plasmin by tissue plasminogen 
activator (figure 2.1) which is important in fibrinolysis (Franc is & Marder 1995), 
ovulation (Piquette et al, 1993) and implantation (Sappino et al, 1989). Elevated levels of 
PAI-l are found in patients with coronary heart disease (Hamsten et al, 1985 Paramo et al, 
1985, Metha et al, 1987) and high PAI-l levels are also a significant risk factor in the 
development of fatal ischaemic heart disease in women (Meade et al 1996). PAI-l 
correlates positively with insulin resistance in diabetics (Juhan -Vague et al 1989) and 
factors such as exercise (Speiser et a! 1988), low calorie diets (Sundell et al 1989, 
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Mehrabian et at 1990, Huisveld et a1 1990) and metformin (Vague et at 1987) which 
improve insulin sensitivity also lower P AI -1 levels. It has therefore been suggested that 
elevated P AI -1 levels may link insulin resistance and atherothrombosis (Juhan-Vague et a1 
1991 ), although the mechanisms by which insulin increases the levels of P AI -1 are yet to be 
completely elucidated. 
Figure 2.1 The plasminogen activator system. 
u-PA t-PA 
J, J, <= Plasminogen Activator Inhibitor- I 
PLASMINOGEN -+ -+ -+ PLASMIN <= a r antiplasmin 
J, 
FIBRIN -+ -+ FffiRIN DEGRADATION PRODUCTS 
u-P A = urokinase type plasminogen activator 
t-PA = tissue type plasminogen activator 
~ = Inhibition 
Insulin resistance in PCOS 
The first link between a hyperandrogenic state and an abnormality in carbohydrate 
metabolism was established in 1921 when Achard and Thiers described "diabetes of 
bearded women" . More interest was aroused in this correlation when Khan et al in 1976 
described the syndromes of extreme insulin resistance in six young women with acanthosis 
nigricans. Two of these women were found to have polycystic ovaries, diagnosed by 
gynaecography in one case and laparoscopy in the other. They also had hirsutism, primary 
amenorrhoea, elevated testosterone levels and virilization in one case though neither of 
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them was obese. However, these syndromes are rare and they represent extreme cases of 
insulin resistance and hyperandrogenaemia. Insulin resistance was described in the more 
commonly encountered form of PCOS (Burghen et al 1980) following a case report in 
which insulin resistance was reversed by oestrogen which resulted in a concomitant 
reduction of androgens (Cole & Kitabchi 1978). Basal insulin levels were higher in the 
eight obese women with PCOS compared with six obese controls and, following an oral 
glucose tolerance test, the glucose sums were significantly higher in the PCOS group. 
They also found a significant correlation between insulin and testosterone levels. In 1983, 
Chang et a! reported similar findings in the PCOS in the absence of obesity and acanthosis 
nigricans. Looking at ten non-obese women with the PCOS and ten non-obese controls, 
Chang found a mean basal insulin level that was significantly higher in the PCOS group 
and, following an oral glucose tolerance test, the mean rise in insulin was also greater. 
Subsequently, other researchers have confirmed that insulin resistance is present in non-
obese women with PCOS (Dunaif et al, 1989, Mahabeer et a! 1989, Conway et a!, 1990, 
Dale et al 1992, Buyalos et at 1992). 
Insulin resistance m PCOS is characterised by a decreased sensitivity to insulin in 
peripheral tissues (muscle and fat) but not in the liver in contrast to the insulin resistance 
of type II diabetes (Dunaif et al 1993, Peiris et al 1989). Furthermore it appears to reflect 
an increased secretion of insulin itself rather than of proinsulin and its split products 
(Conway et al 1993). 
The mechanisms of insulin resistance in PCOS are poorly understood, and the presence of 
insulin resistance in non-obese women with PCOS suggests that the defect in insulin 
action is clearly not due to obesity alone. The mechanisms proposed include a defective 
degradation of insulin, anti-insulin receptor antibodies, elevated counter-regulatory 
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hormones of glucose homeostasis, hyperandrogenism, obesity, insulin receptor defects and 
post-binding defects in the insulin receptor pathway. A defect in insulin degradation was 
ruled out by the finding of hyperinsulinaemia without any insulin degrading activity in the 
study by Burghen et al in 1980. In addition, none of the patients in this study had insulin 
antibodies and the titre of insulin receptor antibody was measured in one patient and found 
to be low. Counter-regulatory hormones such as cortisol and growth hormone were also 
found to be low, and not related to the degree of insulin response to the oral glucose 
tolerance test (OGTT). It has been shown that androgen administration can induce 
insulin resistance (Billiar et al 1987). However, studies in which the hyperandrogenism in 
PCOS has been eliminated by the use of a GnRH agonist have demonstrated that insulin 
resistance can persist after androgen levels normalise, and the severity may not be 
diminished (Geffner et al 1986). 
A reduced binding of insulin to its receptor was suggested by studies in blood cells (Flier 
et al 1985, Jialal et al 1987), though normal insulin receptor binding has been shown in 
adipocytes (Ciraldi et al, 1992). In the latter study, an eight-fold increase in insulin 
concentration was required to attain comparable glucose transport rates in adipocytes from 
eight women with PCOS compared with eight controls suggesting a post-receptor defect in 
the insulin transduction pathway. However, the exact mechanism of this defect is not 
certain. Recently, a decreased expression of an insulin dependent glucose-transporter 
protein GLUT-4 has been reported (Rosenbaum et al 1993), and a decrease in insulin 
receptor autophosphorylation has also been described in women with PCOS (Dunaif et al 
1994). 
Insulin resistance in PCOS seems to be a feature of the subgroup of women with menstrual 
irregularity, but not those with regular menses even where hyperandrogenism is present 
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(Conway et al 1990, Robinson et al 1993). This implies that insulin resistance somehow 
contributes to the mechanism of anovulation in this syndrome, which is supported by in-
vitro studies, which show that insulin stimulates the synthesis of androstenedione and 
testosterone in the theca and stromal cells from human ovaries (Barbieri et al 1986). This 
would suggest that although patients with PCOS are insulin resistant, their ovaries are 
insulin sensitive. However the exact mechanisms of this observation are unknown. 
Metabolic aspects of PCOS. 
As discussed above, insulin resistance is associated with glucose intolerance, hypertension, 
lipid abnormalities, elevated PAl-l levels and an increased risk of coronary artery disease. 
But studies looking at the prevalence of these features in women with the PCOS provide 
either conflicting or inconclusive results. 
Diabetes: Although most studies show that, overall, young women with PCOS maintain 
normal glucose tolerance despite being insulin resistant, there is evidence of an increased 
tendency to non insulin dependent diabetes (NIDDM) in PCOS. Gjonnaes in 1989 found 
an increase in the incidence of gestational diabetes in 89 women with PCOS who conceived 
following ovarian diathermy, and Dahlgren et al in 1992 found that 15% of 33 women aged 
40 to 59 years with a histological diagnosis of PCOS made 22 to 31 years previously had 
diabetes mellitus, compared to 2.3% in the control group. A similar trend was found in a 
different study using the same subjects but a different control group published two years 
later (Dahlgren et al 1994). In a recent study, the incidence of gestational diabetes was 
higher in the pregnancies of 47 in women with PCOS compared with 100 healthy pregnant 
controls (Urman et al 1997). NIDDM in PCOS women tends to develop at a substantially 
earlier age (third to fourth decade) than in the general population (sixth to seventh decade) 
(Harris et al 1987). 
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Hypertension: Most cross sectional studies in young women using single blood pressure 
measurements do not show an increased prevalence of hypertension in women with PCOS 
independent of the effects of obesity. However, two recent studies using 24-hour 
ambulatory blood pressure measurements in such women gave conflicting results. In the 
first study, daytime systolic and mean arterial blood pressures were higher in 36 women 
with PCOS compared with 55 controls (Holte et al 1996). Although the women with 
PCOS had increased truncal obesity, these findings persisted after this was taken into 
account. However, in the second study, there was no difference in blood pressure between 
non-obese women with PCOS and controls of a similar weight and age (Sampson et al 
1996). Hypertension may only become manifest after many years of insulin resistance, 
which may explain these findings. There appears to be no prospective epidemiological 
study looking at this issue in women with PCOS, although in a transectional retrospective 
cohort follow-up of patients with PCOS aged 40 to59 years, women with PCOS had a 
four-fold increase in the prevalence of hypertension (Dahlgren et al 1992). Women with 
PCOS are at increased risk of pregnancy induced-hypertension (Gjonnaess et al 1989, 
Urman et al 1997). 
Lipid abnormalities: The results from studies on lipid states in women with PCOS are 
inconsistent, which is not surprising, as lipid levels may be influenced by body weight, 
steroid hormones and insulin states which are not consistent in these women. Some 
studies have found lower high-density lipoproteins (HDL) in women with PCOS compared 
with controls (Wild et al 1988, Conway et al 1992 & Robinson et al 1996). These results 
do not agree however with those of a recent study, which found no difference in HDL 
levels between lean women with PCOS and weight-matched controls (Sampson et al 
1996). Very-low-density lipoprotein cholesterol (VLDL-C) has been shown to be higher 
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in women with PCOS compared with weight-matched controls (Wild et at 1988}, but 
studies on triglycerides are conflicting. Some show an increased concentration in women 
with PCOS (Mattsson et at 1984, Wild et al 1985) but, where obesity has been taken into 
account, no difference has been found (Conway et at 1992, Robinson et al 1996, Sampson 
et at 1996). No study of women with PCOS has shown a higher mean serum cholesterol 
level independently of obesity. 
PAI-I and possible role in cardiovascular disease and reproductive failure: Insulin 
resistance in the PCOS (Dunaif et a1 in 1989, Mahabeer et at 1989, Conway et at in 1990, 
Dale et at 1992, Buyalos et at 1992) may cause elevated P AI -I. Because of the role of 
PAI-l in fibrinolysis, in locally directed proteolysis during ovarian follicle development in 
rats (Peng et a11993) and in mouse embryo implantation (Sappino et at 1989), high PAI-l 
in PCOS may increase the risk of thromboembolic disease and poor reproductive 
performance. Although there is no direct evidence of an increased risk of thromboembolic 
disease in PCOS, indirect evidence suggests that this may be the case, as women with 
clinical signs of androgen excess often have abnormal coronary angiograms (Wild et al 
1990). Using a risk factor model derived from an earlier prospective population study in 
which myocardial infarction was predicted by serum triglycerides, waist/hip ratio, diabetes 
and hypertension, it has been estimated that women with PCOS would be 7 times more 
likely to develop myocardial infarction compared to age matched controls (Dahlgren et al 
1992). Women with PCOS have also been shown to have more extensive coronary artery 
disease than women with normal ovaries in a study in which the extent of coronary artery 
disease was assessed by quantitative angiography and compared with the presence or 
absence of polycystic ovaries on ultrasound in 143 women who had undergone a coronary 
angiography (Birdsall et al 1997). 
37 
However a recent prospective epidemiological study (HS Jacobs 1996) in which a cohort 
of 842 women with a mean age of 53.8 years in whom an ovarian diagnosis of polycystic 
ovaries was made before 1970 showed that there were I 0 deaths from coronary heart 
disease, yielding a standardised mortality ratio of 1.35 (95% confidence interval 0.65-
2.48). There were two deaths from other circulatory diseases (standardised mortality ratio 
0.27; 95% confidence interval 0.03-0.96; p=0.04. This study therefore showed that 
women with PCOS did not have an increased risk of coronary mortality. It may well be 
that the increased degree of oestrogenisation in PCOS offers a cardioprotective effect, 
which compensates for their cardiovascular risk factors. 
A speculative role for high PAI-I levels in anovulatory infertility PCOS is supported by 
studies which show that components of the PAS are present in follicular fluid (Andolf et al 
1995) and granulosa cells of human ovaries (Piquette et al 1993) and that plasmin weakens 
the follicular wall in-vitro (Beers 1975). Plasmin also activates the conversion of 
procollagenase to collagenase present in the basement membrane around the graffian 
follicle at ovulation (Stetler -Stevenson 1990). In a previous study on rat ovaries (Peng et 
al 1993), using in-situ hybridisation, PAI-l mRNA was mainly found in the cell types 
located in the outer layer of follicles including the theca intema, theca externa, interstitial 
cells and ovarian stroma. Following HCG stimulation, the dominant pre-ovulatory 
follicles which protrude onto the surface of the ovary were surrounded by less interstitial 
and stromal tissue that expressed PAI-l compared to the smaller non-ovulatory follicles 
that were in the interior part of the ovary which were surrounded by layers of PAl-l 
expressing tissue. Thus insulin driven elevation in ovarian PAI-l may contribute to limited 
follicle growth and anovulation by limiting the production of plasmin in the granulosa and 
theca cells of women with PCOS. This hypothesis is consistent with the observation that 
anovulatory women with PCOS are significantly more insulin resistant compared with 
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controls in this study, it was not possible to determine whether elevated PAI-l was a 
unique feature of PCOS. These two studies and other subsequent studies on PAI-l in 
PCOS are discussed in more detail in chapter 5. 
CLINICAL FEATURES 
Women with PCOS typically present with menstrual disturbance, infertility, hirsutism, 
acne, alopecia and miscarriage. Obesity is present in I 0 to 40% of cases (Goldzieher and 
Green 1962, Franks 1989, Conway et al 1989, Balen et al 1995). Physical examination 
may reveal enlarged ovaries on palpation. 
Menstrual irregularity usually dates back to puberty and may take the form of 
oligomenorrhoea, amenorrhoea or frequent periods. However, menstrual cycles may be 
normal. Studies show that oligomenorrhoea is present in 29 to 47% of women with 
PCOS, amenorrhoea in 19 to 51% cases (Goldzieher and Green, 1962; Franks, 1989; 
Conway et al, 1989) and frequent periods in 3% of cases (Balen et al 1995). Normal 
cycles are present in 15 to 30% of cases. 
Anovulatory infertility affects 20% of all couples with infertility (Hull et al 1985), but it 
is a feature of 30 to 74% of women with PCOS (Goldzieher and Green 1962, Franks 1989, 
Conway et al 1989). The exact mechanisms remain largely unexplained, but may include a 
negative effect of LH stimulated androgen production on follicle development (Louvert et 
al 1975), subnormal local FSH levels (Erickson et al 1979), impaired actions of insulin 
like growth factor on granulosa cell aromatase activity (Giudice et al 1995), aberrations in 
the intra-ovarian activin/inhibin system (Roberts et al 1994) and an imbalance in the intra-
ovarian plasminogen-plasmin pathway (Sampson et al 1996, Atiomo et al 1998). 
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Miscarriage is another cause of childlessness in women with PCOS and in a study by 
Sagle et al in 1988, 46 (82%) out of 56 regularly menstruating women with recurrent 
miscarriage were found to have ultrasound evidence of polycystic ovaries. A high 
prevalence (56%) of polycystic ovaries was also found in another study of 500 women 
with recurrent miscarriage (Ciifford et al 1994). It has been suggested that miscarriage 
occurs in women with polycystic ovaries because of hypersecretion of LH, as this appears 
to be a marker of subfertility and early pregnancy loss (Regan et al 1990). This hypothesis 
was supported by the finding of raised LH in women with recurrent miscarriage in 
association with polycystic ovaries in the study by Clifford et al in 1994. However a 
subsequent study in which LH levels were suppressed before pregnancy in a randomised 
controlled trial of I 06 women with a history of three or more consecutive first trimester 
miscarriages, polycystic ovaries and hypersecretion of LH did not find an improvement in 
pregnancy outcome (Ciifford et al 1996). The link between PCO and miscarriage thus 
remains unexplained. 
Hirsutism and acne are the manifestations of hyperandrogenaemia in this syndrome. The 
hirsutism associated with PCOS usually dates back to menarche, is gradual in onset and is 
rarely accompanied by other signs of virilization such as clitoromegaly and temporal hair 
loss. In a study of 1741 women with ultrasound detected polycystic ovaries, hirsutism was 
present in 66.2% of women with PCOS and 34.7% had acne (Balen et al 1995). Other 
studies also show a similar trend with a reported prevalence of hirsutism in 34 to 69% of 
cases and acne in 9 to 24% of cases (Goldzieher and Green 1962, Franks 1989, Conway et 
a1 1989). 
Testosterone and androstenedione levels in anovulatory but non-hirsute women with PCO 
are similar to the levels found in women with hirsutism (Franks 1989, Conway et al 1989), 
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while women with hirsutism and PCO may have normal serum androgen concentrations 
(Franks 1989, Conway et al 1989, Lobo 1991). However, the daily production rate of 
testosterone is elevated in virtually all women with PCO (Yen 1986), and the normal 
serum concentrations of testosterone in women with hirsutism may be a reflection of 
increased clearance by peripheral tissues. 
Obesity in women with PCOS is usually truncal, and they tend to have a high waist hip 
ratio. It is associated with more severe forms of the disease including extreme 
anovulation, oligomenorrhoea and increased hirsutism, but non-obese women with PCOS 
may also present with these features. Weight reduction is associated with the return of 
regular menstruation, fertility, a reduction in hirsutism, an improvement in insulin 
sensitivity, an increase in SHBG levels and a correction of gonadotrophin and sex steroid 
abnormalities (Kopelman et al 1981, Harlass et al 1984, Pasquali et al 1989, Kiddy et al 
1992, Anderson et al 1995). 
ULTRASOUND FINDINGS 
With successive advances in ultrasound technology, the criteria used in the diagnosis of 
PCO have evolved from an overall increase in ovarian size (Kratchowil 1972) to the 
recognition of characteristic follicular patterns of distribution and specific features in the 
ovarian stroma (Swanson 1981, Adams 1985). In a study of 76 women with menstrual 
disturbance and hirsutism, Adams et al in 1985 defined PCO as the presence of I 0 or more 
small follicular cysts 2-8mrn in size distributed evenly around the ovarian periphery with 
an increased amount of stroma and women with ultrasound features of PCO had higher 
testosterone and LH levels, and an increased ovarian volume, compared with women with 
normal or multifollicular ovaries (14.6 cm3 , 6.4 cm3 and 8.0 cm3 respectively). Although 
they did not state how these ultrasound criteria were set, most subsequent clinical studies 
42 
on PCOS use them. These features contrast with multifollicular ovaries, where the 
follicles are fewer in number and there is minimal stromal tissue. 
Not all women with the clinical features of PCOS will have the characteristic ultrasound 
features (Hann et al 1984), but there is a close correlation between these ultrasound criteria 
and histological features of polycystic ovaries (Saxton et al 1990). Women with PCOS 
may also have an increased endometrial thickness from unopposed oestrogenisation, and 
have recently been shown to have an increased ovarian stromal blood flow velocity on 
doppler ultrasound (Zaidi et al 1995). 
AETIOLOGY & PATHOPHYSIOLOGY 
With the heterogeneous nature of the PCOS, it is not surprising that there is no consensus 
about which factors explain its aetiology and/or pathophysiology. Instead, several factors 
have been shown to play a role. Traditionally, endocrine abnormalities arising from the 
hypothalamo-pituitary-ovarian (HPO) axis, or the adrenals, were thought to explain many 
of the aspects of this syndrome, but recent research has focused on the role of insulin 
resistance, intra-ovarian paracrine factors, dysregulation of cytochrome P450c17oc, leptin, 
genetics and intrauterine programming. 
Hypothalamo-Pituitary mechanisms 
The concept of "inappropriate feedback" as the basis of anovulation and the endocrine 
abnormalities in women with PCOS (Yen et al 1976) has for a long time been the favoured 
hypothesis. In this model, it was suggested that the outpouring of oestrogen from extra-
ovarian sources marred the cyclic changes in oestrogen production normally responsible 
for appropriate feedback regulation of the mid-cycle gonadotrophin surge. This resulted in 
an increased pituitary sensitivity to LHRH, an increased pulsatile LH release and a reduced 
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FSH release. This chronically elevated LH level in turn caused increased ovarian 
androgen production by the theca cells, which was not converted to oestrogens because of 
a defective FSH dependent aromatase system in the ovary. The extraglandular 
aromatisation of these androgens (mainly in adipose tissue) to oestrogens, which occurred 
independently of FSH thus, results in the completion of a self-perpetuating cycle. 
In support of this hypothesis, oral administration of oestrone was shown to enhance the 
disparity between LH and FSH found in PCOS, but was not found in normal controls 
(Chang et al 1982). Against this hypothesis, however, is the observation that not all 
women with PCOS have raised LH levels (Givens et al 1976) (up to I 0% of women with 
PCOS have basal levels and a pulsatile pattern of LH release that are indistinguishable 
from normal cycles). In addition, oestrone rises very rapidly in response to gonadotrophins 
in women with PCOS excluding the possibility of primarily peripheral conversion. The 
underlying mechanism for the augmented pituitary sensitivity to LHRH by oestrogens 
remains to be defined. 
It has also been suggested that in the hypothalamus a dissociation of dopaminergic and 
opioid inhibition of GnRH release may result in increased GnRH secretion (Yen 1986) and 
evidence in support of this comes from studies which show that the elevated LH levels in 
PCOS are reduced by exogenous dopamine inhibition (Quigley et a! 1981 ). However the 
reversal of the cyclic release of gonagotrophins in response to several types of treatment is 
not in favour of a primary hypothalamic defect as this cyclicity is programmed in the 
hypothalamus. 
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Adrenal Factors 
Adrenal hyperandrogenaemia 1s a well recognised feature of the PCOS (Lobo 1984, 
Hoffman et al 1984, Carmina et al 1986, Obhrai et al 1990, Fox 1992c), but levels of 
adrenocorticotrophic hormone (ACTH) and cortisol are normal (Lachelin et al 1979). 
Although the cause is unknown, adrenal hyperandrogenaemia has been proposed as a 
possible aetiological factor, based on studies which show that women with congenital 
adrenal hyperplasia (CAH) have an increased prevalence of PCO (Hague et al 1990), and 
on studies which show that synthetic androgen administration to transexuals undergoing 
female to male gender transfer develop ovaries which look polycystic (Amirikia et al 
1986). In addition, suppression of adrenal androgen synthesis in women with congenital 
adrenal hyperplasia (CAH) causes the return of ovulation (Chrousos et al 1982), although 
this effect can also be achieved with low dose corticosteroids which casts doubt on the role 
of adrenal hyperandrogenaemia alone in the aetiology of anovulation. A physiological rise 
in adrenal androgen secretion occurs at puberty. It has been suggested that this process 
may be accentuated and prolonged in the PCOS, which might affect normal hypothalamic 
maturation prior to the menarche causing persistent anovulatory cycles without a persistent 
adrenal abnormality (White & Turner 1994). Because the exaggerated rise of androgen 
levels in response to ACTH is similar to the amplification of LH-dependent androgen 
production by insulin, Fox speculated that insulin might regulate adrenal function in PCOS 
(Fox 1992c). However this hypothesis was not supported by the lack of a correlation 
between insulin and DHEAS levels in his study of oligomenorrhoeic women with PCO. 
Ovarian Factors 
Gonadotrophins, steroids, insulin-like growth factors and their binding proteins, 
activins/inhibins, the renin-angiotensin system and the plasminogen activator system have 
all been proposed as factors which play a role in the intra-ovarian pathogenic mechanisms 
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resulting in disordered folliculogenesis in the PCOS. In the "Two-cell, two-gonadotrophin 
principle" (Erickson 1992), the theca cells synthesise and secrete androstenedione in 
response to LH, which diffuses across the basal lamina into the granulosa cells where it is 
aromatised to oestrone and subsequently oestradiol in response to FSH stimulation. 
Oestradiol is released into the circulation where it modulates the release of gonadotrophins 
from the pituitary resulting in ovulation. Short and London showed that follicular fluid 
from polycystic ovaries had very high concentrations of androstenedione, but no oestrone 
or 17 P-oestradiol and concluded on the basis of this finding that polycystic ovaries had a 
defect in the aromatase system that prevented the conversion of C 19 steroids to C 18 
oestrogens (Short & London 1961, Short 1962). It is thought that this high 
androstenedione/oestrone ratio results in disordered folliculogenesis. Although the 
mechanism of this biochemical defect remains unknown, the suggestions include a 
reduction in bioactive FSH available in the follicles for induction of aromatisation, an 
absent signal transduction system for FSH receptors in the granulosa cells, the presence of 
an FSH inhibitor, and the presence of an aromatase inhibitor. Follicular fluid from women 
with PCOS has however been shown to contain as much FSH as the normal dominant 
follicle (Erickson 1992). It has also been shown that granulosa cells from women with 
PCOS have an inherent ability to respond to FSH induction of aromatase activity, but that 
the graffian follicles never develop to a size where the aromatase enzyme is normally 
expressed (Erickson 1979). It has been suggested that the inhibitor of FSH may be insulin 
like growth factor binding protein (IGFBP), epidermal growth factor or inhibins 
(Redmond 1995). 
The insulin like growth factors (IGFs) are polypeptides which modulate cell proliferation 
and differentiation, and are thought to be important in the growth and differentiation of 
ovarian follicles. They are structurally similar to pro-insulin, and although they are mainly 
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produced in the liver, ovarian production also occurs. They have their own receptors, and 
also bind weakly to insulin receptors at the end organ. In the circulation, they are bound 
by binding proteins (IGFBPs) which influence the amount of free IGF available to bind to 
receptors. There are two subclasses of IGFs depending on whether or not they are growth 
hormone dependent (IGF-1 is and IGF-11 is not). IGFBPI is found mainly in amniotic 
fluid, IGFBP2 in the fetus and neonate, but IGFBP3 is the major binding protein in adult 
serum and is produced in the liver (Suikarri A-M et al 1988). 
In women with PCOS a dysfunctional IGF system may impair follicular function. 
Although IGF-1 is found in normal concentrations in PCOS follicles at a concentration 
similar to that found in serum (Eden et al 1990), women with PCOS have been shown to 
have an 80% decrease in serum IGFBP-I (Pekonen et al 1989, Suikkari et al 1989) as well 
as reduced levels in the follicular fluid. The resulting increased IGF-l/IGFBP-1 ratio 
results in an increased bioavailable IGF-1 that probably stimulates the theca interstitial 
cells to produce androgens, as well as affect granulosa cell function. However, the cellular 
distribution of IGFBP mRNA and protein in PCOS follicles is indistinguishable from that 
in small follicles of normal ovaries (el-Roeiy et al 1994), and in women with and without 
PCOS, IGF-1 has also been shown to accentuate the stimulatory effects of FSH on ovarian 
aromatase activity and oestradiol production equally (Mason et al 1993). It is therefore 
clear from these conflicting findings that the exact role of the IGFIIGFBP system in the 
pathogenesis of PCOS is not fully understood. 
Inhibin and activin are dimeric glycoproteins. Inhibin was first described in 1932 as a 
substance that inhibited anterior pituitary secretions (McCullough 1932). It was extracted 
from follicular fluid in 1985 and found to inhibit FSH synthesis and release in animals 
(Robertson 1985). Inhibin is thought to play a complementary role in the negative 
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feedback effect of oestradiol on FSH secretion during the follicular cycle. Activin 
stimulates FSH secretion (Ling et al 1986), but it may also inhibit FSH release in the 
periovulatory period (Di Simone et al 1994). Activin and inhibin also have autocrine and 
paracrine activity in the human ovary. Inhibin inhibits aromatization while activin 
stimulates it (Di Simone et al 1994, Ying et al 1986). Activin also promotes mitogenesis 
in granulosa cells (Rabinovici et al 1990). In polycystic ovaries, the cellular localisation of 
inhibin and activin has been shown in one study to be similar to that found in normal 
ovaries (Jaatinen et al 1994) while in another study the granulosa cells from small antral 
follicles were less active in polycystic than normal ovaries with respect to inhibin alpha-
subunit mRNA expression. Systemic levels of immunoactive inhibin in PCOS are similar 
to those found in normal women (Buckler et al 1988, Reddi et al 1989), but when 
measured in a recently developed ELISA assay, inhibin A and B concentrations were 
raised in PCOS (Anderson et al 1998) which was thought to be a reflection of the 
increased number of small follicles in PCOS. It is therefore not possible to confirm the 
speculative role of these peptide hormones in the pathophysiology of PCOS. 
The possible role of the renin-angiotensin system in disordered folliculogenesis in the 
PCOS has also been evaluated in a study in which intense staining for renin and 
angiotensin was found in multiple cystic follicles and the stroma of ovarian biopsies from 
women with PCOS (Palumbo et al 1993). The staining was seen in only a limited number 
of follicles in normal control ovaries, suggesting that this system may underlie the basic 
cellular mechanism, which leads to arrest of follicle development in PCO. However 
research evidence for this hypothesis is scanty. 
The plasminogen activator system is a cascade of enzymes and proenzymes, which lead to 
plasmin formation. Plasmin is a proteolytic enzyme, which plays a role in animal 
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ovulation, and it is possible that an . insulin-mediated inhibition of plasmin release, by 
causing an elevation in PAI-l levels, may disturb follicle growth and release in PCOS. 
This issue is fully addressed in four of the studies in this thesis. 
Cytochrome P450c17a 
Recent evidence suggests that PCOS may be influenced by a hyperfunction of the 
androgen-forming enzyme, cytochrome P-450c 17a, within ovarian theca cells. In steroid 
biosynthesis, this enzyme binds both pregnenolone and progesterone, and converts them 
sequentially to 17-hydroxyprogesterone/pregnenolone by 17a-hydroxylation and 
androstenedione/ dehydroepiandrosterone by 17,20-Lyase activity (Fig 2.2 below). 
Evidence of cytochrome P-450c 17a hyperfunction comes from studies which show a 
greater 17-hydroxyprogesterone, androestenedione and oestrone response to the 
administration of a gonadotrophin (Bames et al 1989) in women with PCOS compared 
with controls. This hyper-responsiveness resembled those of males and was not lowered 
following the suppression of adrenal function by dexamethasone implying that the adrenals 
were not the main source of these honnones. 
The cause of cytochrome P450c 17a over-expression in these women is unknown, but it 
has been suggested that it may be explained variously by a direct stimulatory effect of LH 
on the ovarian theca cells, amplification of the effect of LH on theca cells through synergy 
with insulin and insulin-like growth factor-! (without a rise in systemic LH secretion), an 
escape of P450c 17a from desensitisation to LH, and most recently as a direct consequence 
of hyperinsulinaemic insulin resistance (Rosenfield et al 1990, Nestler & Jakubowicz 
1996). 
49 
In the adrenal gland P450c 17a also fonns the 17-ketosteroids, but more 
dehydroepiandrosterone is fonned than androstenedione (figure 2.2). The same gene 
codes for P450c17a in the adrenal gland and ovary (Miller 1988), and an increased adrenal 
17-ketosteroid response to ACTH is common in PCOS (Lachelin et at 1979). Although it 
was previously thought that mild homozygous or heterozygous congenital adrenal 
hyperplasia was responsible, it may be that this response is due to an abnonnal regulation 
of P450c17a in the adrenal cortex. The hypothesis of a dysregulation in P450cl7a 
activity may therefore explain the finding of PCOS in association with nonnal or raised 
serum LH, insulin resistance and adrenal hyperandrogenaemia. 
Figure 2.2 Biosynthetic pathways for steroid hormones. 
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Obesity 
Approximately 50% of women with PCOS are obese, and obesity may also be involved in 
the pathophysiology of PCOS. Generally, a significant correlation exists between obesity 
and infertility (Rogers & Mitchell 1952, Hartz et al 1979), and obesity and miscarriage 
(Hamilton-Fairley et al 1992). There is also a correlation between the age of onset of 
oligomenorrhoea or amenorrhoea and the age of onset of obesity in PCOS (Pasquali et al 
1985) and fertility, hyperandrogenaemia, hyperinsulinaemia and menstruation improve 
with weight reduction in these women. The links between obesity and reproductive 
function are not clear. However the possible mechanisms include increased insulin 
resistance which leads to elevated basal insulin levels, reduced synthesis of SHBG and 
consequently increased free testosterone and a reduced lGFBPI concentration, abdominal 
distribution of fat which is associated with increased insulin resistance, lower SHBG 
concentrations and elevated free testosterone levels in premenopausal women (Kissebah et 
a! 1982, Kissebah et al 1988, Freedman et a! 1990, Kirschner & Bard in 1972), and recently 
leptin resistance. Leptin is a protein secreted by white fat cells, which is thought to send a 
signal to the satiety receptors in the hypothalamus. It is a product of the obesity gene and 
mice that have a deficiency of leptin have a voracious appetite, obesity, and infertility and 
have low gonadotrophin levels. This infertility appears to be reversed on treatment with 
leptin but not dietary restriction (Chehab et al 1996). Serum levels of leptin correlate 
positively with obesity and BM! and fat secretion of leptin is stimulated by insulin. Fat 
cells may also have the defect of tyrosine autophosphorylation, which is present in PCOS. 
It has therefore been hypothesised that in women with PCOS, insulin resistance in fat cells 
impairs the leptin response to obesity. Thus excessive eating continues despite increased 
body weight which aggravates the insulin resistance (J acobs 1996). However most studies 
on leptin in women with PCOS show that the baseline levels are not different from 
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controls (Rouru et al 1997, Laughlin et al 1997, Mantzoros et al 1997, Chap man et al 
1997) and the precise role of leptin in PCOS is unclear. 
Fetal Programming Hypothesis. 
Recently, there has been evidence to suggest that PCOS may originate during intrauterine 
development. Insulin resistance and lipid abnormalities in adult life are associated not 
only with acquired obesity, but with low birth weight and low rates of infant growth, and 
could be a consequence of foetal metabolic adaptations to under-nutrition (Phillips 1996). 
Women with high growth rates in infancy have an increased risk of ovarian cancer, which 
may be a reflection of long term disturbances in the pattern of gonadotrophin release that 
are established in-utero (Barker et al 1995). 
Because ofthe above observations, Creswell and colleagues in 1997 examined 235 women 
aged 40 to 42 years born in Sheffield whose birth records were available and related the 
prevalence of polycystic ovaries and plasma concentrations of gonadotrophins and 
androgens to the women's birth weight and length of gestation. Their results showed that 
obese, hirsute, hyperandrogenic women with polycystic ovaries had a high birth weight, 
while thin women with polycystic ovaries, high LH and normal testosterone had prolonged 
gestation. These findings suggest that PCOS may be programmed from birth, but the 
findings are preliminary and the exact mechanism by which these intrauterine events 
produce these effects is unknown. 
Genetic Theories 
Although there is evidence that the PCOS is familial, its genetic basis is controversial. A 
family history is usually present for hirsutism, menstrual dysfunction and cystic ovaries 
(Givens et al 1971 ). Determination of the mode of inheritance has been difficult because 
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there has been no clearly defined male phenotype. Three studies have however 
demonstrated an association between PCOS and premature male pattern baldness (MPB) 
in male relatives of women with PCOS (Ferriman et al 1979, Lunde et al 1989, Carey et al 
1993). The incidence of MPB was 44% compared to 7% in the non-PCOS related 
families. These observations are consistent with an autosomal dominant mode of 
inheritance. 
In an attempt to define the gene responsible for PCOS, Carey and colleagues in 1993 
identified a base change in the promoter region of the gene encoding P450c 17oc which was 
associated with PCO, but using polymorphic markers this allele did not segregate with 
PCO or MPB within families, thereby excluding it as the major genetic abnormality. 
DIAGNOSIS AND DIFFERENTIAL DIAGNOSES 
In practice, a combination of clinical, ultrasound and biochemical features are used in the 
diagnosis of PCOS, as the presentation is variable. A diagnosis of PCOS is likely if there 
is a history of menstrual disturbance and hirsutism, with ultrasound features of PCO as 
earlier described, in association with raised total or free testosterone, elevated LH (or 
LHIFSH ratio) and hyperoestrogenaemia. 
Women with PCOS may, however, have regular menstrual cycles and their only outward 
manifestation may be recurrent miscarriage or hirsutism. Using ultrasound as a reference 
method, Fox et al in 1991 suggested that a combination of the free androgen index 
(calculated as testosterone (nmoUiitre) x 100/ SHBG) and an elevated LH level were the 
most accurate predictors of PCOS, but this was as good as combinations incorporating the 
progesterone challenge test. 
53 
In women with suspected PCOS, it is important to rule out other endocrine causes of 
oligomenorrhoea/amenorrhoea. These include hypothalamic amenorrhoea (associated with 
weight loss, exercise, anxiety and chronic illness), pituitary adenomas, hyperthyroidsm, 
hypothyroidism, late onset congenital adrenal hyperplasia (LOCAH), androgen secreting 
tumours, premature ovarian failure and Cushings syndrome (White & Turner 1994). 
Hypothalamic amenorrhoea is usually obvious from the history and is associated with low 
LH and FSH levels, pituitary adenomas are also associated with low levels of 
gonadotrophins and may be picked up on radiological tests of the pituitary fossa, thyroid 
disorders may be detected clinically or on thyroid function tests, and LOCAH although 
rare by measuring the 17cc-hydroxyprogesterone response to corticotrophin. Androgen 
secreting tumours may be present if there is a short history of severe hirsutism and a 
testosterone concentration of more than 7 nmol per litre. 
TREATMENT 
Anovulation: The main principles of treating anovulatory infertility are to rule out other 
possible factors which may contribute to infertility such as tubal disease, to correct any 
underlying disorder (e.g. obesity), to induce regular unifollicular ovulation, and to achieve 
a high conception rate but with a low incidence of multiple pregnancy and miscarriage. 
Anti-oestrogens (clomiphene citrate 50 - I OOmg or tamoxifen 20 - 40 mg) are usually the 
first line therapy in inducing ovulation. Clomiphene may cause thickening of the cervical 
mucus, and when an ovulatory dose is reached, assessment of the cervical mucus at the 
time of ovulation is helpful. Anti-oestrogens are usually commenced on day two of the 
cycle and given for five days. If the patient has oligo or amenorrhoea, it is important to 
rule out pregnancy and induce a withdrawal bleed with a five-day course of a progestogen. 
This improves the response rate (Homburg 1988) and sheds any sub-optimal endometrium 
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(Franks et al 1985). The usual starting dose is 50mg, but could be increased to 1 OOmg if 
no response is achieved after three cycles. If a follicular response but no LH surge occurs, 
human chorionic gonadotrophin may be added in mid-cycle. A dose of more than I OOmg 
rarely offers any benefit, and may be associated with side effects. Ovulation rates are high 
with rates up to 80%, however the pregnancy rates are only about 40%. Clomiphene may 
be associated with a risk of ovarian cancer after prolonged use (Rossing et a! 1994) and the 
Committee of Safety of Medicines recommend that it should not normally be used for 
more than 6 cycles (CSM 1995). 
For women who do not respond to anti-oestrogens, the therapeutic options are either 
parenteral gonadotrophin therapy or laparoscopic ovarian diathermy. Exogenous 
gonadotrophins may be either human menopausal gonadotrophin (HMG), or pure human 
FSH. The use of gonadotrophins is associated with the ovarian hyperstimulation syndrome 
and a multiple pregnancy rate of up to 20% (Duncan et al 1994). In one study of HMG in 
PCOS, the cumulative conception rate was 62% and the live birth rate 54% at 6 months 
(Balen et al 1994) and 73% and 62% respectively at 12 months. The multiple pregnancy 
rate in that study was 19%, but fell to 7% after the introduction of real time ultrasound for 
cycle monitoring and there were three cases of ovarian hyperstimulation. The risk of 
ovarian hyperstimulation and multiple pregnancy can be reduced by starting with very low 
doses of gonadotrophin and monitoring follicular development with ultrasound scans. 
Women with PCOS have a higher risk of developing ovarian hyperstimulation syndrome 
(OHSS) with ovulation induction (Wang and Gemzell 1980), but the exact mechanism is 
unknown. This occurs when too many ovarian follicles are stimulated and results in 
abdominal distension, discomfort, nausea, and vomiting and occasional breathlessness. 
The mechanism may involve activation of the ovarian renin-angiotensin pathway and 
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excessive secretion of vascular epidermal growth factor. Ascites, pleural and pericardial 
effusions worsen the condition and the resultant haemoconcentration may lead to 
thromboembolism. The situation worsens if pregnancy occurs. Treatment usually 
involves the prevention of dehydration, pain relief and the prevention of 
thromboembolism. 
For women who fail to respond to the above measures, laparoscopic ovarian diathermy 
may be used. Gjonnaes first described it in 1984, but its mechanism of action is unknown. 
It appears to be as effective as routine gonadotrophins in the treatment of clomiphene 
resistant anovulation, and it is less likely to result in multiple pregnancy and 
hyperstimulated ovaries compared with gonadotrophin therapy (Abdel Gadir et al 1990). 
The main complication of this procedure is peri-ovarian adhesions, although treating one 
ovary may reduce this, as ovulation can be triggered from both ovaries after the treatment 
of one ovary (Balen & Jacobs 1994). Various forms of laser have also been used. 
The pregnancy rates after these procedures (diathermy and laser) vary from 20 to 88% 
(Donesky & Adashi l99S) with an average of SS%. The reason for the variations in 
reported pregnancy rate is unclear. The use of diathermy (rather than laser), younger age, a 
shorter duration of infertility and a higher pre-operative LH level were associated with a 
higher success rate (Li et al 1998). 
Miscarriage rates are about 13% after ovarian diathermy (Li et al 1998) compared to over 
20% after medical treatment (Abdel Gadir et al 1990). There may therefore be a case for 
laparoscopic ovarian drilling replacing gonadotrophins as the second line treatment for 
anovulation in PCOS. 
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Hirsutism 
In addition to the use of local measures for hair removal, the principles of management of 
hirsutism include the determination of the type and source of hyperandrogenaemia (if 
present), exclusion of androgen secreting tumours, the use of androgen suppressive therapy 
if any androgens are significantly elevated and the use of an anti-androgen if the levels are 
normal or close to normal. 
The common anti-androgens include cyproterone acetate (CP A), spironolactone, and 
flutamide. Dexamethasone may be used for suppression of adrenal androgens and the oral 
contraceptive pill or GnRH analogues for the suppression of ovarian androgens and to 
elevate SHBG levels, 
Cyproterone acetate is a potent progestogen with anti-androgenic activity. It is usually 
given in combination with ethinyl oestradiol where hirsutism and menstrual disturbance 
co-exist. High doses may be associated with fluid retention weight gain, liver damage and 
mood changes. Spironolactone the aldosterone antagonist binds oestrogen and 
progesterone receptors and inhibits cytochrome P4SO 17c. The side effects include 
lethargy, dizziness and light-headedness. Some women develop polymenorrhorhoea and 
the oral contraceptive pill may be prescribed if no improvement occurs after a few cycles. 
Flutamide is a pure anti-androgen (Cusan et al 1990). Its main drawbacks are its 
hepatotoxicity and cost (Wysowski et al 1993, Wallace et al 1993). It is usually used as a 
last resort. Anti-androgens may be feminising to male foetuses, and it is important that 
pregnancy is avoided while on them, hence their formulation as oral contraceptives when 
oestradiol is added such as in Diannette. Dexamethasone is a useful adjunct to anti-
androgens when there are elevated androgens of adrenal origin. Where the combined oral 
contraceptive (COC) is thought necessary, progestogens with androgenic activity are best 
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avoided. Although there is evidence of a reduction in hair growth with the COCs, it is 
often not enough to satisfy the patient. They are therefore best used in combination with 
an anti-androgen. 
Local measures, such as electrolysis and waxing, are useful while waiting for drug therapy 
to work. Response to treatment is usually slow and women are usually advised to stay on 
treatment for 1-2 years before tapering off. 
Acne may be treated with broad-spectrum antibiotics, the combined pill, retinoic acid 
derivatives or anti-androgens. Alopecia may be treated with anti-androgens, but generally 
takes a long time to respond to treatment. 
Menstrual irregularity may be controlled by the COCs or cyclical progestogens. Women 
with oligo or amenorrhoea in whom fertility is not a problem may prefer not to be treated. 
They are however at increased risk of sudden vaginal bleeding and may be at increased 
risk of endometrial cancer (Sherman & Brown 1979). It is therefore important to assess 
the endometrial thickness by ultrasound in these women especially when they are over the 
age of 40 years when this should be done annually. 
Metabolic problems also need consideration in the treatment of these women. The best 
treatment for these conditions is weight reduction. It is also advisable to perform an oral 
glucose tolerance test and a lipid profile in obese young women with PCOS. Usually the 
diabetes in PCOS is non-insulin dependent and oral agents are the treatment of choice. 
Where hypertension is present, it is important to avoid a potassium sparing diuretic and 
angiotensin converting enzyme inhibitors if the patient is already on spironolactone 
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because of the risk of hyperkalemia. Calcium channel blockers and thiazide diuretics are 
the most useful antihypertensives in these women. 
In addition to improving insulin sensitivity, metformin, the oral hypoglycaemic has 
recently been shown to result in lower androgen levels, lower PAI-l levels (Nestler & 
Jakubowicz 1996, Velaquez et al 1997) and may be a useful adjunct in the treatment of 
anovulation m these women. However larger clinical trials are required to test this 
hypothesis. 
SUMMARY 
PCOS is a common endocrine abnormality in women of the reproductive age group. The 
clinical manifestations are variable, and the aetiology and pathogenesis are not fully 
understood. Insulin resistance, a genetic defect inherited in an autosomal dominant pattern 
affecting the regulation of enzymes responsible for ovarian androgen production and 
factors originating in the intrauterine period may all play a role. Treatment is symptomatic 
and usually directed at the presenting clinical problem. The metabolic aspects are 
increasingly recognised as an area requiring careful attention because of the possible long-
term sequelae. A better understanding of the underlying pathophysiology of this syndrome 
is the key to developing more logical and effective treatment. 
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CHAPTER THREE 
STUDY DESIGN 
OUTLINE 
A detailed account of the sources and selection of subjects (or material) used in this thesis 
is presented. The definitions, ultrasound methods, data collection and methods of data 
analysis are described. 
OVERALL STUDY DESIGN 
The primary aim of this study was to evaluate systemic plasminogen activation, PAI-l and 
the ovarian expression of PAI-l protein and mRNA in women with PCOS and controls. A 
series of clinical and laboratory based cross sectional studies were performed in which 
these variables were measured in the setting of a district general hospital in the United 
Kingdom (Derriford Hospital, Plymouth). For the clinical studies, suitable patients and 
controls were recruited from the infertility, endocrinology and gynaecology clinics, local 
general practitioners and from amongst female members of staff. For the laboratory based 
studies, suitable paraffin embedded ovarian biopsies taken from women with and without a 
diagnosis of PCOS who had undergone ovarian biopsies between 1982 and 1985 were 
obtained from the archives of the histology department. 
STUDY GROUPS 
Three study groups were used and they were recruited between December 1995 and 
November 1997 (see table 3.1). 
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Table 3.1- General Characteristics Of The Three Study Groups In This Thesis 
GROUP I GROUPII GROUP ID 
PCOS Controls PCOS Controls PCOS Controls 
n=ll n=ll n=41 n=25 n=5 n=6 
Mean Age (years) 27 31.8 28.4 32 27.8 27.5 
Mean Weight (Kg) 86.6 68.6 80.6 75 65 76.6 
Mean BMI (W /B1) 31 26 29.5 28.5 N/A N/A 
Menstrual Cycles Oligo/A Regular Oligo/A Regular Oligo/A Regular 
menorh menorh menorh 
Hirsutism Score** Raised Normal Raised Normal N/A N/A 
Ovarian PCOS Normal PCOS Normal PCOS Normal 
Morphology 
Free Androgen Raised Normal Raised Normal N/A NIA 
Index 
N/A = not measured 
•• = Hirsutism as assessed by the Ferriman Gallwey score 
Amenorh = Amenorrhoea 
Group l was subjects investigated in a pilot study evaluating systemic levels of components 
of the plasminogen activator system (PAS) including PAI-l. It consisted of 11 women with 
PCOS and 12 controls recruited from the subfertility and gynaecology clinics and from 
amongst female members of staff at the hospital and the infertility clinic. 
Group 11 were investigated in a larger clinical study of systemic levels of components of the 
PAS, and metabolic, coagulation and hormonal variables. This consisted of 83 women 
recruited from the endocrinology, infertility and gynaecology clinics, from local general 
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practitioners and from amongst the female staff at the hospital out of which 41 women with 
PCOS and 25 controls were eligible for the study. 
Group m consisted of archival blocks of stored ovarian biopsies taken from five women 
with PCOS and six controls analysed by immunohistochemistry and in-situ hybridisation for 
PAl-l antigen and mRN A. · 
All the subjects in the three study groups were Caucasian. 
ETIDCAL APPROVAL 
These studies were carried out following approval by the Ethical Committee of the South 
and West Devon Health Authority. The aims and nature of the investigations were 
explained and subjects were free to decline if they so wished without any prejudice on their 
clinical management. Informed consent was obtained in writing from all the participants in 
the clinical studies. 
PATIENT RECRUITMENT AND CASE SELECTION 
For the clinical studies, all the members of staff in the department of obstetrics and 
gynaecology, the department of endocrinology and local General Practitioners were 
· informed of the aims and nature of the studies, by a letter and posters placed in the hospital 
wards and clinics. They were requested to make contact if they saw any patients with 
suspected PCOS who would be interested in participating in the study. A search of the 
hospital records, of the endocrinology clinic database from 1995 onwards and a review of 
all ultrasound reports with a diagnosis of polycystic ovaries from 1994 onwards was also 
performed. Women who were considered suitable were approached in writing or by 
telephone asking if they were interested in participating in the study following a full 
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explanation of the aims and methods of the project supplemented with a patient 
information sheet. General practitioner information sheets were also sent out. Interested 
participants were invited to the hospital and prospectively evaluated for the diagnosis or 
exclusion of PCOS by history, biochemical tests, and transvaginal or abdominal ultrasound 
scans. In a few cases a previous ultrasound report of polycystic ovaries as defined below 
was accepted. The following inclusion and exclusion criteria were used for the clinical 
studies. 
INCLUSION CRITERIA USED IN CLINICAL STUDIES OF MET ABOUC AND 
THROMBOTIC FEATURES IN PCOS (Study groups I & 11) 
PCOS 1 CONTROLS . 
~ . . . . . ·. 
Chronic oligomenorrhoea or amenorrhoea Regular menstrual cycles 
Ultrasound features of polycystic ovaries Normal ovaries on ultrasound scan. 
EXCLUSION CRITERIA 
• Current pregnancy 
• Delivery or miscarriage occurring within the preceding 3 months 
• Recent surgery (within 3 months) 
• History of myocardial infarction 
• Use of aspirin or heparin 
• Sex steroid therapy 
• A history of haematological disease, malignancy or liver disease 
• Hyperprolactinaemia 
• A positive synacthen test following raised 17-hydroxyprogesterone levels 
• A history of thrombosis 
The last three criteria were not used in the pilot clinical study. 
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Stage in menstrual cycle during which samples for PAI-l were obtained. 
The samples for PAl-l, taken from the women in study groups I and Jl were obtained at 
random stages of their menstrual cycles. This was because, the only study to my 
knowledge in the literature which had addressed this issue, had shown that systemic PAI-l 
levels did not fluctuate during different stages of the menstrual cycle (Dorr et at 1993). It 
is important to note however that, because by definition women with PCOS have erratic 
periods and may be amenorrhoeic for years, it would have been impractical to insist that all 
the samples for PAI-I were taken from them at a specified day or stage in the menstrual 
cycle. 
The exact day of the cycle when these samples were obtained can be found in the data 
section of the appendix. Briefly, in study group I, in the control group, three women were 
menstruating at the time the samples were obtained, four were pre-ovulatory and five post-
ovulatory. In the PCOS group, one woman was menstruating, two had completed their 
menses but were 14 days or less from the first day of their LMP (last menstrual period) 
and eight women had the samples taken 15 days or more from their LMP. 
In study group 11, in the control group, two women were menstruating at the time the 
samples were obtained, nine were pre-ovu1atory and 14 post-ovulatory. In the PCOS 
group, five womeri were menstruating, five had completed their menses but were 14 days 
or less from the first day of their LMP (last menstrual period) and 31 women had the 
samples taken 15 days or more from their LMP. 
The selection of suitable material for study group Ill was as follows. The histological 
reports of women with PCOS who had undergone a wedge resection for the treatment of 
infertility between 1982 and 1996 were retrieved from the records of our hospital's 
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histopathology department. Control nonnal ovaries were selected from women of a similar 
age who had either undergone an oophorectomy or ovarian biopsy during the same period. 
Only cases where the initial histopathology report unequivocally diagnosed polycystic 
ovaries were selected and cases where the histology report specifically described the 
ovaries as "nonnal" or containing "follicle cysts" (but without any of the other stigmata of 
PCO) were selected. The hospital records of these women were reviewed and the details 
noted included their age, menstrual histories, indication for surgery, medication at surgery, 
weights and results of any endocrine tests if present. This information was recorded on a 
standard profonna (appendix 3) and the histological slides from the women where this 
infonnation was available from their records were reviewed by an independent 
histopathologist blind to the original diagnoses. Cases were defined as PCOS if there was 
in addition to a histology report of PCO, a documented history of oligo or amenorrhoea, 
and a complete agreement with a histological diagnosis of PCO on review of the slides by 
a histologist blind to the original diagnosis. Biochemical evidence of PCOS (raised 
androgens or a raised LWFSH ratio) was considered a desirable additional criterion, but 
this was not made an absolute requirement. Control ovaries were defined as nonnal, if the 
initial histology report stated that the ovaries were "nonnal" or had follicle cysts less than 
2cm in diameter (without the other stigmata of PCO) and if the women had documented 
evidence of regular menstrual cycles at the time of surgery. These slides were also 
verified by the histopathologist. Ovaries with malignancy, endometriosis, large ovarian 
cysts or from women on sex steroids at the time of their surgery were excluded from the 
study. 
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INCLUSION CRITERIA USED FOR LABORATORY STUDIES OF PAI-l PROTEIN 
AND mRNA IN PCOS ( Study Group Ill) 
PCOS CONTROLS 
Documented history of oligomenorrhoea or Regular menstrual cycles 
amenorrhoea. 
Histological features of polycystic ovaries Normal ovaries on histology. 
+/- Documented biochemical evidence of PCOS or ovaries with folliclular cysts 
(raised androgens and raised LHIFSH ratio) without other features of PCOS 
EXCLUSION CRITERIA FOR STUDY GROUP Ill 
Benign ovarian cysts > 2cm 
Malignant ovarian neoplasia 
Endometriosis 
DATA COLLECTION, ASSAYS AND LABORATORY TECHNIQUES 
Details were obtained from the subjects recruited into the clinical studies by direct 
interviews and recorded on standard proformas (appendices 1 &2). The information 
obtained included their age, menstrual, obstetric, medical, family and social histories and 
details about their smoking and alcohol intake. Hirsutism was assessed with a Ferriman 
Gallwey chart, and their heights, weights, blood pressures and waist and hip 
circumferences were measured. Fasting blood samples were taken for P AI -1 and other 
components of the PAS, testosterone, SHBG, LH, FSH, oestradiol and DHEAS in the pilot 
study (Group I) and in addition to these, prolactin, 17-hydroxyprogesterone, insulin, 
glucose and lipids in the main clinical study (group 11). 
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Insulin sensitivity (the degree of insulin resistance) was assessed using a Homeostatic 
Model Assessment (HOMA) computer programme obtained from Dr Jonathan Levy at the 
University of Oxford department of Clinical Medicine. This model is a structural 
computer model of the glucose/insulin feedback system. lt incorporates mathematical 
descriptions of the functions of the various organs involved in plasma glucose control and 
their interactions, based on empirical data of fasting insulins and glucose from subjects in 
the Oxford population. lt provides a model of physiological reality in a "reference 
individual" in that it will find the equilibrum point of plasma glucose, insulin, C-peptide 
and proinsulin in the fasting state. It has two key parameters, which are pancreatic beta 
cell function (%B) and peripheral and hepatic insulin sensitivity (%S). The model can 
predict the plasma glucose, insulin, C peptide and proinsulin for any possible combination 
of these two parameters in the fasting state. Since any one combination of a particular %B 
and %S is associated with only one combination of glucose, insulin, C-peptide and 
proinsulin, it is possible to determine from an individual's plasma concentrations glucose 
and either insulin or C-peptide the particular combination of %B and %S that would have 
produced them. Insulin sensitivities were thus calculated for the subjects in this study 
using their fasting glucose and insulin levels. The insulin results were first converted from 
their original units in mUlL to pmol/L before entry into the model and the conversion 
factor used was X 7.24. 
More details about the exact assays performed and the laboratory techniques can be found 
in the relevant data chapter. Ultrasound scans were performed as detailed below either on 
the same day or at a later date. Following this the participants were thanked and allowed 
home. Any abnormal findings were discussed with the patient, and their General 
Practitioner was informed. 
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Ovarian biopsies from the women in study group Ill were tested for PAI-l protein with the 
steptavidin-biotin method using a monoclonal antibody to PAI-l and PAI-lmRNA was 
evaluated by in-situ hybridisation using a cocktail of digoxigenin labelled oligonucleotide 
probes. More details about these techniques can be found in the relevant data chapters. 
ULTRASONOGRAPHY 
Transvaginal or abdominal ultrasound scans were performed according to the patient's 
preference, but they were informed that visualisation of the ovaries was easier using the 
vaginal route. 7.0 MHz and 3.5MHz transducers were used for the vaginal and abdominal 
ultrasound scans respectively. For the vaginal ultrasonography, the women were requested 
to empty their bladders before the procedures, and asked to lie supine on a couch with a 
wedge to support the pelvis. The transducer was lubricated with KY jelly, protected in a 
sheath and re-lubricated with KY jelly, following which it was introduced into the vagina. 
The time-gain compensatory curve controls were adjusted on the console to improve the 
image quality, the uterus was first examined in the sagittal and coronal plains and the 
maximum endometrial thickness was measured. Next the ovaries were examined. The 
maximum diameter of the ovary was identified, and measured to provide the length. The 
probe was then turned through an angle of 90 degrees to provide measurements of the 
ovarian width and thickness. The numbers of follicles in each ovary were counted and 
measurements of the diameters of the largest and smallest follicles were taken in the 
vertical plane. The distribution of the follicles was noted, and the stromal echogenicity 
was defined subjectively by comparing it to the echogenicity of the uterine wall. Any 
other abnormalities in the pelvis were also noted. 
At the end of the procedure, the probe was removed from the vagina, the sheath removed 
and discarded and the probe cleaned with methylated spirit. 
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For the abdominal ultrasound scans, patients were requested to arrive with a full bladder 
for adequate visualisation of the pelvic organs. The women were asked to lie supine on a 
couch with the suprapubic region exposed. Paper towels were used to protect garments. 
Coupling gel was spread over the transducer that was then placed over the lower abdomen 
in the mid-line just above the pubic hairline. The time-gain compensatory curve controls 
were adjusted on the console to improve the image quality, and the pelvis was scanned in 
longitudinal and transverse sector planes. The uterus was identified and measurements 
made of the endometrial thickness. The ovaries were then visualised in turn using the 
ovarian vessels as reference points and measured as described above. The pelvis was also 
inspected for other abnormalities. During the examination, the ultrasound findings were 
discussed with the patients and any questions answered. At the end of the examination 
they were allowed to empty their bladders and any further questions were answered. 
DEFINITIONS 
General Considerations 
The selection criteria for the definition of PCOS for this thesis had to be decided against 
the background controversies in the definition outlined in chapter 2. The main 
considerations were 
I) Choosing selection criteria with good sensitivity for the diagnosis of PCOS 
2) The ability to compare results with previously published data on similar studies on 
women with PCOS. 
3) The need to use evidence of anovulation (from a history of oligo or amenorrhoea) in the 
inclusion criteria because one of the aims of the studies in this thesis was to consider the 
role of PAI-I in anovulation in PCOS. 
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Two cross sectional studies were published before the onset of recruitment for the large 
clinical study (Dahlgren et al 1994, Sampson et al 1996). In both cases, the diagnosis of 
PCOS was made on a combination of ovarian morphological appearance of polycystic 
ovaries (on histology in one case and ultrasound in the other) and menstrual disturbance. 
Hyperandrogenaemia was not specifically used as a selection criterion. 
Ultrasound Definition of Polycystic and Normal Ovaries 
The diagnostic value of each ultrasound parameter has been difficult to assess since there is 
no gold standard for the diagnosis of the polycystic ovary syndrome phenotype. Although 
polycystic ovaries were initially defined as the presence of 1 0 or more 2-8mrn follicles 
distributed around the periphery or all over the ovary associated with the presence of an 
increased and highly echogenic ovarian stroma on abdominal ultrasound (Adams et al 
1985), it is not clear how these parameters were derived. Ovarian enlargement was also 
included as one of the features of PCO in this study as the mean ovarian volume was 
14.6cm3 in the PCO group compared to 8 and 6.4 cm3, in women with multifollicular and 
normal . ovaries respectively, but the upper limit of "normal" was not defined. 
Subsequently, a diversity of sonographic criteria has been used for the diagnosis of 
polycystic ovaries (Yeh et al 1987, Pache et al 1992, Robert et al 1995), with various 
sensitivities for the detection of the PCOS phenotype (table 3.2). This is not surprising 
given the heterogeneity of the PCOS phenotype. Although the original description of PCO 
was made following abdominal ultrasound scan, many studies have since used transvaginal 
ultrasound for the diagnosis of PCOS. There have been attempts to objectively define the 
vaginal ultrasound features ofPCOS and in one such study, Fox evaluated 10 women with 
a PCOS phenotype defined as a combination of hirsutism and abnormal menstruation and 
20 non-hirsute women with normal cycle length {Fox R 1992e). He found that the women 
with normal menstrual cycles had up to 12 small follicles(< !Omrn) in each ovary with 
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little stroma and all but one of the hirsute patients had increased numbers of small follicle 
with abundant stroma. Because of this diversity in the ultrasound diagnosis of PCOS, 
Dewailly and colleagues in 1993 evaluated the sensitivity and specificity of various 
ultrasound criteria. They concluded that increased ovarian stroma (assessed by 
computerised quantification) was the most valuable diagnostic probe for PCOS. However 
in a further study, 45% of patients with the clinical phenotype of PCOS, had an ovarian 
area which overlapped the range found in controls and patients with hypothalamic 
anovulation (Dewailly et al 1994). This suggests that although ovarian hypertrophy at 
ultrasound is suggestive of PCO, its absence does not exclude the diagnosis. This 
statement is supported by the finding that in the only study using histological correlation's 
to assess the accuracy of the ultrasound diagnosis of PCO (Saxton et al 1990), using the 
criteria originally defined by Adams et al in 1985, there was a perfect correlation between 
the number and distribution of cysts on ultrasound and on histology. However, stromal 
hyperplasia was only present in 61% of the polycystic ovaries. 
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Table 3.2 Sensitivities Of Some Of The Ovarian Sonographic Criteria Used In The Diagnosis Of PCOS. 
Authors Ultrasound Ultrasound Parameter Criteria indicative Sensitivity for PCOS 
Route ofPCO phenotype 
Yeh et al 1987 Abdominal !Number of follicles 5-8mm size > 5 74% 
Pache et al 1992 Vaginal Ovarian volume > 8cm3 70% 
Number of follicles< 6mm >11 70% 
Mean Follicular size <4mm 70% 
Increased stromal echogenicity Present 94% 
Robert et al Vaginal Increased stromal area > 7.6cm3 61% 
1995 Increased maximum ovarian area > 10.8 cm3 55% 
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Against the background of these controversies in the morphological diagnosis of PCO, 
polycystic ovary for these studies was defined as the presence of I 0 or more 2 to 8mm 
follicles distributed around the periphery or all over the ovary associated with the presence 
of a bright ovarian stroma (See figure 3.1 ). In the presence of a stroma of equivocal 
echogenicity, either the presence of an enlarged ovary (volume of> 9cm 3) or a peripheral 
distribution of ovarian follicles, in addition to the other criteria was taken as indicative of 
polycystic ovaries. These criteria were chosen because they were consistent with the 
criteria stipulated by Adams and colleagues in their original definition of PCOS. Stromal 
echogenicity was not made a stringent criterion because of the subjectivity of its 
evaluation. Normal Ovaries were defined as those with less than I 0 follicles and with at 
least one follicle of a maximum diameter greater than 8mm. 
Menstrual Pattern 
Generally, there is no widely accepted definition of a normal menstrual cycle in terms of 
cycle length, and there do not appear to be any prospective studies looking at fertility rates 
in women with extreme degrees of cycle length and variability. In this thesis, 
oligomenorrhoea was defined by the presence of a history of an average cycle length of 3 5 
days or more with variability between cycles of 10 days or more of at least 6 months 
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Figure 3.1 Vaginal Ultrasound Scan Of A Polycystic Ovary 
Figure shows a polycystic ovary in longitudinal section. Note the numerous numbers of 
small follicles distributed around the periphery of the ovary, the increased stromal 
echogenicity and ovarian enlargement. 
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duration. This limit was set because the upper limit of nonnal for a menstrual cycle length 
is arbitrarily defined as 5 weeks (Hull & Abuzeid 1992) and this definition is consistent with 
the only cross-sectional study of PCOS and P AI -1 where menstrual pattern had specifically 
been incorporated in the definition of PCOS (Sampson et al 1996). Amenorrhoea was 
defined as the absence of periods for six months or more. For study group m, where this 
infonnation was derived from the hospital records (see case selection below) a 
documentation of a history of oligomenorrhoea or amenorrhoea was accepted regardless of 
the duration. Nonnal menstrual cycles were defined as spontaneous menstrual cycles with 
a duration of2l-35 days with less than a 10-day variability between cycles. 
Histological evidence of Polycystic ovaries 
This was defined as ovaries containing multiple cystic follicles of approximately equal size 
situated superficially beneath a thickened outer ovarian cortex with little or no evidence of 
ovulation as determined by the presence of corpora lutea or corpora albicantia. These 
criteria were consistent with those used in the first study looking at some components of 
the PAS (PAI-l and fibrinogen) in women with PCOS (Dahlgren et al 1994). In that study, 
PCOS was histopathologically defined from ovarian biopsies from women who underwent 
wedge biopsies 25-34 years before the study. 
Polycystic Ovary Syndrome 
The definition of PCOS in this thesis was based on a the presence of a combination of a 
morphological appearance of polycystic ovaries as defined above (on ultrasound for the 
clinical studies, and on histology for the laboratory based studies) and a clinical finding of 
oligo or amenorrhoea, with other possible causes of oligo or amenorrhoea ruled out by 
specific endocrine tests. Despite the non-inclusion of hyperandrogenaemia in the 
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definition, women with PCOS in the clinical studies had significantly higher free 
androgens (measured by the free androgen index), and Ferriman Gallwey scores than the 
control groups providing reassuring evidence that the inclusion criteria used for this study 
were satisfactory for the diagnosis of PCOS (see tables 4.1 and 5.1). 
In this thesis, the terms "insulin resistance" and "reduced insulin sensitivity" are 
synonymous. Thus low insulin sensitivity implies increased insulin resistance. 
DATA STORAGE AND GENERAL STATISTICAL METHODOLOGY 
The data from each subject was stored on individual proformas (see appendix I ,2 &3) and 
subsequently transferred into a spreadsheet (microsoft excel) for basic data analysis after 
the exclusion of identifying data. Sample size calculations were performed prior to the 
large clinical study. The distribution of continuous variables was identified using a normal 
probability plot. Parametric data (normally distributed) were described by their means and 
standard deviations (SD), and the probability of differences between groups of normally 
distributed data being the result of chance was tested with an unpaired student's t test. 
Non-parametric data were described by their median and range, and the difference between 
groups of non-parametric data was tested with a Mann-Whitney U test. Some of the 
measured variables had a very limited range of values and for these neither a t-test nor 
Mann Whitney test was appropriate. In these cases, Fisher's exact test was used to 
compare the proportions of 'high' values for the groups. An analysis of covariance was 
used to evaluate the effects of possible confounding variables on dependent variables. A 
Pearson's correlation coefficient was used to test the relationship between groups of 
normally distributed data. A multiple regression analysis was used where indicated to 
evaluate the effects of potential independent variables on a dependent variable. A p value 
of 5: 0.05 was accepted as statistically significant. 
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CHAPTER FOUR 
THE PLASMINOGEN ACTIV ATIOR SYSTEM IN WOMEN WITH 
POLYCYSTIC OVARY SYNDROME (PILOT STUDY). 
OUTLINE 
A pilot study 1s described in which plasminogen activator inhibitor-! (PAI-l), 
plasminogen, fibrinogen and oc-2 antiplasmin concentrations and euglobulin clot lysis 
times (ECL T) were determined in a group of oligomenorrhoeic women with polycystic 
ovaries and compared with a control group of women who had regular menstrual cycles 
and normal ovaries on ultrasound. 
INTRODUCTION 
As discussed in chapter 2, insulin resistance and a corresponding elevation in PAI-l in the 
PCOS may contribute to an increased risk of thromboembolic disease, anovulatory 
infertility and miscarriage. Prior to this pilot study, there was only one published cross-
sectional study on PAI-l in the PCOS (Dahlgren et al 1994), and in the study, 28 peri-
menopausal women with PCOS and 56 age and weight matched controls had metabolic 
and haemostatic variables evaluated. No difference was found in systemic PAI-l between 
28 women with PCOS and 56 controls, and there was also no difference in the fasting 
insulin levels between both groups in the study. This may have been partly explained by 
the fact that 20% of the control population had hypertension suggesting that there was a 
high prevalence of metabolic disorders possibly because most women in the study were in 
their fifties when the prevalence of these metabolic disorders rise. 
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This pilot study was performed to determine whether elevated PAI-l levels were present in 
PCOS, determine the feasibility of a larger definitive study and provide baseline data for 
sample size calculations prior to it 
SUBJECTS AND METHODS 
Eleven women with the PCOS and 12 controls took part in this study (group I as 
described in chapter 3). The study design and patient recruitment are described in 
chapter 3. These women were requested to come up to the hospital for the study 
between 8 and lO am in the morning because of the diurnal variation in PAl-l (Juhan-
Vague et al 1992) and participants were requested to fast overnight and refrain from 
smoking from midnight. On arrival at the hospital, their weights and heights were 
recorded and they were then sat upright or in a supine position for 15 minutes during 
which clinical details were obtained (age and menstrual, obstetric, medical, family and 
social histories). They were given a Ferriman Gallwey chart (Ferriman D & Gallwey J 
1961) to score their perceived hirsutism. 
Then, 18 to 20 ml of blood were taken from an antecubital vein on the left forearm with 
minimal or no venous occlusion into four to five citrate tubes for ECLT, PAI-l, 
fibrinogen, plasminogen and a-2antiplasmin (prolonged venous occlusion can stimulate 
the production of tissue plasminogen activator (tPA) and PAI-I from the endothelial cells). 
Five mL of blood were collected into a separate tube for testosterone, SHBG, LH, FSH, 
oestradiol and DHEAS assays. Blood pressure was then checked on the right arm and the 
sphygmomanometer cuff was inflated midway between systolic and diastolic pressures for 
I 0 minutes. After this test, another 18 to 20 mL of blood were collected from below the 
cuff for post-venous occlusion samples. Tables 4.1 and 4.2 show the clinical and 
biochemical features of both groups and provide confirmation that the recruited subjects 
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had PCOS. 
Table 4.1- Clinical Variables For Patients With PCOS Versus Controls. 
Clinical Variable : PCOS (n:;:; 11) 
) 
Controls (n= 12) ; P 
' 
: 
.... 
Mean Age± SD (y) 27 ± 3.6 31.8 ± 7.3 0.06 
Mean BMI ±SO 31 ± 5.3 25.9 ± 2.6 0.003 
(kg/m2) 
Median hirsutism score 8 (1-22) 1 (0-8) 0.003" 
(range) 
Median cycle length in 20.75 (7.5-104) 4 ( 3.7-5.0) 0.0000 
weeks (range) 7. 
Number with history of 7 (64%) 4 (33%) 0.22 
Subfertility (%) 
Number of nulliparas 7 (64%) 7 (58%) 1.0 
(%) 
Number with previous 2 (18%) 3 (25%) 1.0 
miscarriage(%) 
Number of smokers 4 (36%) 4 (33%) 1.0 
(%) 
Number of alcohol 2 (0-8) 3 (0-14) 0.49. 
units/wk (range) 
Mean systolic blood 123 ± 14 114 ± 15 0.14 
pressure ± SO (mmHg) 
Mean diastolic blood 82.7 ± 6 72.7 ± 9.9 0.008 
pressure ± SO (mmHg) 
NOTE. BMI = body mass index , * = Determined by the Mann Whitney U test. 
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. Table 4.2 - Hormonal variables for patients with PCOS versus controls. 
llormonul Variable JlCOS (n = 1 J) : Controls (u = 12) p 
' 
Mean FAI ± SD 11.02 ± 8.21 2.2 ± 0.9 0.0053 
Mean SHBG ± SD (nmol/1) 30.4± 17 54.5 ±27 0.02 
Mean Testosterone± SD (nrnol/L) 2.67±1. 1 1.19 ± 0.7 0.001 
Mean DHEAS ± SD (Jlmol/L) 10.8 ± 4.5 7.4 ±2.7 0.04 
Median oestradiol (pmol/L) 82 (46- 463) 135.5 (20-353) 0.93. 
(range) 
Median FSH (U/L) (range) 4.6 (1.8-5 .2) 4.55 (2.9-23.1) 0.44. 
Median LH (UIL) (range) 7.0(1.1-13.5) 4.05 (1.6-36.4) 0.23. 
Mean LHIFSH ratio ± SD 1.7 ± 0.9 1 ± 0.43 0.03 
* Determined by the Mann Whitney U test. 
F AI = Free androgen index. (testosterone I SHBG x I 00) 
SHBG = sex hormone binding globulin DHEAS = Dehydroepiandrosterone sulphate 
FSH = Follicle stimulating hom1one LH = Luteinizing hormone 
The samples for ECLT, PAI-l , fibrinogen, plasminogen and a.-2-antiplasmin were 
immediately placed on ice and centrifuged within 30 minutes of collection at 2000g for 15 
minutes at 4 °C. Hormonal assays were performed in the combined laboratory at Derriford 
Hospital in Plymouth. Plasma was frozen at -70 °C and tested within three months for 
PAI-l activity, alpha-2 anti-plasmin and plasminogen concentrations. ECLT were 
measured immediately on fresh plasma. 
80 
Laboratory Assays 
The PAS is assessed using tests that measure a combined effect of plasminogen activators 
and inhibitors such as the euglobulin clot lysis time (ECL T), or fibrin plate lysis and specific 
assays of the activators and inhibitors of this system and the change in the values of these 
factors in response to venous occlusion which stimulates fibrinolysis. 
ECL T was performed as previously described (Dacie & Lewis 1995). The principle of this 
assay is that plasma is diluted and acidified forming a precipitate (euglobulin) which 
contains plasminogen activator, plasminogen and fibrinogen. Most of the inhibitors are left 
in the solution. The precipitate is re-dissolved, the fibrinogen clotted with thrombin and the 
time for clot lysis measured. The normal range for this assay is 90 - 240 minutes. 
PAI-l activity was tested using a commercially available chromogenic assay 
(Chromogenix, Sweden). The principle of this assay is that a fixed amount oft-PAis added 
in excess to undiluted plasma, where part of it rapidly forms an inactive complex with PAl-
I. In the presence of a stimulator, the residual t-PA activates plasminogen to plasmin. The 
amount of plasmin formed is inversely proportional to the PAl-l activity in the sample. 
The amount of plasmin is determined by measuring the amidolytic activity of plasmin on a 
chromogenic substrate S-2403. The release of p-nitroaniline (pNA) is determined at 
405nm. The range of normal values for PAI-l is less than 15 arbitrary units per millilitre 
(aulml). The intra-assay coefficient of variation for this assay was 2.4% at a level of 12 
aulml, and 0.4% at 23 aulmL while the inter-assay coefficient of variation 7.6% and 1.6% 
at 12aulmL and 23 aulmL respectively. 
Plasminogen and a-2 antiplasmin levels were also tested using chromogenic assays 
(Instrumentation Laboratory, Milano Italy). The principle of the plasminogen assay is that 
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an excess of streptokinase is added to diluted plasma. The plasminogen present will 
combine with streptokinase fonning a complex with plasmin-like activity. This acts on a 
chromogenic substrate releasing pNA, which is monitored at 405nm and is directly 
proportional to the plasminogen level. The normal range for this assay is 80 to 120% and 
the sensitivity 15%. In the a-2 antiplasmin assay, diluted plasma samples are incubated 
with an excess of plasmin. a-2 anti plasmin has a powerful and rapid plasmin - inhibitory 
potential, and the residual plasmin is measured by its activity on a chromogenic substrate. 
The amount of the pNA released is inversely proportional to the a-2 antiplasrnin level. The 
normal range of this assay is 80 to 120% and the sensitivity 15%. 
Fibrinogen concentration was tested using an automated coagulation laboratory analyser 
(Instrumentation Laboratory, Milano, Italy) which measures the intensity of light scattered 
by a plasma sample before during and after clot formation. The light scatter reached at 
equilibrum is proportional to the fibrin concentration and therefore the total clottable 
fibrinogen. The normal range is 2 to 6 g/1. 
FSH and LH concentrations were tested using the Amerlite enhanced luminesence method 
(Johnson and Johnson, New Brunswick, NJ, USA). 
Serum DHEAS, serum testosterone, oestradiol and SHBG levels were tested using 
radioimmunoassay kits (Johnson and Johnson, New Brunswick, NJ, USA; Medgenix, 
Cheveus, Belgium; Sorin diagnostics, Salluggia, Vercelli, Italy and Farmos diagnostics, 
Espoo, Finland respectively). 
Free androgen index was calculated using the formula (Testosterone/ SHBG x 100). 
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The inter and intra -assay coefficients of variation for all these assays were less than 9% and 
the sensitivities for testosterone, DHEAS, SHBG, oestradiol, LH and FSH were 
0.2runoi!L, 0.4 Jlmoi/L, Snmoi!L, 16.5 ± 2 pmoi/L, 0.2 lUlL, and 0.5 IUIL respectively. 
All of these assays were subjected to regular external quality assessment schemes apart 
from ECLT and PAI-l, which were not routinely performed in the coagulation laboratory. 
Statistical analysis 
Means and standard deviations were calculated for the clinical and biochemical variables, 
and for the assays of the PAS (tables 4.1-4.3). The analysis used to compare the two 
groups depended on the distribution of the variables. For those variables where probability 
plots indicated a normal distribution, a student's t-test was used to compare the means. 
Two other variables, oestradiol and LH (U/L) were 'normalised' by the removal of an 
outlier. Where appropriate, t-tests took account of any differences in standard deviations 
between the two groups. For variables which were clearly not normally distributed 
according to a normal probability plot (hirsutism score, cycle length, alcohol intake, 
oestradiol, FSH, LH, basal ECLT, post venous occlusion ECLT, and post venous occlusion 
PAI-l activity), a Mann-Whitney U test was appropriate for comparing the two groups. 
Some of the measured variables had a very limited range of values and for these neither at-
test nor Mann Whitney test was appropriate. In these cases, Fisher's exact test was used to 
compare the proportions of 'high' values for the two groups. An analysis of covariance 
was used for plasminogen activator inhibitor- I to take account of the possible effect of 
BMI and testosterone as confounding variables. A p value s 0.05 was accepted as 
significant. 
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RESULTS 
Women with PCOS were significantly younger and had a greater BMI compared with the 
. 
controls (Table 4.1 ). They also had significantly higher Ferriman Gallwey scores, cycle 
lengths, free androgen index, testosterone, DHEAS, LHIFSH ratios and lower SHBG 
levels (Table 4.1 & 4.2) and the diastolic blood pressures were significantly higher in the 
PCOS group. Table 4.3 shows the results of assays of the PAS (see appendix I for all the 
individual results). The mean basal PAI-l activity and the mean basal fibrinogen 
concentrations were significantly higher in the women with PCOS than in controls 
(p=0.049 and 0.004 respectively). The mean pre-venous occlusion ECL T was longer in 
the women with PCOS (p=0.016). 45% of the women with PCOS had a blunt response to 
the venous occlusion test as compared to 9% in the control group (p = 0.06). A blunt 
response to the venous occlusion test was defined as less than a 28% reduction in ECL T. 
This was based on data from a previous study (Gris et al 1993) in which a control 
• 
population of 90 apparently healthy women was used to define a normal response to the 
venous occlusion test. A reduction in ECL T of less than 28% was below the first 
percentile. There was a very close positive correlation between ECL T and PAI-I levels in 
both groups (r = 0.88 in controls and r = 0.90 in women with PCOS). 
The effect of possible confounding variables (body mass index, and testosterone) on PAI-l 
was assessed by applying an analysis of eo-variance to PAI-l with body mass index and 
testosterone as co-variates. In all cases no significant difference between the control and 
polycystic ovary syndrome groups was found when either one or both of these variables 
were included as a co-variate. 
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Table 4.3 - Assays of the plasminogen activator system for patients with PCOS versus 
controls. 
.,...\ssay Paranu·t~r rcos (n = 11) Controls (n = 12) I) 
Med b I ECLT( 1an asa ) range m mmutes - -412 5 (120 577) 187 5(105 420) 0.016 
Median post VO ECL T 150 (45-562.5) 82.5 ( 45-405) o.055. 
(range) in minutes. 
Mean basal fibrinogen concentration ± 4 .02 ± 0.64 3.18 ± 0.6 0.004 
SD (g/L) 
Mean post VO fibrinogen 4.66 ± 0 .7 3.8 ± 0.6 0.007 
concentration± SO (g/L) 
Mean basal PAI-l activity± SO 19.7 ± 12 10.9 ± 7.9 0.049 
(au/ml) 
Median post VO PAI-l activity ± SO 16 (4-37.5) 8 (1 .5-26) 0.116. 
(au/ml) 
Mean basal plasminogen level ± SO 96 ± 21 95 ± 8 0.095 
(%) 
Mean basal alpha 2 a-plasmin level ± 103 ± 6.7% lOO ± 8.8% 0.38 
SD(%) 
vo == Venous occlusion 
ECLT == Euglobulin clot lysis time 
PAl- 1 == Plasminogen activator inhibitor- I 
A-plasmin == antiplasmin 
* == Determined by the Mann Whitney U test 
85 
DISCUSSION 
The cross sectional design of this pilot study was chosen to determine if elevated PAI-l 
was present in PCOS compared with a similar control group and the results showed that 
women with PCOS had a longer baseline ECL T, a blunt response of the ECL T to the 
venous occlusion test, and a higher PAI-l activity which implied that women in the PCOS 
group had an impaired plasmin producing capacity compared to the controls. The ECL T is 
a reflection of all components of the fibrinolytic system and the very close correlation 
between PAI-l and ECLT on linear regression does suggest that the ECLTs were largely 
determined by PAI-l levels. However it is important to note that tissue plasminogen 
activator (tPA) was not measured in this study and the other measured components of the 
PAS were not evaluated in a multiple regression analysis to determine which of them best 
predicted the ECL T. These were not thought to be necessary in this pilot study. 
The selection of the study group may be criticised on the grounds that most of the 
ultrasound scan procedures for the diagnosis of polycystic ovaries had been transvaginal 
while the criteria used in the selection of the PCOS group were those described by Adams 
and colleagues in 1985, using abdominal ultrasound scans and that the definition of PCOS 
should have incorporated biochemical evidence of hyperandrogenaemia. However the 
endocrine characteristics of the PCOS group included an elevated free androgen index and 
a raised LH/FSH ratio which were consistent with the diagnosis of PCOS (Franks 1995). 
Although the women with PCOS were younger than the controls, it is unlikely that this 4-
year difference in mean age could have been responsible for the observed results in this 
relatively young age group. On the other hand, as demonstrated by the analysis of eo-
variance, the results may have been explained by the greater BM! in the PCOS group, as 
obesity is associated with impaired fibrinolysis and elevated PAI-l levels (Ogston et al 
1964, Vague et a! 1989). However in a paper subsequently published just after the 
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completion of data collection for this study (Sampson et at 1996), PAI-l was raised in 24 
non-obese women with PCOS and extreme menstrual disturbance compared with 10 age 
and weight-matched controls with regular menstrual cycles suggesting that elevated PAI-l 
was present in PCOS independent of BMI. This issue is addressed in the next chapter 
where controls of a similar BMI to women with PCOS were recruited. 
It would have been ideal to measure insulin resistance in this pilot study so as to evaluate 
the relationships between PAI-l and insulin in these women. However a positive 
correlation between fasting insulin concentrations and PAI-l was shown in the 2 papers 
published on PAI-l and PCOS before this study (Dahlgren et at 1994, Anderson et at 
1995) and this was not thought to be necessary for the purposes of this pilot study. The 
elevated diastolic blood pressure found in the PCOS group is consistent with the metabolic 
syndrome X, but in this instance it may have been a reflection of the increased BMI in the 
PCOS group, as obesity is a risk factor for hypertension. 
In summary, this pilot study found a prolonged ECLT and elevated PAI-l levels in 
oligomenorrhoeic women with PCOS compared to controls with regular menstrual cycles, 
although women with PCOS were more obese which may have biased the results. These 
results not only implied that women with PCOS were at increased risk of thromboembolic 
disease, but it also suggested an alternative explanation for the pathophysiology of 
anovulation and miscarriage in them, in which the balance in the plasminogen activator 
system from elevated PAI-l levels results in the deficient formation of plasmin. As 
plasmin is required for extracellular proteolysis this would lead to impaired follicular 
rupture, anovulation, failed implantation and miscarriage. It was then clearly important to 
establish whether elevated PAI-l was present in PCOS independent of BMI and this issue 
is addressed in the next chapter. 
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CHAPTER FIVE 
PLASMINOGEN ACTIVATOR INHIBITOR-I (PAI-l) AND METABOLIC 
FEATURES OF POLYCYSTIC OVARY SYNDROME (PCOS). 
OUTLINE 
The results of a definitive study measuring systemic PAI-l activity and other factors in the 
plasminogen activator system, are presented and discussed. The inter-relationships 
between PAI-l, and metabolic aspects of the insulin resistance syndrome in women with 
PCOS and controls are also evaluated. 
INTRODUCTION 
In the previous chapter, a pilot study showed that women with PCOS had a significant 
elevation in PAI-I activity and a prolongation of euglobulin clot lysis times (ECLTs) 
compared to a control group of women without PCOS. The results were consistent with 
the hypothesis that an insulin mediated elevation in PAI-I may increase the risk of 
atherothrombosis in women with PCOS and contribute to their anovulatory infertility and 
recurrent pregnancy loss by limiting the plasmin mediated proteolysis required for these 
processes (Beers 1975, Sappino et al 1989, Gris et al 1993, Patrassi et al 1994, Tsafiri et al 
1989). Because the results of the pilot study may have been biased by a significant 
increase in body mass index (BM!) in the PCOS group and because obesity is related to 
PAI-l and impaired fibrinolysis ((Ogston et al 1964, Vague et al 1989), this study was 
performed to measure systemic PAI-l activity in a larger number of women with and 
without PCOS, and to determine whether elevated PAI-l levels were present in 
oligomenorrhoeic women with PCOS independently of BM!. In addition, the relationship 
between metabolic aspects of the insulin resistance syndrome (syndrome X) such as 
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obesity, insulin resistance and lipids and PAI-l activity were assessed. The null 
hypothesis was that the mean PAI-l activity in oligomenorrhoeic women with PCOS was 
not different from regularly menstruating controls of a similar BMI. 
SUBJECTS AND METHODS 
This was a cross sectional study comparing women with PCOS to controls of a similar 
BMI. Prior to the study, a sample size calculation was performed based on the following 
factors. 
I. o, the minimum detectable difference between population means. 
2. cr2, the population variance expected from the data. 
3. a, the significance level at which the probability of a type I error (i.e. falsely rejecting 
the null hypothesis) was acceptable, and 
4. 1-p, the power of the test to detect a difference between population means (where p is 
the probability of committing a type II error of falsely accepting the null hypothesis). 
In considering what minimum detectable difference between population means (o) to set 
for our study, it was felt that a difference associated with a clinical finding of PCOS was 
desirable. Prior to the pilot study, there had been no study showing a difference in mean 
PAI-l activity between women with PCOS and controls. The pilot study showed a 
difference of mean PAI-l activity of 9aulml between women with PCOS and controls, 
therefore the 8 was set at this level. The standard deviations of 7.91 in the control group 
and 12.05 in the PCOS group obtained in the pilot study were used to calculate the 
variance (cr2) expected from the data. The a was set at 0.05 (5%) based on the usual 
convention (Zar J 1996), and calculations were performed using a statistical computer 
programme for studies with powers (I-P) ranging from 84-99.9% (see table 5.1 ). 
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Table 5.1: Power of a two-sample t-test to detect a 9au/ml difference of mean PAI-l 
activity between women with PCOS and controls. 
SnmpJc Sizes P()wer O·Pl 
nl= l5 , n2=30 84 
nl=25, n2=40 95 
nl=30, n2=50 98 
ni =40, n2=60 99.5 
nl =50, n2=75 99.9 
n1=controls, n2 = PCOS. 
By convention, the p in sample size calculations is usually set at 10 or 20% (Swinscow 
TDV 1996). It was therefore decided desirable to recmit 30 to 40 women with the PCOS 
and 15 to 25 controls for this study as this was expected to provide a study with at least 
84% power to detect a difference of 9 au/ml in PAI-l activity between the two groups with 
a 5% chance of a type I error and less than a 20% chance of a type IT error. 
Data collection. 
The patient recruitment, inclusion and exclusion criteria for PCOS and controls and the 
method of data collection are as described briefly in chapter 3. During the recruitment 
process, controls of an increased BMI were specifically sought from the local dieticians 
clinic and from amongst female members of staff to ensure that the BMI in both groups 
were similar, as it was expected that women with PCOS would have an above average 
BMI as was the case in the pilot study. 
Tables 5.2 and 5.3 show the results of the clinical and endocrine features of both groups. 
The findings in the PCOS group were consistent with the diagnosis including higher 
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Ferriman Gallwey scores, free androgens index, LH levels, and they were more likely to 
have a positive history of infertility. Interested participants were requested to come in to 
the hospital fasted, having refrained from smoking from 12.00 midnight the day before the 
tests. All the tests were carried out between 7.30 and I 0.00 am in the morning to minimise 
the diurnal variation in PAI-l levels ( Juhan-Vague et al 1992). On arrival at the hospital, 
written consent was obtained, and the patients were rested sitting for I S minutes during 
which clinical details were obtained (age, menstrual and obstetric histories, medical and 
drug history, family history and a Ferriman Gallwey score for hirsutism performed). 
Blood was then taken from an antecubital vein of either forearm with minimal or no 
venous occlusion for PAI-l, tPA, plasminogen, fibrinogen, a-2 antiplasmin, glucose, total 
cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, insulin, testosterone, LH, 
FSH, SHBG, prolactin and 17 hydroxy progesterone. The samples for PAI-l, tP A, 
plasminogen, fibrinogen and alpha-2 antiplasmin were placed immediately in an ice tray, 
following which their blood pressures were checked on the opposite arm using the 
appropriate size cuff according to the mid arm circumference and using Korotkoff IV 
sounds as the diastolic blood pressure. The mid arm circumference was taken as a point 
midway between the acromion and the elbow, and a large blood pressure cuff was used if 
it was greater than 3Scm. The blood pressure cuff was left inflated midway between 
systolic and diastolic pressures for 10 minutes or however long the women could tolerate it 
for. Following this, post-venous occlusion samples were taken mainly for tP A and kept 
immediately on ice. 
The blood pressure cuff was then deflated and their heights, weights, waist circumference 
and hip circumference were checked. The waist and hip circumferences were measured 
with the patients wearing indoor clothes. Height was measured in metres using a soft tape, 
body weight was measured in kilograms to the nearest 0.1 kg and the BM! thus calculated 
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as weight I height2 . Waist circumference was measured with the women wearing indoor 
clothes at the level of the umbilicus, and the maximum hip measurement at the level of the 
greater trochanters was used as the hip circumference. The waist/hip ratio was thus 
derived from these measurements. Following this a separate appointment was made for 
the ultrasound scan where this was not possible on the same day. The blood samples were 
then taken to the laboratory for separation, storage and analysis. 
Table 5.2 - Clinical variables for patients with PCOS versus controls. 
Clinicnl Variable PCOS (n=41) Controls {n = 25) p 
Mean Age ± SO (y) 28.4 ± 5.9 32 ± 5 0.01 
Mean BMI ± SO (kg/m2) 29.5 ± 5.6 28.4 ± 6.3 0.25 
Mean Waist-Hip ratio 0.90 ± 0.055 0.90 ± 0.053 0.94 
Mean hirsutism score 11.3 ± 7.02 6.5 ± 5.16 0.002 
± SO 
Median No. of periods in previous 12 6(0-11) 12 ( 6-14) <0.001 
months 
Number with history of Subfertility (%) 17 (41 %) 5 (20%) <0.05 
Number with family history of 12 (29%) 2 (8%) 0.051 
thrombosis(%) 
Number of smokers(%) 10 (24%) 6 (24%) 0.97 
Number of alcohol units/wk (range) 0.5 (0-30) 0.5 (0-15) 0.75 
Mean systolic blood pressure ± SO 117.3 ± 13.6 111.4 ± 13.2 0.083 
(mmHg) 
Mean diastolic blood pressure± SO 78.3 ± 10.9 73.4 ± 10.9 0.08 
(mrnHg) 
NOTE. BMI = body mass index 
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Table 5.3 - Hormonal variables for patients with PCOS versus controls. 
Hormonal Varhable PCOS (n = 41) Controls (n = 25) 
Median FAI (range) 6.4 (0.6-21 .2) 3.2 (0.5-10.1) 
Median SHBG(range) nmol/L 34.75 (16.4-129) 55 (23-131) 
Median Testosterone (range) nmoi/L 2.5 (0.3-5.2) 1.5 (0.6-5.4) 
Median FSH (UIL) (range) 5 . 9 (2 - 1 8 . 1 ) 5.5 (2.5-34. 1) 
Median LH (U/L) (range) 12.3 (4.4- 44.2) 7 (2.3-63.7) 
Median LHIFSH ratio (range) 2.35 (0.34- 4.89) 1.27(0.27-6.77) 
Median Prolactin (range) 231.5 (76-784) 2 17.5 (88-646) 
Median 17-0HP (range) 5.4 (0.4-22.8) 8.2 ( 1-18.6) 
F AI = Free androgen index. (testosterone I SHBG x 1 00) 
SHBG = Sex hormone binding globulin 
LH = Luteinizing hormone 
Assays 
FSH = Follicle stimulating hormone 
17-0HP = 17 Hydroxyprogesterone 
p 
<0.001 
0.001 
0.002 
0.42 
0.041 
0.06 
0.67 
0.036 
The blood samples for PAl-l, tPA, plasminogen and alpha -2 anti plasmin and fibrinogen 
were centrifuged within 30 minutes of collection at 4 °C for 20 minutes at 3000g. Next, 
the platelet free plasma was separated into microcentrifuge tubes (Camlab limited, 
cambridge ref QP/5 19), changing pipettes between pre and post occlusion samples. A 
small amount was tested for fibrinogen. They were then stored at -70 °C for later analysis 
ofPAl-1 , tPA, plasminogen and a.-2 anti plasmin. These assays were all subsequently 
performed within 8 months of collection except tP A, which was not performed because of 
limited financial resources. The assays for glucose, hormones, and lipids were performed 
on the fresh samples in the Combined Laboratory at Derriford Hospital Plymouth. Serum 
was stored at -20° C, and analysed for insulin within 12 months of collection. 
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The methods used for PAI-l, plasminogen, a- -2 anti plasmin and fibrinogen were the 
same as those used in the pilot study. However we did not repeat the ECLT as we had 
found a very close positive correlation between ECL T and PAI-l levels in our pilot study 
(r = 0.88 in controls and r = 0.90 in women with PCOS). The post venous occlusion 
samples that were taken mainly for the measurement of tP A were not tested because of 
limited financial resources as previously stated. The methods, intra and inter-assay 
coefficient of variation, and sensitivities for the assays for FSH, LH, testosterone and 
SHBG were the same as in the pilot study. Free androgen index was calculated using the 
formula (Testosterone/ SHBG levels x 100). 
Glucose was tested using the hexokinase method on a Hitachi 911 automated analyser. 
The sensitivity of the assay was 2mmol/L and the intra and inter assay coefficients of 
variability 2.2% and 2.3% respectively. 
Cholesterol was tested using an enzymatic endpoint method on a Hitachi 747 automated 
analyser. The sensitivity of the assay was I mmol/L and the intra and inter assay 
coefficients of variability 1.8% and 2.4% respectively. Triglycerides were tested on a 
Hitachi 747 automated analyser. The sensitivity of the assay was O.lmmoi/L and the intra 
and inter assay coefficients of variability 1.3% and 2.4% respectively. HDL Cholesterol 
was tested on the Beckman CX7 automated analyser. The sensitivity of the assay was 0.2 
mmol/L and the intra and inter assay coefficients of variability 2.6% and 5.6% 
respectively. LDL Cholesterol was derived by calculation using the Friedwald formula. 
Prolactin was tested usmg the automated chemiluminescence assay on the chiron 
ACS: 180 analyser standardised against the WHO 3rd international reference preparation 
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84/500. The sensitivity was 6.4 miUIL the intra assay coefficients of variation were 2.5%, 
2.8% and 3.8% at 57, 721 and 2565 lUlL respectively and the inter assay coefficients of 
variation were 3.6%, 4.0% and 4.5% at 57,721 and 2565 lUlL respectively 
The assays for insulin and 17-hydroxyprogesterone were performed in external 
laboratories. Insulin assays were done at the biochemistry laboratory at the Heath hospital 
Cardiff using a radioimmunoassay (Medgenix, Chevrus, Belgium) with a sensitivity of 
4mU/L and an inter assay coefficient of variation of I 0.9% and 15.6% at 17.4 and 129 
mUlL respectively. This assay was specific for insulin and did not cross-react with 
proinsulin. Assays for 17-hydroxyprogcsterone were done at the immunoassay 
laboratory at St. Bartholomew's hospital in London. Insulin sensitivity (the degree of 
insulin resistance) was assessed using a Homeostatic Model Assessment (HOMA) 
computer programme as discussed in chapter three. 
Statistical Analysis 
Summary statistics for the clinical, biochemical and haematological data were presented as 
means and standard deviations if normally distributed, medians and ranges if the 
distribution was not normal, and as proportions for categorical variables. For quantitative 
variables, assessment for the normality of the spread was carried out using a normal 
probability plot. For those variables that were normally distributed, a student's t-test was 
used to compare the means in the PCOS and control groups. For those variables where 
there was clear evidence of non-normality, a Mann-Whitney test was used. Other 
variables, which were either categorical or which had a small range of values, were 
analysed where possible using a chi-squared test. In all cases, a two-tailed test was 
applied. 
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An analysis of eo-variance was performed to compare the pre-venous occlusion PAI-l 
levels of the PCOS and control groups using age and BMI as co-variates as these variables 
may be related to PAl-l levels. A linear regression analysis was used to evaluate the 
overall individual relationships between BMI, triglyceride, insulin, and HDL cholesterol 
on the one hand and PAI-l levels on the other. A multiple regression analysis was 
performed with pre-venous occlusion PAI-l as the dependent variable and insulin, 
triglycerides, BMI, HDL cholesterol, free androgen index, family history of thrombosis 
and group (whether PCO or control) as independent variables. A "p" value of< 0.05 was 
accepted as statistically significant. 
RESULTS 
Eighty-three women were recruited into the study from which 66 were suitable for 
inclusion based on the entry criteria. Forty-one of these women had PCOS as defined by 
the presence of a combination of oligo or amenorrhoea and ultrasound features of 
polycystic ovaries, and 25 were regularly menstruating controls. The individual results 
from all these women can be found in appendix 2 and the scatter plot of PAI-l for both 
PCOS and controls is found in figure 5.1. There was no significant difference found in the 
mean BMI (P =0.25) and waist hip ratio of both groups (P =0.94), but the mean age in the 
control group was significantly higher than in the PCOS group (32 ± 5 vs 28.4 ± 6 years, P 
= 0.01). 
A normal probability plot showed that PAI-l activity was not normally distributed in the 
overall population and a Mann Whitney test was therefore used to compare the median 
levels in the PCOS and control groups. This showed that PAI-l activity was not 
significantly increased in the PCOS group compared with the control group { 12 (2-38.5) 
vs 8 (0-36) aulml respectively, p=0.17 } as shown in table 5.4. The normal range for PAl-
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l activity with the assay used in this study was up to 15aulml. 43% of the women in the 
PCOS group had a result above this level compared to 28% in the control group, but this 
difference was not statistically significant (p=0.29). An analysis of covariance with age 
and BMI as co-variates found no evidence of an effect of either covariate (BMI, p=0.53 & 
age p=0.24) on PAI-l activity. 12 women with PCOS had a positive family history of 
thrombosis (6 in first degree relatives) compared to 2 women in the control group (29% vs 
8%, P = 0.051 ). As a family history of strokes and myocardial infarction were also 
elicited separately, with no difference found in both groups, this family history of 
thrombosis was assumed to refer to venous thrombosis. There was no difference between 
groups in the prevalence of a family history of type 11 diabetes or hypertension. 
Women with PCOS had significantly higher fasting insulin levels, lower insulin sensitivity 
and a lower HDL cholesterol ratio compared with controls (P< 0.01). But there was no 
significant difference in the serum concentrations of plasminogen, a-2 antiplasmin, 
fibrinogen, glucose, triglycerides, total cholesterol and LDL cholesterol ratio {Table 5.4). 
A linear regression analysis for all patients showed a significant positive correlation 
between BMI, triglycerides, fasting insulin and PAI-l activity ( r=0.65 & p < 0.00 I, r= 
0.57 & p < 0.001 and r = 0.57 & p < 0.001) and a negative correlation between HDL 
cholesterol and PAI-l (r = -0.41 & p < 0.0 I). Multiple regression analysis found that 
triglycerides were the most significant predictor of PAI-l activity (p < 0.0001). However 
fasting insulin levels, a positive family history of thrombosis and a low HDL cholesterol 
ratio (p=0.0005, p=O.OI3 & p=0.026 respectively) were also significant predictors of PAI-
l activity. The fitted prediction model was: Predicted PAI-l= 9.942 + 6.412 Triglycerides 
+ 0.2245 Insulin + 6.457 FH thrombosis - 5.311 HDL cholesterol. Which means that for 
example for every increase of I in the triglyceride value, the expected increase in PAI-l 
97 
activity is 6.412. The value of R 2 was 63.9% suggesting that the above model explained 
63.9% ofthe variability in PAI-l values. 
Table 5.4- PAI-l and metabolic variables in patients with PCOS versus controls. 
Variable PCOS (n = .JI) Controls (n = 25) p 
Median PAI-l activity (range) 12 ( 2-40.5) 8 (0-36) 0.17 
au/ml 
Mean plasminogen level ± SO 97.7 ± 18.8 98.7 ± 19.8 0.84 
(%) 
Median fibrinogen (range) giL 3.31( 2.2-5.31) 3.23 (2 .36-5.62) 0.38 
Mean alpha 2 a-plasmin level ± 99.1 ± 11.5% 97.8 ± 10.4% 0.65 
SO(%) 
Mean fasting glucose level ± SO 4.94 ± 0.48 4 .84 ± 0.34 0.32 
mmol/L 
Median fasting Insulin level ± SD 17 ( 4 .6-134.5) 9.6 (3 .7-41.5) 0.009 
mulL 
Median Insulin Sensitivity (range) 43.17% (5.48- 160) 82.8% (21.8-193) 0.005 
%S 
Median HOL cholesterol ratio 1.46 (0.65-2.67) 1.93 (0.96-2.51) 0.007 
(range) 
Median Triglycerides (range) 0.94 (0.46-4.91) 1.05 (0.37-3.56) 0.92 
mmol/1 
Mean fasting total cholesterol ± 5.28 ± 1.17 5.74 ± 1.20 0.15 
SO mmol/L 
Mean LDL cholesterol ratio± SD 3.11 ± 0.92 3.18 ± 0.96 0.77 
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Figure 5.1 Scatter Plots Of PAI-l For PCOS and Controls 
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DISCUSSION 
The key findings from this study were that systemic PAI- l activity was not significantly 
raised in oligomenorrhoeic women with PCOS compared to regularly menstruating 
controls of a similar BMI and that the only significant metabolic features in the PCOS 
group were a higher fasting insulin level, reduced insulin sensitivity and lower HDL 
cholesterol ratios. There was no significant difference in fasting blood glucose, 
triglycerides, total cholesterol, LDL cholesterol and blood pressure in both groups. PAI- l 
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activity was also found to be significantly related to BMI, triglycerides, fasting insulin, 
HDL cholesterol levels, and a positive family history of thrombosis. 
The definition of PCOS used in this study may be criticised because evidence of 
hyperandrogenaemia was not made an absolute requirement. However as discussed in 
chapters 2 & 3, there is no gold standard for the definition or diagnosis of the PCOS and 
the finding of a higher median free androgen index, fasting insulin and LHIFSI-1 ratio in 
the PCOS group provided reassuring evidence that the inclusion criteria used for this study 
were satisfactory for the diagnosis of PCOS. In addition, none of the other published 
cross-sectional studies on PAI-l in PCOS (Dahlgren et al 1994, Sampson et al 1996, 
V elaquez et al 1997) included hyperandrogenaemia in the entry criteria which makes it 
easier to compare the results from our study with these studies. Another potential criticism 
of this study is that the PAI-l and lipid measurements were taken at random with respect 
to ovarian activity. Although the amount of PAI-l expressed in ovarian tissue has been 
shown to vary with gonadotrophin levels (Peng et al 1993), studies on systemic PAI-l 
have shown that there are no significant fluctuations during the menstrual cycle (Dorr et al 
1993) and there are also no significant fluctuations in lipid levels (Lebech et al1990). 
The mathematical model used to evaluate insulin resistance in this study was practical and 
simple compared to some of the other methods available for evaluating insulin resistance 
such as the glucose clamp tests. However it is important that certain points are made about 
this model. Firstly, it does not differentiate between hepatic or peripheral insulin 
sensitivity (Rudenski et al 1991 ), as it assumes that changes in insulin sensitivity at the 
periphery and at the liver are parallel. Secondly, the ideal experimental determination of 
data for fasting glucose and insulin is best done taking average concentrations of glucose 
and insulin over three five minute samples which reduces assay noise and compensates for 
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the innate pulsatility of insulin secretion. This was not done in this study, which may have 
affected the validity of the results of the mathematical model. The reason for this was that 
it was anticipated that using only one glucose and insulin sample in this model would 
reduce the financial costs from performing three assays on the three samples obtained from 
each subject. However, in retrospect, by pooling the three five minute plasma samples for 
insulin or glucose, only one assay would still have been required. Nevertheless, the model 
served its purpose for this study which was primarily to compare insulin sensitivity in both 
study groups and not to determine the mechanisms of insulin resistance (or reduced insulin 
sensitivity) in both groups. Thus although only one blood sample was taken for glucose 
and insulin estimation, it did not appear to matter much as the results showed that insulin 
sensitivity was still significantly lower in the PCOS group as expected. 
The PAI-l results from this study were consistent with the study carried out by Dahlgren et 
al ( 1994) in which 28 peri-menopausal women with PCOS and 56 age and weight matched 
controls had metabolic and haemostatic variables evaluated. Except that in their study no 
difference was found in the fasting insulin levels between the two groups. However this 
may have been partly explained by the fact that 20% of their control population had 
hypertension suggesting that there was a high prevalence of metabolic disorders possibly 
related to most women in the study being in their fifties. On the other hand, the results 
conflict with the conclusions drawn from 2 other cross-sectional studies on PAI-l 
(Sampson et a! 1996, Velaquez et al 1997) and the results of the pilot study in chapter 4 
(Atiomo et al 1998) all of which found raised PAI-l in women with PCOS. However all 
these studies had drawbacks which made their conclusions debatable. 
In the study by Sampson et al (1996), looking at PAI-l in 24 non-obese women with 
ultrasound evidence of PCOS and menstrual disturbance (group 1) compared with 26 
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women with ultrasound evidence of PCOS and regular cycles (group 2) and 10 age and 
weight matched controls with normal menstrual cycles and normal ovarian ultrasound 
(group 3), mean PAI-l activity was elevated in group 1 compared to the other groups. 
These authors concluded that PAI-l was higher in women with PCOS. However the 
difference in mean PAI-l levels between groups 1 and 3 (which were similar to the 2 
groups in this chapter) was not statistically significant ( I 0.0 vs 5.1 au/ml p=0.059). It 
may be argued that this occurred because of their relatively small control group, and that 
larger numbers might have shown a significant difference. But in this study with more 
than double their control populations we did not find a significant difference in PAl-l 
activity. It is important to note that a student's t test was used in their study to compare the 
differences in mean PAI-l between groups because the data was normally distributed, as 
compared to a Mann Whitney test in ours. The drawback of the Mann Whitney test is that 
although it is the appropriate test to compare data derived from populations when the data 
are non-parametric, it is also more likely that a type 11 error (risk of falsely accepting the 
null hypothesis) can occur. This was the ideal test to use given that the PAI-l results from 
our study were not normally distributed. However the fact that the proportion of women 
in our study with PAI-l results within the normal range was similar in both the PCOS and 
control group does suggest that our results were reliable. In the study by Velaquez et al 
( 1997), basal PAI-l levels were significantly higher in the PCOS group (p<O.O 1) as found 
in the pilot study and a significant reduction in PAI-l activity was found after treatment 
with an 8 week course of metformin in 16 non-diabetic women with PCOS and 6 normal 
controls. In both these studies women with PCOS had a significantly greater BMI which 
was not present in the study reported in this chapter where the control population had a 
similar BMI to the PCOS group. 
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Although the mean age of the control group was 3.6 years more than the PCOS group, and 
PAI-l activity reduces with increasing age, it is unlikely that such a small difference in 
ages would have caused a bias in the PAI-l results. This is supported by the fact that the 
analysis of eo-variance did not find any evidence of an effect of age on PAI-l activity. 
The finding of a higher fasting insulin concentration independent of BMI in women with 
PCOS in this study is consistent with many previous studies which have demonstrated 
insulin resistance and fasting hyperinsulinaemia in both obese and non-obese women with 
PCOS. It has been speculated that this insulin resistance causes a metabolic risk profile 
associated with an increased risk of cardiovascular disease (Jacobs 1996) as found in 
Syndrome X (Reaven 1994 ). However the degree to which the features of insulin 
resistance in syndrome X overlaps with that found in PCOS is uncertain. In this study, 
women with PCOS had significantly higher fasting insulin levels, lower insulin sensitivity 
and lower 1-IDL cholesterol ratios, but none of the other features of the metabolic 
syndrome X which also include high blood pressure, hypertriglyceridaemia, elevated PAI-
l, and elevated uric acid levels. Although uric acid was not measured in this study, normal 
serum concentrations have been found in women with PCOS (Anttila et al 1996). It may 
be argued that single blood pressure measurements as used in our study are not as sensitive 
as 24-hour ambulatory blood pressure profiles for the detection of hypertension, and that 
this was the reason there was no difference in blood pressure in this study, however in a 
recent study where blood pressure was measured in women with PCOS and controls, using 
24-hour ambulatory profiles, no significant difference in any measured blood pressure 
variable was found (Sampson et al 1996). Similarly, studies on lipid states in women with 
PCOS are not consistent, for example the lower HDL cholesterol ratios found in women 
with PCOS in the study in this chapter have been found in some (Mattesson et al 1984, 
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Wild et al 1985, Conway· et al 1992) but not all studies (Graf et al 1990, Sampson et al 
1996). 
The similar waist-hip ratios in both study groups was unexpected as the PCOS is usually 
associated with central obesity. However these results may have arisen because of a 
measurement error as the subjects in this study were measured dressed. 
It is clear that the results of some of the studies of the metabolic profile of women with 
PCOS conflict with the results of this study because some studies have included women of 
higher BMI in the PCOS group compared to the control population. The discrepancy 
between the lipid, blood pressure and P AI-1 values in found in this study, where the 
controls have been matched for BMI and that described in the syndrome X may represent a 
distinction between the mechanism of insulin resistance in women with PCOS and that 
related to simple obesity. This hypothesis is supported by the findings of a study by Dunaif 
et al ( 1992) in which insulin action in vivo was determined with euglycaemic clamp tests 
and in vitro in isolated abdominal adipocytes in 16 obese and 14 non obese women with 
PCOS compared with 15 obese and 17 non-obese age and weight matched non-diabetic 
ovulatory women. They found that the EDlo insulin for hepatic glucose production was 
significantly increased only in the obese PCO women compared with obese controls 
suggesting an interaction between obesity and PCOS. These findings are consistent with 
that of this study where despite both the PCO and control groups being obese (mean BMis 
of 29.5 and 28.4 respectively), fasting insulin levels were significantly higher in the PCOS 
group who were also significantly less insulin sensitive. 
The finding of a significant overall correlation between BMI, triglycerides, fasting insulin, 
and P AI -1 activity on linear and multiple regression analysis, is consistent with the 
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findings of previous studies on women with and without PCOS (Shaw et al 1963, Ogston 
et al 1964, Vague et al 1986, Vague et al 1989, Juhan-Vague et al 1989, Dahlgren et al 
1994, Anderson et al 1995, Sampson et al 1996, Velaquez et al 1997). However the exact 
mechanism responsible for these correlations are unknown. Insulin has been shown to 
stimulate PAI-l synthesis and release in porcine endothelial cells and in the hepatoma cell 
line in-vitro. These correlations may be a reflection of insulin resistance, which is 
associated with obesity and raised triglycerdes. This is supported by the results of multiple 
regression analysis in some studies showing that in most cases these correlations disappear 
after adjustment for insulin (Vague et al 1986, Vague et al 1989, Juhan-Vague et al 1991 ). 
However this hypothesis is not supported by the finding of normal PAI-l levels in non-
diabetic patients with Cushing's disease or acromegaly in spite of hyperinsulinaemia and 
insulin resistance (Scelles et al 1992). Some studies have also shown that acute elevation 
of endogenous insulin with an oral glucose load (Juhan -Vague et al 1991), the acute 
administration of exogenous insulin (Potter Van Loon et at 1990) or the infusion of insulin 
for 24 hours (Juhan -Vague Petal I991), does not affect PAI-l activity. However it has 
been suggested that triglycerides could be prime candidates for triggering excessive 
secretion of PAl-l (Stiko-Rham et at 1990). This is supported by the finding in this study 
on multiple regression analysis that triglycerides were a significant independent predictor 
of PAI-l activity, that there were similar triglyceride levels in both groups and that there 
was also no significant difference in PAI-l. The relationship between triglycerides and 
PAl-l has also been shown not to be consistent as a study in which P AI -I levels were 
compared in three groups of hypertriglyceridaemic patients: one with obesity, one of 
normal body weight and one with alcohol induced hypertriglyceridaemia showed a weak 
overall correlation between PAI-l and triglyceride levels (Raccah et al 1996). 
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The finding of a three-fold increase in the prevalence of a positive family history of 
thrombosis in women with PCOS in this study was an unexpected but interesting finding 
as this has never been previously described in the literature as far as I know. It was not 
mirrored by prothrombotic changes in PAI-l, fibrinogen, plasminogen and a-2 antiplasmin 
levels which are hypothetical causes of thrombophilia. This finding led to the testing of 
the stored platelet free plasma obtained from these women for the more common causes of 
familial thrombophilia such as activated protein C (APC) resistance, antithrombin Ill, 
protein C and proteinS. The results of this analysis are presented as a separate chapter (8), 
but in summary it showed that there was not an increased prevalence in any of these 
factors in the PCOS group. However it is interesting to note that there was an independent 
correlation between the presence of a positive family history of thrombosis and PAI-l on 
the multiple regression analysis as PAI-l is not a common cause of familial thrombophilia. 
One would have expected that as there were more people with a familial history of 
thrombophilia in the PCOS group, PAI-l activity would have been significantly raised. 
In summary, this cross-sectional study showed that systemic PAI-l activity was not raised 
in 41 oligomenorrhoeic women with PCOS compared with 25 regularly menstruating 
weight matched controls. The only significant metabolic features of the PCOS group were 
insulin resistance, hyperinsulinaemia and lower HDL cholesterol ratios, but not the 
hypertriglyeridaemia, hypertension and raised PAI-l described as part of the metabolic 
syndrome X. An interesting but unexplained finding was an increase in the presence of a 
positive family history of thrombosis in women with PCOS. These findings were not 
consistent with the hypothesis that elevated PAI-l levels put women with PCOS at 
increased risk of thromboembolic disease or that it contributed to their anovulatory 
infertility and miscarriage, but it raised a few questions about the exact mechanism of the 
interaction between the insulin resistance of PCOS and the metabolic syndrome X and the 
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link between PCOS and thrombosis. It is however important to note that this study 
addresses statistical differences, which may not be the same as differences, that are 
biologically important, and differences that are not apparent at a systemic level may be 
found at the end organ. Therefore only experimental work on the effect of different tissue 
levels of PAI-l on various biological processes of interest will provide that information. 
The next 2 chapters contain the results of studies where some basic descriptive information 
on the tissue expression of PAI-l in the human ovaries were obtained as a preliminary step 
to dynamic studies on the effect of various tissue levels of PAI-l on the ovulatory process. 
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CHAPTER SIX 
IMMUNOIDSTOCHEMICAL LOCALISATION OF PLASMINOGEN 
ACTIVATOR-I PROTEIN IN POLYCYSTIC OVARIES. 
OUTLINE 
A study on the immunohistochemical localisation and quantitation of P AI -1 in ovarian 
biopsies from women with PCOS and normal ovaries is described. Detailed accounts of the 
general principles of immunohistochemistry and the experimental procedures used in this 
study are presented. 
INTRODUCTION 
The histologic make up of the mammalian ovary consists of several tissue types, which 
secrete a variety of factors that play a vital role in follicle growth, development, and 
ovulation. These factors include, sex steroids, peptides and growth factors (Taymor 1996), 
but how these highly integrated processes result in the full development of one follicle at 
ovulation is not fully understood. 
In women with polycystic ovaries, the number of primordial follicles present are similar to 
those found in normal ovaries (Hughesdon 1982), but they contain an increased amount of 
primary, secondary and tertiary follicles which rarely develop beyond a diameter of 6 to 
8mm diameter (Fauser 1994). The factors leading to this are still poorly understood, but 
proposed mechanisms include a negative effect of LH-stimulated androgen production on 
follicle development (Louvert et al 1975), subnormal FSH levels (Erickson et al 1979)' 
impairment of the synergistic actions between FSH and insulin like growth factor on 
granulosa cell aromatase activity (Giudice et al 1995), aberrations in the intraovarian activin 
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I inhibin system (Roberts et al 1994), and an alteration in the ovarian renin angiotensin 
system (Palumbo et al 1993). 
PAI-l and tissue plasminogen activator are present in follicular fluid (Beers 1975}, and 
granulosa cells from human ovaries undergoing assisted conception (Piquette et al 1993). 
As ovulation approaches, an increase in plasminogen activator secretion by rat granulosa 
cells has been observed (Beers et al 1975). Plasmin which activates the conversion of 
procollagenase to collagenase, is thought to be necessary for the breakdown of the type IV 
collagen present in the basement membrane around the graafian follicles at ovulation 
(Stetler Stevenson 1990), and a suppression of ovulation rates has been demonstrated in 
the rat ovary following the use of specific antibodies to tPA and a-2 antiplasmin. In 
another study on rat ovaries (Peng et al 1993), using in-situ hybridisation PAl-l mRNA 
was mainly found in the cell types located in the outer layer of follicles including the theca 
intema, theca externa, interstistial cells and ovarian stroma and following HCG stimulation, 
the dominant pre-ovulatory follicles which protrude onto the surface of the ovary were 
surrounded by less interstistial and stromal tissue that expressed PAI-l compared to the 
smaller non-ovulatory follicles that were in the interior part of the ovary which were 
surrounded by layers of PAl-l expressing tissue. These studies suggest that PAI-l may 
play a role in peri-follicular proteolysis, protecting relatively immature follicles from 
premature rupture and any excess PAI-l might prevent follicular growth and rupture. 
Because of the close correlation between insulin resistance and PAI-l, it has been 
suggested that an imbalance in the intraovarian plasmin pathway (Sampson et al 1996) may 
partly be responsible for the disordered folliculogenesis found in PCOS. It is thought that 
this imbalance arises secondary to an insulin driven overproduction in PAI-l with a 
reduction in the amount of plasmin available for extracellular proteolysis in the ovary. 
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that they may contain unwanted antibodies against other constituents present in human 
tissue, resulting iri a high incidence of non-specific staining of tissue sections. Monoclonal 
antibodies are made from hybridomas prepared by the fusion of immune spleen cells and a 
myeloma cell line. They are highly specific as the antigen-combining site in all the 
molecules are of identical specificity. These antibodies may be labelled with fluorescin or 
an enzyme to enable microscopic detection of antigen/antibody hybrids in-situ. The 
principle behind immunofluorescent labelling is that a fluorescent marker molecule is 
stimulated at one wavelength and emits light at a different wavelength. This fluorescent 
signal is viewed against a dark background. The fluorochrome may either be coupled 
directly to the primary antibody, or indirectly via the labelling of a secondary reagent. 
Direct techniques are rapid but of lower sensitivity and rely on the supply of labelled 
primary antibodies, whereas indirect labelling can be used with any primary antibody. 
The most common enzyme used with immunoenzymatic labelling is horseradish peroxidase. 
It can be detected by reactions, which produce an insoluble product. The commonest 
substrate contains diarninobenzidene (DAB) and hydrogen peroxide. Aminoethylcarbazole 
(AEC) and hydrogen peroxide may also be used, as DAB may be carcinogenic. Calf 
intestinal alkaline phosphatase is an alternative enzyme to peroxidase. Substrates to this 
enzyme include napthol phosphate and hexazotized new fuschin or fast red. The advantage 
of calf intestinal alkaline phosphatase over horseradish peroxidase is that endogenous tissue 
peroxidase activity is not a problem. Endogenous tissue peroxidase in white cells and red 
cells may cause problems if the substrate reacts with both the ·endogenous enzyme and the 
horseradish peroxidase labeL This can be prevented by introducing a blocking step during 
the procedure. Tissue alkaline phosphatase activity is less of a problem, but its activity can 
be blocked by levamisole. 
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Table 6.1 (Individual patient characteristics. Patients 1-5 had polycystic ovaries and 
6-11 were controls). 
Patient .AO'e Wei ht · Pari Hormones Histo · · 
37 51.7 1+0 n/a Infertility and oligomenorrhoea 
2 18 59.7 0+0 T= 3.8nmoVL. Amenorrhoea and hirsutism 
..., 
.) 27 95 0+0 LH/FSH ratio=2 Amenorrhoea 
4 30 57.6 0+1 T= 2.7nmoVL. Amenorhoea and infertility 
5 27 60 0+0 n/a Amenorrhoea 
6 38 69.8 2+0 n/a Heavy periods 
7 23 66 n/a n/a Pelvic mass 
and oligomenorrhoea 
8 38 n/a n/a n/a Abdominal pain 
9 26 91 0+1 n/a Abdominal pain 
10 26 88.5 0+3 n/a Infertility recurrent miscarriage 
11 14 67.7 0+0 nla Abdominal pain 
T =Testosterone (normal range 0.6-2.2 nmoVL) 
n/a = information not available from records 
General principles of immunohistochemistry 
Immunohistochemistry is the technique by which antigens are detected in-situ in human cell 
and tissue samples. It involves the incubation of these tissues with a known antibody to the 
antigen in question. The antibody is linked with a marker molecule, which can be detected 
microscopically by fluorescence, or the ability of the marker molecule to react with a 
substrate and yield a visible reaction product. 
Samples used for immunohistochemistry may be paraffin embedded formalin fixed tissue, or 
frozen sections. With the former, tissue morphology is well preserved, but antigenic 
material tends to be masked or denatured. The preservation of tissue architecture is not as 
good with frozen sections, but antigenic denaturation is minimal. Antigenic reactivity can 
be restored by treating sections with proteolytic enzymes (e.g. trypsin or pronase). The 
antibodies used may be polyclonal or monoclonal. Polyclonal antibodies are raised by 
immunising animals with the purified antigen. The main drawback of these antibodies is 
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However the in-situ location of P AI -1 has never been previously described in the human 
ovary. The aim of this study was to determine the in-situ localisation of PAI-l in the 
human ovary, and then compare the amount of PAI-l protein detected in polycystic ovaries 
with control ovaries. This was expected to provide a better understanding of the 
pathophysiology of impaired folliculogenesis and anovulation in PCOS. 
METHODS 
The study design and case selection are as described in chapter 3. Five women with 
polycystic ovaries and six with normal ovaries were suitable for inclusion in the study. 
Three women within the polycystic ovary group had documented biochemical evidence in 
support of their diagnosis. The hormone results of the remaining two were not available in 
the notes. Except for one woman with menstrual cycles lasting 60 days, all the women in 
the control group had regular 28-day cycles. Four of them were in the follicular phase of 
the menstrual cycle, while the other one was in the luteal phase at the time of their surgery. 
It was felt that as this study had never been done before, this sample size was all that was 
required to detect any marked differences in PAl-l staining, and so they were processed as 
a pilot. Table 6.1 shows the clinical and biochemical profile of the subjects. The biopsies 
taken from these women were then processed for the immunohistochemical detection of 
PAI-l. 
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that they may contain unwanted antibodies against other constituents present in human 
tissue, resulting iri a high incidence of non-specific staining of tissue sections. Monoclonal 
antibodies are made from hybridomas prepared by the fusion of immune spleen cells and a 
myeloma cell line. They are highly specific as the antigen-combining site in all the 
molecules are of identical specificity. These antibodies may be labelled with fluorescin or 
an enzyme to enable microscopic detection of antigen/antibody hybrids in-situ. The 
principle behind immunofluorescent labelling is that a fluorescent marker molecule is 
stimulated at one wavelength and emits light at a different wavelength. This fluorescent 
signal is viewed against a dark background. The fluorochrome may either be coupled 
directly to the primary antibody, or indirectly via the labelling of a secondary reagent. 
Direct techniques are rapid but of lower sensitivity and rely on the supply of labelled 
primary antibodies, whereas indirect labelling can be used with any primary antibody. 
The most common enzyme used with immunoenzymatic labelling is horseradish peroxidase. 
It can be detected by reactions, which produce an insoluble product. The commonest 
substrate contains diaminobenzidene (DAB) and hydrogen peroxide. Aminoethylcarbazole 
(AEC) and hydrogen peroxide may also be used, as DAB may be carcinogenic. Calf 
intestinal alkaline phosphatase is an alternative enzyme to peroxidase. Substrates to this 
enzyme include napthol phosphate and hexazotized new fuschin or fast red. The advantage 
of calf intestinal alkaline phosphatase over horseradish peroxidase is that endogenous tissue 
peroxidase activity is not a problem. Endogenous tissue peroxidase in white cells and red 
cells may cause problems if the si.Jbstrate reacts with both the ·endogenous enzyme and the 
horseradish peroxidase label. This can be prevented by introducing a blocking step during 
the procedure. Tissue alkaline phosphatase activity is less of a problem, but its activity can 
be blocked by levamisole. 
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Immunoenzymatic techniques may also be direct or indirect In the direct method, the 
enzyme is usually coupled to the antibody covalently. However the enzyme may also be 
bound by antibody which has been raised against the enzyme. These immune complexes 
of enzyme and antibody can be linked to the primary antibody by a bridging antibody 
raised in the same animal as the primary antibody. It is important that the anti-enzyme 
antibody is raised in the same animal in which the primary antibody was raised. Some 
examples of this are the peroxidase antiperoxdase method and the alkaline phosphatase 
antialkaline phosphatase method. 
Enzymes may also be coupled to the antibody through a reaction between the protein 
avidin and the vitamin biotin. This is based on the fact that avidin has a very high affinity 
for biotin and is thought to ensure strong binding of the final enzyme label to the tissue. In 
this method, a biotinylated link antibody forms a bridge between the unlabelled primary 
antibody and a pre-formed complex of avidin and biotinylated enzyme complex. 
Staining may be specific, non-specific or a false negative. Specific staining reveals the 
true antigenic content whereas non-specific staining does not. Common causes of non-
specific staining include polyclonal antisera and non-specific binding of the antibodies to 
collagen in the tissue. Polyclonal antisera may contain unwanted antibodies against 
antigens other than the one of interest, and monoclonal antibodies reduce this problem. A 
blocking step in which the tissue is first incubated with non-immune serum is occasionally 
used to prevent non-specific staining. It is worth noting that an antigen may be detected 
in a cell in which it was not originally synthesised as a result of diffusion and artefactual 
uptake of extracellular antigens. False negative staining may occur as a result of the 
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denaturation of antigens during tissue processing, a low level of antigen in the cell, or 
rapid exportation of an antigen from a cell in which it was originally synthesised. 
Controls reactions are usually performed to detect false positive and negative staining. 
These include omitting the incubation of the tissues with the primary antibody to detect 
false positives, and staining a different tissue already known to produce the antigen of 
interest to detect a false negative. Measurement of staining in cells can be done 
subjectively or objectively. Subjective measurement involves scoring the intensity of 
staining of histological slides through the light microscope as "+", "++", or"+++" over a 
background negative area. Objective measurement involves the use of image analysers 
(Bradbury et a! 1982). 
Immunohistochemical detection of PAl-l (See appendix 3 for details of experimental 
work). For this study, the steptavidin-biotin method was used (1-lsu et a! 1981 ). The 
tissues had been fixed in 4% paraformaldchyde and embedded in paraffin. 
Immunohistochemistry was initially performed on sections of tissue known to express 
PAI-I; inflamed appendix (Whawell et al 1993) and placenta (Estelles et a! 1994) to 
determine ideal working dilutions. For the study, four-micron sections were cut. After 
mounting on 3-aminiopropyltriethoxysilane coated glass slides, they were left in a 37°C 
incubator overnight. The next morning, these slides were transferred to a 60°C incubator 
for a maximum of 2 hours. The antibody used was a commercially available monclonal 
antibody to PAI-I (murine monoclonal antibody raised against purified active PAI-l 
secreted by the human melanoma cell line: American Diagnostica Incorporated, product 
number 3785) which had been successfully used in formalin-fixed, paraffin-embedded 
tissue (Jankun et a! 1993). The epitope specificity of this antibody was unknown, however 
there was no cross reactivity with PAI-2 or PAI-3. 
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The ovarian sections were dewaxed in xylene, rehydrated in alcohol and treated in 3% 
volume hydrogen peroxide in I 00 mls of methanol for ten minutes to block endogenous 
peroxidase. They were then washed well in running water, and trypsinised at a pH of 7.80 
at 37°C for 30 minutes for antigen retrieval. Next, the sections were blocked in 20% 
normal goat serum for I 0 minutes at room temperature to reduce non-specific background 
staining and then incubated with the primary antibody at a dilution of I in 25 and I in SO 
for one hour at room temperature in a humid chamber. The primary antibody was drained 
off the slide and the sections were washed with tris (hydroxymethyl) methylamine buffer. 
Following this, the sections were incubated with the secondary antibody {biotyinylated 
goat antimouse/rabbit IgG (Dako UK) } for 30 minutes, and washed with tris 
(hydroxymethyl) methylamine buffer again before incubation with steptavidin-biotinylated 
horseradish peroxidase complex for 30 minutes. After washing the slides, they were 
incubated with a solution of 3,3"-diaminobenzidede (DAB) for ten minutes and nuclear 
staining was performed with hematoxylin. The sections were then dehydrated in graded 
alcohol, cleared in xylene and mounted for viewing. One negative control slide was 
subjected to all these steps except for the incubation with the primary antibody. Areas 
containing PAI-l stained brown. 
Slides were evaluated by two independent histologists blind to the diagnosis in each case, 
the location ofPAl-1 was noted and the intensity of staining assessed subjectively. 
Objective quantification of staining. 
Prior to image analysis, hematoxylin was removed from the sections by placing them in a 
3.5% solution of hydrochloric acid in methylated spirit for one hour, and 
histomorphometric analysis was done with a Leica Quantimet 570 image processor 
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(Cambridge UK). The system is equipped with a 3CCD Hitachi HV-C20 camera on a Ziess 
photomicroscope U. Images were acquired as 512 x 512 pixels, in 256 grey level digital 
images. Using the principle of Beer's Law, this system processed the amount of light 
transmitted through the sections and provided a numerical value for each pixel as grey 
levels, transmittance or optical density. For this study, grey level measurement data was 
used. High pixel values represented increased light transmittance, reflecting an area of 
limited staining and low pixel values dense staining. Under low magnification, on a Kyola 
SDZ trinocular microscope x 45 magnification, the maximum diameter of every intact 
follicle in each section was measured and the total number of follicles present was noted. 
The sections were viewed under high magnification 400x (OBJ40x photomag x10), and 
interactive thresholding performed to eliminate artefacts from the images. An image frame 
65 Jlm horizontally and 12 vertically was defined for quantitation of staining. This provided 
a horizontal profile of grey levels for 65 Jlm obtained from 234 pixels within the frame. 
Horizontal profiles were then taken from four randomly selected points evenly distributed 
radially around the margin of each follicle. Images were oriented such that this proftle 
started just within the follicle antrum and extended outwards through the granulosa cell 
layer, into the theca cell layer and stroma. 
Data storage and analysis 
The data array from each profile were stored electronically as individual files which were 
then all imported into a spreadsheet for basic data analysis. The total, mean and minimum 
grey level pixel value for each horizontal profile was calculated. Comparison of the means 
of all these values derived from all the horizontal profiles obtained from polycystic ovaries . 
was compared with those obtained from the control group using a Student's t test. This t-
test assumed that the profiles were independent but as they came from just I I patients in 
total, this was not the case. A more appropriate analysis was felt to be a nested analysis of 
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variance (ANOV A), which took account of variation within and between patients in both 
groups. A linear regression analysis was used to evaluate the overall correlation between 
the mean minimum grey level pixel value derived from the 4 profiles taken from each 
follicle and the maximum diameter of that follicle. 
RESULTS 
Immunohistochemical detection of PAI-l was predominantly found in the granulosa and 
theca cells in the follicles in both polycystic and normal ovaries with some weak signal in 
the endothelial cells and serosal surface (figure 6.1 ). There was good agreement between 
the histopathologists that overall, there was more intense staining was found in the 
granulosa cells (figure 6.2), but no obvious difference was identified between the control 
and study groups on visual inspection. 
In both the PCOS and control groups, P AI -I was detected around the developing follicle at 
all stages (pre-antral and antral) leading up to ovulation. PAI-l staining was present in the 
low columnar follicular cells surrounding the primary (pre-antral) follicle (figure 6.3), the 
granulosa and theca cell layers of the secondary (pre-antral) follicle (figure 6.4 ), the theca 
cell layer of the tertiary (antral) follicle (figure 6.5) and the granulosa and theca cell layers 
of the atretic follicles (figures 6.1 and 6.2). 
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Figure 6.1 Follicle from a polycystic ovary: immunostaining of granulosa cell layer 
(GCL) and theca cell layer (TCL) with anti PAI-l monoclonal antibody; brown reaction 
product. 
This section was one of those where hematoxylin was removed prior to image analysis. 
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Figure 6.2 Edge of follicle from a polycystic ovary under high magnification: 
immunostaining of granulosa cell layer (GCL) and theca cell layer (TCL) with anti PAI-l 
monoclonal antibody; brown reaction product. 
This section was one of those where hematoxylin was removed prior to image analysis. 
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Figure 6.3. PAI-l staining in the single layer of low colwnnar follicular cells surrounding 
the primary (pre-antral) follicle; brown reaction product. 
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Figure 6.4 PAI-1 staining m the granulosa and theca cell layers of the secondary (pre-
antral) follicle; brown reaction product. 
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Figure 6.5 PAI-l staining m the theca cell layer of the tertiary (antral) follicle; brown 
reaction product. 
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There were, in total, 17 intact follicles in the polycystic ovary group and 15 in the control 
group. There was no significant difference in the mean diameter of the follicles between 
polycystic and control ovaries {3.02mm (0.4-5.79) vs 3.26mm (0.77-10)}. A total of68 
horizontal profiles from the follicles in the polycystic ovary group and 63 in the control 
group were used for quantification. Using the students t-test, the mean of the minimum 
grey level pixel values derived from every horizontal profile in the polycystic ovary group 
was significantly lower than in the control group suggesting more intense PAI-l staining 
(57 sd ± 37.6 vs 73.4 sd ± 42.7 grey levels, p= 0.02), but there was no evidence of a 
difference in the total or mean grey level pixel values (see table 6.2). However, a nested 
analysis of variance of the minimum grey levels with three factors: the group (Controls or 
PCOS), the patient (nested within group) and the follicle (nested within each patient) 
revealed that there was no evidence of a significant difference between controls and PCOS 
(p = 0.53). The mean minimum grey level was calculated for each subject, giving 11 
scores in total, six controls and five PCOS. A student's !-test applied to these values also 
did not find a difference between groups (p = 0.29). 
There was a significant inverse correlation between the mean minimum grey level pixel 
value derived from the 4 profiles taken around the follicles and their maximum diameter in 
the polycystic ovary group but not in controls (r = -0.58, p = 0.01 in PCOS and r = -0.34, p 
= 0.2 in controls). 
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Table 6.2 (Pixel values from the entire horizontal profile expressed as grey levels). 
i Controls (n = 6.1 J)COS (n =68 , p \'aluc-
1 profiles) pmftles) : 
' : 
.. 
Mean total pixel values (SO) 34534 (6043) 33245 (6567) 0.24 
Mean average pixel value (SO) 147(25) 142(28) 0.24 
Mean minimum pixel value 73(42.7) 57(37.6) 0.02* 
(SD) 
* P = 0.53 on ANOV A. 
DISCUSSION 
The finding of PAI-l m the cells surrounding the oocyte, from the early stages of 
follicular development (primary follicle) , through the secondary follicle, the graafian 
(tertiary) follicle and the atretic follicle is consistent with a clear role for PAI- l in human 
folliculogenesis. However, this study -did not demonstrate a significant difference in the 
intensity of PAI-l staining between the PCOS and control groups. Thus, the hypothesis, 
suggesting that raised PAI-l levels may contribute to impaired folliculogenesis in women 
with PCOS has not been supported by the findings of this study. 
The main drawbacks of this study were the small sample size, and the fact that the ovarian 
biopsies from the control population had been obtained in both the luteal and proliferative 
stages of the menstrual cycle, and as such had been subject to different levels of 
gonadotrophin stimulation. This could potentially have caused an inconsistent expression 
of PAI-l in the ovaries in this study group making the quantitative data derived from this 
group on image analysis less than ideal for analysis. However it was difficult to obtain a 
reasonable number of biopsies from "normal" ovaries taken from women in a similar age 
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group as the PCOS group to make exclusion on the basis of cycle stage possible probably 
because there were very few or no indications to biopsy a normal looking ovary from a 
young woman in the reproductive age group. It may be argued that to increase the number 
of control ovarian biopsies used in this study one could have removed the age limit. 
However PAl- I expression increases with age and this would have caused a bias, and a 
significant number of ovarian biopsies from women in the older age group were diseased 
and unsuitable for the study. 
It would have been ideal to obtain biochemical confirmation of PCOS in the PCOS group, 
but this was not possible in all cases as evidence from the records of the women in this 
study showed that a biochemical diagnosis of PCOS was not always necessary for a 
diagnosis of PCOS to be made and wedge resection performed. Efforts were made to 
contact the women without biochemical evidence of PCOS to come in for blood tests, but 
this was not achieved because most of the women had either moved out of the area or had 
changed their names and addresses making it difficult to trace them. 
The end product from the immunohistochemical reactions was objectively quantified 
using microdensitometry. This technique has been used before in immunohistochemistry, 
during which the staining intensity was shown to be proportionally related to time and 
antigen concentrations (Van Der Loos et al I 994). However, quantitative data can show 
poor inter-experimental reproducibility owing to variability in antibody dilution, 
incubation time, temperature and the state of preservation of antigens after fixation. All 
the sections used in our study were processed in one batch on the same day, and all the 
biopsies were taken within the same period to minimise any possible bias from the above 
factors. However the grey level data may have been subject to inconsistencies in the state 
of preservation of antigens after fixation as it was not possible to control for this. 
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The absence of a significant difference in the total grey level scores from the horizontal 
profiles in the PCOS and control groups did indeed suggest that overall, there was no 
difference in PAI-I. However because there was no consistency in the thickness of the 
granulosa and theca cell layers and the distance of the horizontal profile within the follicle 
antrum it was felt that the minimum grey level score would provide the most objective 
measure of staining. These minimum grey level data did indeed suggest that overall more 
PAI-I was detected around the follicles in polycystic ovaries. This difference was not 
statistically significant on analysis of variance, which may have been because of the small 
sample size. The correlation between follicle size and perifollicular minimum grey level 
scores suggesting that more PAI-l was detected around the larger follicles compared to the 
smaller ones especially in women with polycystic ovaries was an unexplained finding as 
from the studies on PAI-lmRNA expression in rat ovaries (Peng et al 1993), one would 
have expected that more PAI-l would be expressed in the smaller sized follicles. 
In summary, this study was the first to demonstrate the in-situ location of PAI-l in the 
human ovary by immunohistochemistry, and it showed that PAI-l was mainly expressed in 
the granulosa and theca cell layers which was in support of it's previously suspected role 
in ovulation. Computer image analysis for quantitation suggested that there was a 
significant increase in the intensity of PAI-l staining in polycystic ovaries when all the 131 
acquired image profiles were used in the data analysis, but this difference disappeared 
when the fact that these profiles were obtained from a total of 11 subjects was taken into 
account in an analysis of variance. The role of PAI-l in disordered folliculogenesis in 
women with polycystic ovaries by limiting plasmin production and proteolysis around the 
developing follicles was not clear from these data, however a larger study may shed more 
light on this subject. Future experimental work looking at ovarian granulosa cell PAI-l 
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I . 
production in resp9ilse. to d,iffereilt potc:!ntial stimulants of 'PAI;l such as insulin, in 
polycystic and control ovaries' may also,be'helpful. 
CHAPTER SEVEN 
PLASMINOGEN ACTIVATOR- INHIBITOR-I MESSENGER RNA 
EXPRESSION IN THE POLYCYSTIC OVARY. 
OUTLINE 
The methods and results of a study to demonstrate the expression of PAI-l mRNA by in 
situ hybrization with synthetic oligonucleotide probes in ovarian biopsies from women 
with PCOS and normal ovaries are presented. The general principles of in-situ 
hybridisation, the experimental procedures used in this study and the problems 
encountered are discussed. 
INTRODUCTION 
Women with PCOS have poorly developed ovarian follicles, and they suffer from 
anovulatory infertility of poorly explained aetiology. Systemic levels of PAI-I are raised 
in some women with PCOS, and it has been suggested that an insulin driven increase in 
PAI-l may be partly responsible for the disordered folliculogenesis in women with 
polycystic ovary syndrome (Sampson et al 1996, Atiomo et al 1998, and see chapter 5) by 
inhibiting the conversion of plasminogen to plasmin by tissue plasminogen activator. 
In the previous chapter, the tissue distribution of PAI-l antigen in the human normal and 
polycystic ovary was studied by immunohistochemistry and found to be localised to the 
granulosa and theca cell layers in both groups with most PAI-I found in the granulosa cell 
layer. The expression of the PAI-l gene by the different ovarian cell types in the human 
ovary has never been described although PAI-l mRNA has been reported in the granulosa 
cells of women undergoing assisted conception (Piquette et al 1993). In a previous study 
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on rat ovaries (Peng et al 1993), using in-situ hybridisation PAI-l mRNA was mainly 
found in the cell types located in the outer layer of follicles including the theca intema, 
theca externa, interstistial cells and ovarian stroma which was in contrast to my findings 
on immunohistochemistry. In addition, following HCG stimulation, the dominant pre-
ovulatory follicles which protrude onto the surface of the ovary were surrounded by less 
interstistial and stromal tissue that expressed PAl-l compared to the smaller non-ovulatory 
follicles that were in the interior part of the ovary which were surrounded by layers of 
P AI -I expressing tissue. Based on these results, it was interesting to speculate whether an 
increased expression of the PAl-l gene contributed to the limited follicle growth seen in 
women with PCOS. 
This study was therefore set up to describe the gene expression of PA£-1 in human normal 
and polycystic ovaries in situ and determine whether PAI-l played a role in impaired 
folliculogenesis in PCOS. 
METHODS 
The study design and case selection were described in chapter 3. Paraffin embedded 
histological sections from the same ovanan biopsies used m chapter 6 
(immunohistochemical localisation of PAl-l) were used for this study. The biopsies were 
taken from five women with PCOS and six controls between 1982 and 1985. These 
numbers were considered sufficient to initially establish the technique of in-situ 
hybridisation, as this had not been performed in our laboratory at Derriford hospital 
Plymouth before. The clinical and biochemical profile of these women was described in 
chapter 6 and table 6.1. 
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General principles of in situ hybridisation 
In situ hybridisation was first described by research workers in the United Kingdom and 
United States of America in 1969 ( John et al, 1969, Gall and Pardue, 1969). It allows the 
demonstration of nucleic acid sequences in their cellular environment by the introduction 
of an exogenous labelled but complementary polynucleotide strand (probe) to a milieu of 
denatured DNA, which associates (hybridises) with a dissociated polynucleotide strand 
(target) to form a hybrid duplex in situ. This hybrid is detected by autoradiography if the 
label is a radioisotope, or by regular light or fluorescence microscopy otherwise. 
The principles of the technique involve the pre-treatment of cellular preparations to 
unmask target nucleic acids, hybridisation of a nucleic acid probe of complementary base 
sequence to the target, and the detection of the label attached to the probe which allows the 
demonstration of specific nucleic acid sequences within cells. 
The following types of nucleic acid probes may be used in in situ hybridisation. 
These include, double-stranded DNA probes derived from an isolated and cloned segment 
of genomic DNA, single-stranded cDNA probes made from mRNA using reverse 
transcriptase, chemically synthesised oligonucleotides and single stranded RNA probes. 
The larger fragment DNA probes are more sensitive than synthetic oligonucleotide probes 
(Berent et al 1985), because the smaller size of oligonucleotide probes relative to 
conventional cDNA probes covers a smaller target. Cocktails of several oligonucleotide 
probes are therefore required to compensate for the low specificity. Oligonucleotide 
probes are however readily available through automated synthesis, and their small size 
gives them good cellular penetration properties which largely compensates for the smaller 
target they cover. Complementary single stranded RNA probes (cRNA) have a high 
binding stability. 
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Probes used for in situ hybridisation may be labelled with isotopic or non-isotopic reporter 
molecules. Biotin and digoxigenin are examples of non-isotopic reporter molecules, and 
examples of isotopic reporter molecules include 3H, 32P, 358, or 125 I. Biotin labelled 
probes unfortunately have a disadvantage as biotin has a widespread endogenous tissue 
distribution (Wood and Wamke 1981) occasionally making it difficult to differentiate 
between true and false positive results. Digoxigenin (Herrington et al 1989) on the other 
hand has superior sensitivity to biotin (Morris et al, 1990; Furunta et al, 1990) with very 
low non-specific background staining. Radioisotopes generally have a short half-life, 
require long exposure times for detection, and come with the known hazards of 
radioactivity. 
Prior to the procedure, it is important to achieve optimal fixation for good results, as it 
allows the preservation of cell morphology and nucleic acids, particularly for RNA 
detection, which is very susceptible to digestion by endogenous ribonucleases. Tissues 
are therefore best fixed or frozen as soon as possible after surgical excision to prevent 
this. Many different fixatives can be used, however cross-linking fixatives, such as 
formalin and paraformaldehyde, give the best retention of nucleic acids, by forming 
chemical bonds with cellular proteins (Singer et al, 1986). 
DNA and RNA can be degraded by nuclease activity. Nucleases present on the skin may 
contaminate solutions used in hybridisation methods sufficiently to degrade the quality of 
naked DNA and RNA. For this reason, gloves should be used in handling tissues, and 
precautions have to be taken to ensure the absence of exogenous nucleases from solutions. 
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It is important to coat the glass slides used for in-situ hybridisation to ensure section 
adhesion, and either aminopropyl-triethoxysilane (Van Prooijen-Kneght et al, 1983) or 
poly-L-lysine (Huang et al, 1983) may be used. 
A number of pretreatments are used, both to reduce non-specific background and 
increase probe penetration, and these depend on the method of fixation. Hydrochloric acid 
(0.1 M) for example reduces non-specific background in formol-sublimate fixed tissue. 
Acetylation can also used to reduce binding to basic groups within the tissue (Hayashi et 
al, 1978). 
Permeabilisation of the section is necessary for formalin fixed tissue to reduce the effect 
of cross-linking. This can be achieved by proteolytic digestion with proteinase K (Pringle 
et al, 1987) or pronase (Brigati et al, 1983). It is important to control this step carefully as 
underdigestion will result in insufficient exposure of the nucleic acid, and over digestion 
can sufficiently weaken the protein structure surrounding the sequences as to bring about 
its loss into solutions. 
A prehybridisation solution applied pnor to addition of the probe contains high 
concentrations of single stranded sheared DNA and anionic macromolecules, which block 
sites of potential non-specific probe interaction. 
The aims of hybridisation are to ensure maximal reaction of the probe with target 
sequence with minimal non-specific interaction with nucleic acids and other cellular 
components. A number of variables in the conditions used for hybridisation affect this aim 
and these include; Temperature and ionic strength, accelerators (dextran sulphate), buffers, 
probe concentration, and blocking agents 
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(i) Temperature and ionic strength - the optimum temperature for efficient hybridisation of 
homologous nucleotide sequences is 20-30°C below the melt temperature (Tm) 
(denaturation temperature) of the specific hybrids. The Tm is the temperature at which 
50% of the duplexes are dissociated and is proportional to the guanine-cytosine (G-C) base 
pair content. Where there is a high percentage of these, the third hydrogen bond associated 
with the base pair results in a higher melt temperature than in sequences in which 
adenosine and thymidine (A-T) pairing predominates. The inclusion of formamide, a 
helix destabiliser, into the hybridisation mixture reduces the Tm by 0.7°C for each I% 
formamide. 
(ii) Accelerators - inclusion of dextran sulphate increases effective probe concentration 
and hybridisation rates by volume exclusion. Dextran sulphate has the added advantage 
of reducing non-specific binding of probe to positively charged molecules in the tissue. 
(iii) Buffers - Tris/phosphate/sodium citrate based buffers are used to maintain neutral pH. 
(iv) Probe concentration - low probe concentrations are important for the reduction of non-
specific binding. 
(v) Blocking agents - a number of other macromolecules can be included in the 
hybridisation mixture to reduce background, including salmon sperm DNA, transfer RNA 
and Denhart's solution. 
Post-hybridisation washes, are used to wash off mismatched and non-specifically bound 
probe. Usually these washes include the sequential immersion of the specimens in salt 
solutions alone or with formamide. The temperature, formamide and ionic concentration 
of this solution can be varied to improve the specificity of the final detected signal. 
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The choice of a detection system is determined by the probe label used, and this may be 
direct (e.g with flourescin labelled probes), or indirect by the sequential application of 
histochemical reagents (e.g with biotin). 
In order to confirm the specificity of signal a number of controls are usually employed. A 
positive control and a no hybrid control are usually included. A positive control probe 
usually demonstrates RNA/DNA preservation in the tissue, and this will exclude one cause 
of false negative results. 
For negative controls, omission of probe from the hybridisation mixture, allows the 
exclusion of non-specific reactions m the detection systems. However this does not 
provide information on background staining engendered by the probe, and negative control 
probes (designed to unrelated RNA species) will provide this additional information. 
It is important to prevent contamination from exogenous ribonucleases during all steps of 
the procedure until hybridisation by treating all glassware and solutions with diethyl 
pyrocarbonate (DEPC). 
Localisation of PAI-l mRNA by in situ hybridisation. 
i) PAI-l Probes 
Prior to the study, I tried to obtain a cDNA probe to PAI-l which had been used in the UK for 
a previous study on the gene expression of PAI-l in transplant kidneys (Wang et al 1994), but 
it was not possible to track down the author who had specifically obtained the probe. A 40-
oligomer probe for the detection of PAI-l was commercially available (Cambridge bioscience 
UK). This probe was supposed to have been tested on paraffin embedded tissue, but the 
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company could not provide any publications in support of this claim. Therefore for practical 
reasons, it was decided to use a cocktail of synthetic oligonucleotide probes. It was 
anticipated in addition to being easy to obtain, that these probes would provide the added 
potential benefits of a high efficiency of hybridisation, and increased sensitivity compared 
with the single commercial oligonucleotide probe. 
Oligonucleotides of 30 bases in length were synthesised. Shorter sequences would have 
formed less stable hybrids, and with longer ones there were potential problems with 
homology. Probes of this length also allow more flexible limits of stringency to be used and 
still remain specific as well as being long enough to diminish the chance of cross-
hybridisation with similar sequences in the human genome. Base sequences complementary 
to 5 regions of the known nucleotide sequence of the DNA coding for human PAI-l (Ny et al 
1986) were selected so that they did not occur too closely to each other (greater than 20 bases 
apart) to avoid any possibility of interference of probe hybridisation once they have been 
labelled by the addition of a tail. The base sequences (see figure 7. 1) selected also had 
approximately a 50% G-C content to increase the stability of DNA/RNA hybrids. 
Table 7.1 
Oligonucleotide sequences selected for synthesis of PAl-l probes. 
Prob~ · Sequence (5.·3· ) Nuclcotid~ Position 
I CAT,AGC,TGC,TTG,AA T,CTGCTG,CTG,GGT,TTC 198- 169 
2 TCC,A TG,GCC,CCA,TGA,GCT, CCT,TGT,ACA,GAT 27 1-242 
3 CTT,GAC,CGT,GCT,CCG,GAA,CAG,CCT,GAA,GA 378-349 
A 
4 CTT,CAC,CCA,GTC,A TT,GA T,GA T,GAA,TCT,GGC 435-406 
5 CTT,CCA,CTG,GCC,GTT,GAA,GTA,GAG,GGC,A TT 540-511 
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To ensure the specificity of these sequences for PAI-l, the following human nucleic acid 
databases GenBank, EMBL and HGMP-RC cDNA sequences, on the UK Human Genome 
Resource Centre intemet web site were searched using a search engine (BLASD found on 
the web site. The results confirmed a perfect match with PAI-l and no other known DNA 
sequences. 
The first three (three and not all five because of financial considerations) oligonucleotide 
sequences were then chosen for synthesis. These PAI-l probes were synthesised using 
phosphoramadite chemistry (Beaucage and Caruthers, 1981) on a DNA synthesiser at the 
department of Pathology, University of Bristol. 
The oligonucleotide probes were labelled (see appendix 4) at the 3 · hydroxy end with 
digoxygenin using the homopolymer tailing method with terminal deoxynucleotide 
tranferase (Boerhinger Mannheim). Digoxigenin was chosen as the label because the 
laboratory used for this experiment did not carry a licence for radioactive experiments, and 
because of the previous experience of the supervisor of this project. 
ii) Control probes 
In order to demonstrate RNA preservation in the tissues, oligonucleotide probes 
complementary to mitochondrial ribosomal RNA normally expressed in most tissues were 
used as positive controls. Mitochondrial RNA is highly expressed within all tissues and 
there was also previous experience within the Department with this probe (Hilton et al 
1994). 
For negative controls, the probe was omitted from the hybridisation mixture. 
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iii) In situ hybridisation 
The details of the method including the preparation of the solutions and labelling of the probes 
with digoxygenin are given in appendix 4. 
Preliminary experiments performed on paraffin embedded sections of inflamed appendix 
in 1997 using the mitochondrial ribosomal RNA probe alone established that the technique 
of hybridisation worked and determined the optimal dilutions for some of the reagents. 
Following this, the experiment was performed on the study material using the cocktail of 
oligonucleotide probes for PAI-I and mitochondrial RNA probes. For negative controls, 
no probe was included in the hybridisation mixture and inflamed appendix which had 
previously been known to express PAI-l (Whawell et al 1993) were used as positive 
controls. 
In situ hybridisation was carried out as follows; 
Four micon sections mounted on aminopropyl silane coated slides were dewaxed in xylene 
and graded alcohols, then washed in hot SSC (sodium chloride and trisodium citrate 
dihydrate solution) to denature any RNA secondary structure. They were then treated with 
proteinase K (at two concentrations 2 and 5 Jlg/ml to expose the target sequences). These 
two dilutions of proteinase K were used in the preliminary experiments to determine an 
optimal dilution for the test material. Sections were then briefly refixed in 0.4% 
paraformaldehyde for 20 minutes at 4° C. Next the slides were then incubated with the 
prehybridisation solution for 30 minutes at 37° C and with the hybridisation solution 
overnight at 37oc. The hybridisation solution consisted of 50 Jll of buffer containing 
0.1 ng/Jll probe, 30% formamide, 600mM NaCI, 0.1 M phosphate buffer, l 0% dextran 
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sulphate and l50)lg/ml sheared SSDNA (Salmon spenn DNA). Post-hybridisation 
washes were perfonned with 2 x SSC/30% fonnamide at 37oc to wash off any 
unhybridised or mismatched probe. Sections were blocked for I 0 minutes in a solution of 
3% bovine serum albumin, triton X and tris-buffered saline to prevent non-specific 
antibody binding. Following this they were incubated with anti-digoxigenin antibody 
conjugated to alkaline phosphatase at I :600 and I :300 (Boehringer-Manheim) for 30 
minutes. Two dilutions of alkaline phophatase were used in the preliminary experiments 
to detennine an optimal dilution for the test material. NBT/BCIP (Nitrobluetetrazolium, 
and bomochloroindolylphosphate) were applied as substrates for the colour reaction and 
left in the dark overnight. The next morning, the slides were rinsed, counter-stained with 
hematoxylin and mounted in Apathy's medium. 
RESULTS 
There was clear expression of mitochondrial ribosomal RNA in the cytoplasm of cells 
from the inflamed appendix used in the preliminary experiment (Figure 7 .I). No 
detectable staining for PAI-l mRNA was found in the cytoplasm of any of the ovaries, and 
only a weak expression of mitochondrial ribosomal RNA was detected (Figures 7.2 & 7.3). 
Some staining for PAI-l mRNA was noted in the nucleus of a few granulosa cells, 
however this was most likely non-specific staining, as mRNA is usually found in the 
cytoplasm. There was also no detectable staining for PAI-l mRNA in the sections of 
inflamed appendix, which had served as a known positive control tissue. No staining for 
PAI-l or mitochondrial RNA was found in the negative control tissue. 
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Figure 7.1 Clear expression of mitochondrial ribosomal RNA in mucosa of inflamed 
appendix used as positive control for insitu hybridisation. 
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Figure 7.2 Absent signal for PAI-l mRNA in cytoplasm of cells in polycystic ovaries, 
but note granulosa cell nuclear staining (dark reaction product). 
140 
Figure 7.3 Weak expression of mitochondrial ribosomal RNA in polycystic ovary. 
DISCUSSION 
The results from this study showed that PAI-l mRNA was not detected in either polycystic 
or normal ovaries, and that it was also not detected in inflamed appendix which had served 
as the positive control tissue for PAI- l (Whawell et al 1993). 
The fact that mitochondrial RNA was detected in the ovaries and inflamed appendix 
suggests that there was no problem with the technique of in situ hybridisation itself , 
however the negative results for PAI-l may have occurred for any or a combination of the 
following factors. Firstly the cocktail of PAI- l oligonucleotide probes used for this study 
may not have been sensitive enough for the detection of PAI-l mRNA and secondly 
overall tissue RNA preservation may have been poor in the sections from ovaries and 
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inflamed appendix samples used for this study because of the effects of endogenous 
ribonucleases (RNAses) on PAI-I mRNA. 
It is unlikely that a reduced sensitivity of our probes was the single contributory factor to 
the negative results, as with previous research using northern blot, a single 17 base 
oligonucleotide probe containing one internal mismatch provided enough signal to be 
distinguishable from background signal in a study comparing long DNA fragments with 
oligonucleotides (Berent et al 1985). However it is ·important to note that these material 
would not have had the potential problem of endogenous RNAses present in our study 
material. It is therefore likely that our results arose because of a combination of poor 
tissue RNA preservation and low probe sensitivity. 
Degradation of mRNA by intrinsic RNAses can be limited by rapid fixation of tissue 
specimens, and this is shown by the decreasing yields of RNA obtained from freshly fixed 
biopsies, laparotomy and postmortem gut spet:imens (Yap & McGee 1992). It is therefore 
important that tissue to be used for in situ hybridisation is fixed as soon as possible after 
surgical biopsies, for optimal RNA preservation. The ovarian biopsies used for this study 
were surgically excised 12-15 years prior to the study, and it is not possible to comment on 
the speed of their fixation. It may be argued that the successful detection of mitochondrial 
RNA in the ovarian samples suggests that poor RNA preservation in isolation may not 
have been the problem, however the weak and patchy demonstration of mitochondrial 
RNA indicates that poor RNA preservation was a major factor as staining for 
mitochondrial RNA in these ovarian biopsies was weaker than that found in the inflamed 
appendix used as a positive control (see figures 7.3 and 7.1). 
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The non-specific nuclear signal possibly occurred because nucleotides in the digoxigenin 
tail were hybridising in a non-specific manner to nucleotides in the nucleus, many of, 
which were undergoing apoptosis leading to fragmentation and destruction of DNA 
(Hilton et al 1997). 
The following options were considered in an attempt to improve the detection of PAl-l; 
obtaining a cDNA probe, repeating the study with sections from fresh fixed ovarian 
biopsies, increasing the number of oligonucleotide probes in the cocktail, and performing 
in-situ gene amplification (in situ polymerase chain reaction). 
All previous studies of PAI-I mRNA detection on human granulosa cells had used a 
cDNA probe during northern blot (Piquette et al 1994, Piquette et al 1993, Reinthaller et al 
1990, Jones et al 1988). A cDNA probe for PAI-I may therefore have improved the 
sensitivity from our sections, however there was no guarantee that it would have been easy 
to obtain one, or that it would have worked if the samples had been fixed suboptimally 
leading to poor RNA preservation. Obtaining freshly fixed ovarian biopsies from women 
with PCOS was considered, however we anticipated ethical constraints as ovarian biopsies 
were no longer performed in our hospital as part of the treatment for infertility in PCOS 
because of the risk of peri-ovarian adhesions and subsequent infertility. In situ gene 
amplification, a recent technique, which is based on the in situ annealing and 
polymerisation of oligonucleotides to complementary nucleotides located at each side of 
the target DNA or RNA (Walker et al 1995), was considered. In this technique, the 
product obtained is then visualised directly by the incorporation of labelled nucleotides, or 
indirectly by following the amplification by insitu hybridisation with labelled probes. All 
of these options including the synthesis of additional oligonucleotide probes would have 
incurred additional financial and human resources, which were already in short supply at 
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this stage of my research projects. . It was therefore felt that as the results of the large 
clinical study on PAI-l in women in polycystic (chapter 5), and the study on 
immunohisochemicallocalisation of PAI-l in polycystic ovaries (Chapter 6) did not show 
a significant difference in systemic or local PAI-l compared with controls, the study was 
best discontinued. 
In summary this study to evaluate the expression of PAI-l mRNA in ovarian biopsies from 
women with and without PCOS using a cocktail of synthetic oligonucleotide PAI-l probes 
did not find any detectable PAI-lmRNA, although signals for the positive control probe 
(mitochondrial ribosomal RNA) were detected. The possible explanation of these findings 
were a combination of the effect of endogenous ribonucleases and an insufficiently 
sensitive oligonucleotide probes. The options considered in order to improve mRNA 
detection included obtaining a cON A probe, increasing the number of oligonucleotides in 
the cocktail, performing in-situ gene amplification, and repeating the study with fresh 
ovarian biopsies and frozen sections. However these were not done because of limited 
financial and human resources. 
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CHAPTER EIGHT 
ACTIVATED PROTEIN-C (APC) RESISTANCE AND POLYCYSTIC OVARY 
SYNDROME 
OUTLINE 
This chapter presents the results of a study to determine whether there was any 
relationship between the increase in the prevalence of a positive family history of 
thrombosis in the PCOS group (see chapter 5) and an increased prevalence of activated 
protein C resistance. 
INTRODUCTION 
In the normal physiology of haemostasis (figure 8.1), clotting factors, natural 
anticoagulants, fibrinolysis, platelets and endothelial cells are the main factors, which 
determine the risk of venous thrombosis. The production and structure of these 
components may be affected by genetic or acquired risk factors, which may increase the 
risk of venous thrombosis. Some of the acquired risk factors for venous thrombosis 
include venous stasis from prolonged bed rest, surgery, obesity, pregnancy, smoking, 
increased age and damage to the blood vessel wall. The heritable defects which are at 
present accepted as proven to be associated with familial venous thromboembolism are 
deficiency of antithrombin Ill, protein C or protein S and factor V leiden mutation 
(activated protein C resistance) (Walker 1997)._ Antithrombin is a naturally circulating 
anticoagulant, which inhibits activated factors XII, XI, IX and X. The rate of interaction 
between antithrombin Ill and activated clotting factors is increased in the presence of 
heparin. Protein C is a vitamin-K dependent plasma protein, and it is a key player in 
physiological anticoagulation. After its activation on the surface of endothelial cells by a 
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complex of thrombin with thrombomodulin, activated protein C inhibits coagulation by 
selectively degrading coagulation factors Va and VIlla. Protein-S, another vitamin K -
dependent plasma protein is thought to function as a cofactor to APC. 
Figure 8.1 The coagulation cascade 
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Of the heritable coagulation defects, the commonest appears to be that associated with 
APC resistance, which has been shown to be present in 30 to 50% of cases with venous 
thrombosis (Griffin et al 1993, Koster et al 1993, Svensson & Dahlback 1994) and 45% 
of relatives of people with venous thrombosis (Svensson & Dahlback 1994). 
Antithrombin Ill deficiency appears to be present in 1 in 200 to 400 individuals (Tait et al 
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1994) and protein C deficiency in I in 300 to 500 (Tait et at 1995). So far no large study 
has reported the prevalence of protein S deficiency (Walker 1997). 
The role of APC resistance in familial thrombophilia was first identified in 1993 by 
Dahlback et at (1993) during the investigation of 51 year old man with a history of 
multiple thrombotic events. They found that the addition of activated protein C to his 
plasma did not result in a normal anticoagulant response as measured by prolongation of 
an activated partial thromboplastin time (APTT). Four of the proband's relatives also had 
histories of thrombosis, and they and several other family members also responded poorly 
to APC in the APTT. After ruling out several other theoretical possibilities that could 
have provoked the poor anticoagulant response to APC, the authors postulated that the 
findings were due to a deficiency of a hitherto unknown co-factor to APC. 
Subsequently, DNA studies have shown that APC resistance is caused by a point mutation 
in the factor V gene (named Factor V Leiden or factor V:R506Q) which renders the 
activated factor V molecule resistant to APC inactivation (Bertina et at 1994, Voorberg et 
at 1994, Zoller et at 1994a, Zoller et at 1994b ). The mutation replaces arginine { R} with 
glutamine {Q} at position 506 of the factor V molecule. A remarkably high prevalence of 
APC resistance and the factor V:R506Q mutation have been found in healthy controls in 
several European countries, most notably Greece (14%), France (10%), United kingdom 
(9%), Germany (8%), Sweden (7%) and the Netherlands (5%) ( Koster et at 1993, 
Svensson et at 1994, Beauchamp et at 1994, Soubrier et at 1995, Rees et al 1995). So far 
the mutation has not been identified in Italian, Japanese, Chinese, African or Arab 
populations which could account for the relatively low incidence of venous thrombosis in 
these races. 
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Recurrent pregnancy loss has been associated with deficiencies of antithrombin III, protein 
C and protein S (Zanardi et al 1995), and APC resistance has been shown in 20% women 
with a history of second trimester miscarriage and 5% in the first trimester but the exact 
role of these thrombophilic defects in recurrent pregnancy loss is debatable. APC 
resistance has also been linked with an increased risk of pre-eclampsia (Davidson et al 
1995). Polycystic ovaries are the commonest finding in women with recurrent pregnancy 
loss (Ciifford et al 1996) and women with PCOS have an increased risk of developing pre-
eclampsia (Gjonnaess et al 1989, Urman et al 1997). In the study carried out in chapter 5 
(PAl-l and metabolic features of PCOS), although none of the women themselves had 
suffered from a thromboembolic event, 29% of women with PCOS gave a positive family 
history of thrombosis compared to 8% in the control group. A family history of strokes 
and myocardial infarction was also elicited separately and this family history of thrombosis 
was assumed to refer to venous thromboembolism. This suggests that women with PCOS 
may have an increased prevalence of inherited thrombophilic defects, which in addition to 
placing them at increased risk of thrombosis could also possibly explain the link between 
PCOS and recurrent pregnancy loss. Prior to this study there had been no previous 
studies in the literature on the prevalence of these thrombophilic defects in women with 
PCOS, and this study was therefore performed to determine the prevalence of APe-
resistance in women with PCOS compared with controls. The prevalence of deficiencies 
of protein C, protein S and anti-thrombin were also determined in the women with a 
positive family history of thrombosis. 
SUBJECTS AND METHODS 
The overall recruitment of subjects and their general characteristics are described in 
chapter 3 (study group II). Table 8.1 shows the characteristics of the women who gave a 
positive family history of thrombosis and their affected relatives. Approval was sought 
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from the local research ethics committee, and stored frozen platelet free plasma from 
patients who took part in the study in chapter 5 were thawed within one year of collection 
for the assays on APC-resistance, protein S, protein C and anti-thrombin Ill. 
Assays 
APC resistance: In general, the standard screening test for the APC resistance phenotype 
measures two APIT' s , one performed in the presence of APC which results in a 
prolonged APIT, and the other in its absence. The relationship between the two APITs is 
usually expressed as an APC-ratio. APC resistance is indicated when the ratio is below or 
equal to a cut off value defined as the lower limit of a normal range (calculated as the 
mean A PC-ratio from 50 to I 00 healthy controls minus two standard deviations). Typical 
APC ratios obtained on most instruments are :5: 1.5 for homozygotes, :5: 2.3 for 
heterozygotes and :5: 2.5 for individuals with a normal factor V genotype. With a 
diagnosis based on an APC-ratio <2.23 (mean-2SD) the standard APC resistance test has 
been shown to have a sensitivity of 76% and specificity of 98% for the factor V:506Q 
mutation in a group of patients with venous thrombosis (Ailluad et al 1995). However by 
using a modified APC resistance test, in which the patient sample is diluted in factor V-
deficient plasma the sensitivity and specificity for the factor V:R506Q mutation is 
increased to almost I 00% (Dahlback 1995). 
For this study, APIT ratios for APC resistance were calculated using a commercially 
available kit (Coatest APC resistance, chromogenix Sweden). With this kit, the 
measurement principle of APIT is that plasma is incubated with a standard APIT reagent, 
and coagulation is triggered by the addition of CaCI 2• All the controls and test cases were 
diluted I :5 in factor V deficient plasma (I mm uno LTD, Kent). The precision for APC 
ratios using the chromogenix kit showed a between series coefficient of variation of 1.4% 
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for ratios of 2.0 and 3 to 5% for ratios of 3.6 to 4.1. The normal range of APC ratios 
established from the local Plymouth population is 1.85 to 2.80 (mean ± 2SDs), and so far 
the sensitivity and specificity for the detection of the factor V :R506Q mutation using this 
range has been I 00% (Condon J, personal communication). 
Anti-thrombin Ill, Protein C and Protein S activity were determined using automated 
coagulation analysers based on chromogenic reactions (Instrumentation Laboratory-
Milano, Italy). 
The principle of the antithrombin Ill assay is that antithrombin Ill has a powerful and 
immediate antithrombin action in the presence of heparin. The assay involves the 
incubation of the test sample with an excess of thrombin in the presence of heparin, and 
the detection of the residual thrombin on a synthetic chromogenic substrate. The 
paranitroaniline release, monitored at 405nm, is inversely proportional to the antithrombin 
Ill level. The normal range is 80%-120% and the sensitivity is 15%. 
The protein C assay is based on the initial activation of protein C in a test sample with 
protein C activator (derived from the venom of the copperhead snake). The amount of 
activated protein C is determined by measuring the amidolytic activity on a chromogenic 
substrate. The normal range is 70%-140% and the sensitivity is 15%. 
The assay for Protein S is based on the principle that the functional activity of protein S, 
cofactor of activated protein C, is proportional to the prolongation of the PT of a protein S 
deficient plasma to which diluted sample has been added. The normal range is 60-140% 
and the sensitivity is I 0%. 
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All assays had been successfully subjected to the UK national external quality assessment 
scheme for blood coagulation based in Sheffield. 
Statistical Analysis 
Results were stored on a spreadsheet (microsoft excel) for analysis, and are presented as 
proportions of the overall population with results outside the normal reference range. 
Comparisons between groups were performed using the chi-squared test. A p value of< 
0.05 was accepted as statistically significant. 
RESULTS 
Of the 41 women with PCOS and 25 controls, 12 women in the PCOS group and 2 in the 
control group gave a positive family history of thrombosis as detailed in table 8.1. In all of 
these women with a family history of thrombosis, the APC ratios, protein C, protein S and 
antithrombin Ill levels were normal (table 8.2). 
There was no significant difference in the overall proportion of women with low APC 
ratios in women with PCOS compared with controls (three women in the PCOS group 
(7%) vs one woman in the control group (4%), p=0.5), and the prevalence of APC 
resistance in the entire study population was 6.5%. 
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Table 8.1 General Characteristics Of The Women With a Positive Family History 
Of Thrombosis. 
5 PCOS 1.68 57 20.2 
6 PCOS 31 1.76 107 34.5 
33 1.575 66 26.6 
11 PCOS 26 1.55 59 24.5 
23 PCOS 25 1.675 74 26.3 
25 PCOS 19 1.725 118 39.6 78 
33 PCOS 3 1.65 86 31.6 69 
36 Control 3 1.53 53 22.6 Uncle Not 
known 
50 PCOS 1.52 53 Grandmother 30 
55 PCOS 28 1.55 97 Mother 37 
5 Control 33 1.55 96 Aunt 34 
6 PCOS 33 1.68 100 35.4 Mother 
71 PCOS 37 1.54 66 27.8 Father 77 
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Table 8.2 APC ratios, protein S, protein C and antithrombin Ill levels in the 
Women With a Positive Family History Of Thrombosis. 
Stud~· Number ;Diagnosis APC-ratio Antithrombin Jlrotcin C -ProteinS 
t Ill(%) (%) ~(0/o) 
3 PCOS 2.6 92 98 119 
5 PCOS 2.6 84 91 106 
6 PCOS 2.4 90 125 114 
10 PCOS 2.4 85 86 110 
11 PCOS 2.5 92 102 85 
23 PCOS 2.5 93 101 100 
25 PCOS 2.3 89 112 103 
33 PCOS 2.4 114 130 120 
36 Control 2.5 85 78 78 
50 PCOS 2.5 94 82 98 
55 PCOS 2.5 98 100 110 
57 Control 2.6 100 81 118 
66 PCOS 2.6 100 120 118 
71 PCOS 2.4 95 118 107 
DISCUSSION 
The results showed that women with PCOS did not have an increased prevalence of APC-
resistance, compared to controls, that the prevalence of APC resistance in both groups 
were within the normal range expected for the general population in the UK (Rees et al 
1995) and that none of the women with a positive family history of thrombosis were 
positive on the thrombophilia screen for antithrombin Ill, protein C and protein S. 
Although these results suggest APC-resistance most probably does not play a role in the 
PCOS, it is not possible to conclude that the same applies to antithrombin III, protein C 
and protein S deficiency because they were only tested in the 14 women with a family 
history of thrombosis and not the entire population. 
On closer inspection of the characteristics of the 14 women with a family history of 
thrombosis in only six cases (five PCOS and one control) did the thrombotic event occur 
before the age of 50 years. As inherited thrombophilic defects are relatively rare but more 
common in the younger age group, one could argue that this study was not justified based 
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on the fact that it was unlikely that any thrombophilic defect was going to be found in this 
small "at risk" population of six, and that a larger study may have been appropriate with a 
prior sample size estimation. However this study could be justified by the putative links 
between these thrombophilic defects and recurrent pregnancy loss and pre-eclampsia. 
These are unexplained phenomena, which occur in women with PCOS, and the results of 
this study could serve as a pilot study on which to base any calculation for a sample size. 
The results from this study did not suggest that an increased prevalence of APC-resistance 
in PCOS could be found in larger studies but that further studies on other inherited 
thrombophilic defects might be necessary. 
APC-resistance is ideally detected by DNA studies to determine whether patients are 
heterozygotes or homozygotes for the factor V leiden mutation. However in our 
laboratory, the sensitivity and specificity so far for the detection of heterozygotes for the 
Factor V Leiden mutation has been I 00% when factor V deficient plasma is used. This 
is consistent with previous studies (Dahlback 1995) and supported by the fact that genetic 
tests confirmed that all of the women with low APC-ratios in this study were 
heterozygotes for the factor V Leiden mutation on follow in the haematology outpatients 
clinic (Prentice AG, personal communication). 
Although these inherited thrombophilic defects did not appear to be related to the finding 
of an increased family history of thrombosis in PCOS, it is important to remember that 
women with PCOS have other features which could place them at increased risk of 
thromboembolic disease such as insulin resistance and obesity. As there appears to be a 
genetic component in the PCOS making insulin resistance and obesity more likely in their 
relatives, it is possible that these factors may have contributed to the increased family 
history of thrombosis observed in the PCOS group. Unfortunately this hypothesis could 
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not be tested because there were no details on the insulin states and BMis of these 
relatives. However the finding of a correlation between a positive family history of 
thrombosis and PAI-l in the multiple regression analysis in chapter 5 does suggest that 
insulin resistance and elevated PAl-l may explain the increased family history of 
thrombosis observed in the PCOS group. On the other hand the study in chapter 5 also 
suggests that, although women with PCOS were insulin resistant compared to weight 
matched controls, their PAI-l levels were not correspondingly elevated. 
In summary, the prevalence of APC resistance was determined in women with PCOS and 
controls using an APTT based assay. The prevalence of deficiencies of antithrombin Ill, 
protein C and protein S in a subgroup of women with a positive family history of 
thrombosis were also determined. The results showed that the prevalence of APC 
resistance was similar in both the control and study groups and similar to the prevalence in 
the general population. No deficiency of antithrombin Ill, protein C or protein S was 
detected in the subgroup of women with a positive family history of thrombosis. Further 
studies are suggested to determine the prevalence of venous thrombosis in women with 
PCOS. 
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CHAPTER NINE 
CONCLUSIONS 
This study was designed to determine whether elevated PAl-l levels were part of the 
metabolic aspects of PCOS and to investigate the expression of PAl-l protein and mRNA 
in the polycystic ovary compared with normal ovaries. It was thought that the results might 
help discover whether PAl-l and the PAS contribute to the pathophysiology of anovulation 
and pregnancy failure in women with PCOS and whether these women were at increased 
risk of thromboembolic disease from a prothrombotic PAS. Although some of the stated 
aims were achieved, questions have been raised. 
The clinical pilot study of systemic plasminogen activation in chapter 4 showed that 11 
oligomenorrhoiec women with PCOS had a prolonged ECLT and PAI-l compared to 12 
controls with regular menstrual cycles, which suggested that elevated PAI-l was a feature 
of the PCOS and that in addition to placing women with PCOS at increased risk of 
thromboembolic disease, it was consistent with the hypothesis that PAI-l played a role in 
the pathophysiology of anovulation and miscarriage in PCOS. 
Unfortunately, women in the pilot group of PCOS were of a significantly greater BMI 
compared with the controls, which may have explained the elevated PAl-l in PCOS as 
obesity correlates positively with PAl-l levels. 
This pilot study enabled us to calculate the required sample size for the larger clinical study 
(chapter 5), determine the overall feasibility of a large clinical study on the PAS in the 
PCOS in the setting of a district general hospital where these studies were carried out, and 
highlight any potential difficulties which were to be avoided in the larger study. 
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The large clinical cross-sectional study of PAI-l and the metabolic aspects of the PCOS in 
chapter 5 showed that systemic PAI-l activity or any other measured component of the 
PAS were not significantly different in 41 oligomenorrhoeic women with PCOS compared 
with 25 regularly menstruating controls of a similar BMI. It also showed that the only 
significantly different metabolic features of the PCOS group were insulin resistance, 
hyperinsulinaemia and lower HDL cholesterol ratios. The study did not confirm that 
hypertriglyeridaemia, hypertension and raised PAI-l described in syndrome X were 
present. These findings were not consistent with the hypothesis that elevated PAI-l levels 
put women with PCOS at increased risk of thromboembolic disease or that it contributed 
to their anovulatory infertility and miscarriage. 
Another interesting but unexplained finding from this study was the approximately three-
fold (but not significant) increase in the presence of a positive family history of thrombosis 
in women with PCOS. 
The results from the clinical studies in this thesis must however be interpreted with caution 
for the following reasons. Firstly they were primarily designed to detect statistical 
differences in the systemic levels of metabolic and haemostatic variables, which may not 
be the same, as differences that, are biologically important. Secondly these systemic PAI-
l measurements were one aspect of a dynamic plasminogen activator system which could 
have been influenced by the many variables which affect the PAS. The observed 
variability of the mean and median PAI-l values observed in these studies may therefore 
have been larger than one would have observed if all these variables were perfectly 
controlled, increasing the potential of a type 11 statistical error. Although very good 
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standardisation was obtained by the measures taken in the studies, perfect standardisation 
was impractical to achieve. 
Experimental work at the level of the end organ often provides more insight into the exact 
role of a putative factor in a biological process of interest involving that organ, and the 
studies on the ovarian expression of PAl-l protein and mRNA were designed for this 
purpose. The results of the study on the immunohistochemical detection of PAI-l in 
polycystic ovaries demonstrated that PAl-l was mainly expressed in the peri-follicular 
region in human ovaries supporting the hypothesis of a role in ovulation. The failure to 
demonstrate a statistically significant difference in PAl-l staining on quantification by 
computer image analysis cast doubts on any role in anovulatory infertility in PCOS. The 
previous argument about the possibility of a false negative result from insufficient 
standardisation of all the possible variables which may affect a dynamic PAS also applies 
to any conclusions drawn from the quantification by image analysis. 
Nevertheless this was the first study to describe the in-situ localisation of PAI-l protein in 
the human ovary. It was disappointing that the study on PAI-l mRNA expression in 
stored biopsies of polycystic and control ovaries failed to detect PAl-l mRNA, although 
signals for the positive control probe were detected. Although it is possible that the 
negative results occurred either because endogenous ribonucleases had degraded PAI-l 
mRNA in the study material or the cocktail of oligonucleotide probes used for PAl-l the 
study were not adequately sensitive, this study was very useful in highlighting the 
occasional difficulties encountered in laboratory research. 
The study on APC-resistance in the PCOS is an example of how new questions can be 
raised in research as it was prompted by the unexpected finding of an increased prevalence 
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of a positive family history of thrombosis in women with PCOS. The results suggested 
that women with PCOS were not at increased risk from thrombosis because of APC 
resistance. The prevalence of APC resistance was similar in both the PCOS and control 
groups and not significantly different from the prevalence in the general population. No 
deficiency of antithrombin Ill, protein C and protein S was detected in the subgroup of 
women with a positive family history of thrombosis. However the number of women in 
this subgroup was too small to draw any meaningful conclusions on whether these factors 
played a role in the PCOS given their relatively low frequency in the general population. 
This study did not support the hypothesis that elevated PAI-l was a feature of the PCOS, 
but the in-situ expression of PAI-l protein was shown for the first time to be localised 
mainly to the granulosa and theca cell layers of both polycystic and normal ovaries 
supporting a previously suspected role in human ovulation. Women with PCOS were not 
found to have an increased thrombotic risk from APC resistance. It was not possible to 
speculate confidently on a clear role for PAI-l in contributing to the poor reproductive 
performance observed in the PCOS or in causing an increased thrombotic risk. It however 
raised questions about the exact pathophysiology of the metabolic consequences of insulin 
resistance in PCOS and a possible link between PCOS and venous thrombosis. 
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Further Research Questions Generated By This Work 
• Are the metabolic consequences of insulin resistance in women with PCOS different 
from those in other forms of insulin resistance ? 
• Are women with PCOS at increased risk of venous thrombosis ? 
• Is there an increased prevalence of a positive family history of thrombosis in women 
with PCOS? 
• Is the production of PAI-l by granulosa cells from women with PCOS in response to 
insulin, gonadotrophins or steroids different from controls ? 
160 
Contents 
Profonnas for study group 1 
PAI-l assay 
Individual data for study group I 
Proformas for study group 2 
Individual data for study group 2 
Profonnas for study group 3 
Protocol for Immunohistochemistry 
APPENDICES 
Reagents & Protocols Used For In-Situ Hybridisation 
161 
163 
166 
168 
172 
176 
180 
181 
187 
•• o'"---,r 'I,-, ::----
' 
APPENDIX ,1 _,p!{~FORMAS:}?OR STUDY GROUP 1, 'PAI~l ASSAY:, 
INDI::\I:IDliAJi.,DAlfA FOR: SJ1UDY GROUP 1 
.-
162 
PCOS PROFORMA FOR STUDY GROUP 1 
163 
164 
165 
PAI-l assay 
Materials 
The reagent PAl kit came with instructions for the preparation of Tris.HAc Buffer stock 
solution, Acetate buffer, t-PA, P AI depleted plasma (human), S-2403, plasminogen, and 
stimulator. They were prepared as instructed in the manufacturers data sheet. 
Standards 
Standards were prepared as follows. 
-To make a standard equivalent to 0 AU/ml ofPAI-1, 25}lL of 40IU/ml tPA was added to 
one test tube. To make 40 AU/ml, 25}lL of Tris buffer working solution was added to 
another test tube. 
- 25 }lL of PAl depleted plasma was then added to each of the two test tubes. 
-Next, 4.00ml of sterile water as added to each of the two test tubes. 
- The test tubes were mixed well. 
- and kept at 2 to 8°C. 
Different standards concentrations were obtained by mixing these two standards according 
to the following: 
PAl level in plasma (AU/ml) 40 AU/ml PAl 
!lL 
40 1000 
30 750 
20 500 
10 250 
0 -
A fresh set of standards was used for every test run. 
The samples were prepared as follows 
0 AU/ml PAl 
}lL 
-
250 
500 
750 
1000 
-25 11L of 40 IU/ml, t-PA (20-24°C) was added to the test tube 
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- 25)lL of the sample was added 
-The tubes were mixed and incubated for exactly 10 minutes at 20-24°C 
- 4.00ml of sterile water were added 
- Tubes were again mixed well and kept at 2 to 8°C 
We proceeded with the assay immediately after preparation of standards and samples. A 
uniform time span was kept for both samples and standards from preparation of dilution's 
to start of assay, avoiding differences exceeding I 0 minutes. 
Assay 
I. Assay mixture 
Just before the assay, cold (2 to 8°C) solutions of I volume of plasminogen, I volume of 
S-2403 and 3 volumes ofTris working solutions were mixed. 
2. The following solutions were added in a test tube; 200)lL incubated and diluted test 
plasma or standard (2 to 8°C), 200)lL of Plasminogen/S-2403(fris (2 to 8°C), I OO)lL of 
Stimulator, working solution (20 to 24 °C). They were then mixed and incubated at 37°C 
for 50 minutes. At the end of this period, 20% Acetic acid was added and the solution 
mixed. 
The contents were transferred to a microtitre plate, and the absorbence read against 
distilled water at 405nm. The absorbence (A) of the standards was plotted against their 
concentration of PAl on a linear graph paper. The PAl concentration for the 
corresponding A of the unknown sample was read from the standard curve. 
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INDIVIDUAL DATA FOR STUDY GROUP 1 
Study No Age _Gr~ WeighllKG) Hetghi(M) SMI FG score Oay!~c! Cycle lenghl (wks) Subferlili!): ~>2Bwk miscarrla2 PMH-CVA(N PMH-B.P. NIOOM lOOM PMH-DVT 
5 31 Control 73.6 1.65 27.03 8 14 4.5 Yes 0 oNo No No No No 
si Ta:23 ·--·- 3.7 ---- ----- 0 No ·- No No No No 8 1-----29 Control 1.525 1 2 No 0 
----g 66.5 ·--,:n .. 22.46 --- -------- Yes ------ 0 No No No No 32 Control 7 1-- 26 4 0 No 1.7 22.15 ·---- 4 No 3 oNo No No No 10 44 Control 64 I 14 Yes 
13 29 Control 69 1.664 24.92 0 6 3.7 No 2 oNo No No No No 
14 35 Control 77.5 1.62 29.53 5 15 4~. 2 oNo No No No No 
15 31 Control 81.6 1.65 . 29.97 ---0 ·---23 4 No 0 2 No No No No No 
16 41 Control 60 1.55 24.97 2 16 4 No 0 1 No No No No No 
18 22 Control 55.4 1.55 23.06 5 28 4 No 1 oNo No No No No 
19 41 Control 71.2 1.65 26.15 0 14 4 No 3 1 No Yes No !No INO 
-
- 3 4.5 23 26 Control 65.56 1.6 25.61 0 Yes 0 0 No No No No No 
25 ·---21 Control·- 77.5 1.625 . 29:35 1 4 5 Yes 0 0 No No No No No 
1 32 PCOS 63 1.6 32.42 16 7 32 No 2 1 No No INO INO NO 
2 25 PCOS 83 1.8 25.62 1 712 104 'i'es -0 oNo No No Iiio NO 
"3 - 23 PCOS- ·---1-15 ·--1.825 -34.53 ---2 ·---Hi No 0 0 No No 0 No NO 
4 27 PCOS 90.5 !--· 1.825 34.27 10 30 u Yes 0 1 No INO 0 No 1'10 
7 24 PCQ2._ 70 1.62 28.67 6 53 24 Yes 0 oNo No NO No NO 
8 30 PCOS · --6-3.5 -----r:m -22.63 6 21 17.5 No 2" oNo No ~0 No No 
, 1 30 PCOS 82.1 f625 31.09 9 52 55 Yes 1 oNo No ~0 No NO 
-12 30 PCOS 106 1.7 36.~~ 13 62 13 Yes 0 oNo No No No INO 
20 31 PCO~-~ 63.6 1.6 24.84 ---'f 21 !'i Yes 0 oNo No No No INO 
21 22 PCOS 84 1.575 33.66 8 60 7.5 ~- ii o Iiio I No No No No 22 24 PCOS 112.491 1.702 38.83 22 1 24 No 1 oNo No No No INO 
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IFH · PCO IFH · Dlabe'FH · Tllro [FH · CVA [SmoKing per day [Alcohol (UI'"' [BPSystolic [Bf'~stotic [1~T(ml~ 2ECLT(mins) VOclift_ %VQdifll1 12 m 
,IN-.:;._o __ 17[N~o._,[Y -~""----ll:'N,o ____ ,I~~.E._---+---··--1,o;;:l-··----·-·'---6=l-----,,,: 9::0:I·-----~60 165 75 eo 3.52 4.18
1 
__!_!i 
!No [No \No No jYes 0 0 . 1DQ 60 195 90 105 2.83 3.44 IN,~o--f.;IN;::-o--J:[N;;=:-o- -!i;;Ye=--s--I['N:'=="--- o 0 110 70 120 60 60 50 3.25 3.99 2.3 1 Y~~es __ 1l;N;;::-~-~~~~No __ liiY~es __ 11~No ____ t_r=-=-=-=-=-=-j~oj·===========-~-21l=-=-=~-1~3Dt:=:==j8~o:===j3~so~=====~225t=~1~65][~~===~3 .. g1t;7t===j3~.77~9ETI2-I~N~o-~IN~o_11~N~o~INo [No o 7 _____ ~11:;2~o 1 ______ ;8~D __ ~~1B0!~-~-~~--~1~I~~7-~~~-~--~~--~3-~91~-~~I No [No [No :No I Nil o 14 13o1 _____ ~ -----'-11:;1.~2;;:-. 51 ____ 6~0---=;; 52: .. 5;-t-~ 481 .. 6~6667';-t---;2~.35 _ _:3;;--;1 .. 1~3--;; 1..~5 1 No ~~~---riN~o ___ 11~~---IIN~o--~----=o1 ______________ ~1Dr----~1D~o 1 ___ ~tur_--~1~D5 ___ --,=~so_~~41ts,r~42! .. 8~5714+--~31..~.n __ 74 .. 4~3~3~.6 1 
No [No [Yes [No [Yes _Q -~ ---,1;~4o1 __ ........:9aD·--~ :IJO~r---~21':1;;,;7' .. :;.~5--....; 11.;;11:2;';: .. 5+=341..0::::9'00~9~1l----,~~l---" 31,;:··4::+-~1.1 1 1 ~N~o __ 11;N~to~_ 1 j:o~==~~~~N~o-·f.IY~r,.~.===:, ______ 1,o~ 1 ____________ 4~r----~~~----~5~s1 ____ 2~B~5 11 ___ ~1~42:.,s;r--~142~: .. n-5-~5~o __ ~2!~ .. ee __ ~3 .. ~~11.~.41 No 11~N~o __ 1 ~,,1l: __ 1',~No __ 11No o~----------4~~--;'~'"l-----~7~o1 ___ ~11:2~0r---~~6o_~s~o""~;~5o1 _~~2: .. ~B~·~3~·-;r....;O~I .. 81 ~~~~--II~N~o_1~o~_11~No~_ 1i~No=--l----·•:9~l· o 110 ____ 7=5=l----~4~20r---.~4o5 1 __ -=1~1~3~1 .. 57.711==429l---,4~1..9~4~-'·5~>-.2~~-~2! .. 6 No [No o [No [No 1· 2 oo 8 ~ 142.5 e: 36.6668 2,9: !~8 3.3 
Y.~:o=----!iN~o--l['!•s [Yes [N() a :z11 8 31 360 3.7' 4.n 3.5 
NO No [Yes [No [NO " _1 30 . 8 ~5l-----7i;;-j;t--.,...1i;'i.,;3~5i_;'13:7-i---;i';4.'.1i*-l----7i;' 4.6_2;-t . ...:: 91~ .. 89l 
!S [No [No [No 1 40 9 5; ~~ 1 22.8571 3.81 4.34 9.4 I~-~~~--PvYe=-s-IIN~o--1,~N~o--l------'o~l-----------•l-·----~1'~o~------·~ao1·-----~2!'1~D1------~sof---~1r~57 .. 1~42•s~l•r--~3~1..4~5----731 .. ~a~1 
---·---~1-----·-------~l-------:;~~~----.;o~l---~i.*-------T.<~t---~~~""'r--........:~f---.;o;;~;:.;,r "i:=---~l-i:=-----1\:iN=-o-ljNo [No 0 ____ DO ----;8~0 .. ---~525lr-----~ 480irt---~ 45...:8:=..;.5771i..=i429!----,3~1 .. Bit----:4m.lr3'T.f: 
Yes [No [Yes o 8 IJO ------;;e,o"' ____ 1~20t·-----.,·4i5;;+--.....,,7~7'5 62.5 3. ~~~====~~~===~N~o===t~~~~===J1'~Na~===t======~~oJI~==----_-_-_--_~--~-~~21 i-~------~-;~~~2~of====~7~o====~4~e5~==~1~5o==~3~11~5~~~====~u===~~~~~ lii:=---fi~---li.Ni:=--o-IINo [Yes 0 -~~ _ 90 412.5 1~u 2o.:.o ....!.j, 
No [Yes [No 0 3 uu 80 150 40 iD~ II<CN;;.,~_--Ii~---f.Ni:=--o-·\liN~a·--IINo 20 7 130 eo 352.5 120 ~,5_ 13. 
jNO ()_ No INO [No 10 0 110 8~ _Sfl_ ~ :)7 4.85 5.15 14.9 
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...... 
~ 
0 
SHBGtn~ 
37 
35 9 
48.8 
81.4 
62.9 
61 
33.2 
27.1 
55.2 
49.5 
132.8 
51.3 
31.6 
28.3 
21.1 
19.5 
7.6 
75.8 
28.4 
36.2 
35.4 
25.8 
23.4 
Testosterone(nmolll) 
1.3 
0.8 
1' 1 
1------·!2 
. .....!.~ 0.9 
-----· 
--· 1:2 
- 0.5 
0.8 
0.3 
3.4 
1.7 
1.1 
2.8 
2 
0.6 
2.5 
3.5 
2.9 
4.7 
2.2 
3.4 
3.5 
DHEAS(umoUL). 
10 
7.1 
---------5~6 
---6.2 
-----6 
----- ·· ··s.ii 
------·--a.ii 
4:1 
---·--T<i 
·--·--a:s 
14.8 
----7:3 
-·--s:s 
7.5 
. 10.5 
·==- 5<'~ 10 
13.8 
l1.4 
17.4 
----5.3. 
18.6 
15.3 
Esradiol(pmoUI) _ LH(U/!:l _ 
1--___ 282 36.4 
20 --3:7 
- ------- ---·,3.4 -·---s:; 
----;37 
--u 
-------
---3-; 49 
. ·------------
---5:2 23 
-----246 
--3.2 
150 8.4 
-----54 -=~ 2.~ 
------353 1.8 
-- 145 4.4 
40 2.8 
46 t,,~ 
400 5.9 
r----· 76 3.4 62 2.5 
87 ---9.2 
114 7 
1i8 --7-:1' 
463 --(3 
----~ 11.1 
-----52 13.5 
------67 
-e:s 
~~! !.!!'!:! LHIFSH Plas-1(%!_ Plas-2(%). A.2.aP-1C A.2.aP-2( PAI-1/one PAI-1/two 
----23.1 1575758 84 100 87 98 8.5 1.5 
----7 
o:S28571 91 115 84 103 7 12 
---3.9 
·1.307892 100 -- 127 98 121 4 8 
---8:1 0.950817 104 139 108 126 27 26 
·----7 0.442657 ---- --,Ss 107 102 125 65 7 
------7 
-0.742857 --si ·--- ---7 111 104 112 7 
----3 
-1.os6667 ·--- ---,28' -97 101 123 4 8 
4 1.6 91 94 98 98 22 20.5 
-----3 
'0.766667 89 98 94 100 7 8 
-----3 
'0:533333' 91 104 108 118 8 7 
-~ 1.517241 114 115 115 118 20.5 24 
---5.1. 0.54902 91 105 104 106 14 14.5 
3.4 0.323529 104 114 100 102 15 16 
1.8 3.277778 92 102 98 113 2ii 29 
4.8 0.73913 60 99 102 110 30.5 32.5 
2 1.25 75 67 108 120 11 8.5 
---·5:2 1.789231 --131 ---165 98 111 37 --m 
5.2 1.346154 93 109 102 104 7 4 
5 1.42 118 151 112 130 18 19 
--- 4 1.075 57 71 102 115 f8.5 15.5 
5 2.22 89 132 92 117 2.5 5 
4 3.375 122 118 113 111 1J 14 
·-·----5 
--1.92. 98 101 i'ili 105 38.5 37.5 
APPENDIX 2- PROFORMAS AND INDIVIDUAL PATIENT DATA FOR STUDY 
GROUP2 
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STUDY CODE 
INFORMATION SHEET? 
CONSENT? 
NAME 
DATE OF BIRTH 
BIRTH WEIGHT 
DATE AND TIME 
YES NO 
D D 
D D 
.. ........................................ ... .............. .. ................. ................................. ... ........ ........... 
MEDICATION 
ASPIRfN YES/NO 
HEPARIN YES/NO 
SEX STEROIDS YES/NO 
FERTILITY DRUGS YES/NO 
OTHER ..... ..... ........ ...... ... .. .. .. .. ... ............... ....... .. ... ... ............. ........ .. ... . 
PARITY .................... .. 
DATE OF LAST PREGNANCY .... ........ ........ .. 
NUMBER OF LIVING CHJLDREN ............ ... NUMBER OF MISCARRIAGES .............. .. 
PREGNANCY OUTCOMES 
YEAR GESTATION OUTCOME OTHER (if miscarried ? pregnancy test 
DELIVERED ? d&c) 
PERIODS 
MENARCHE ... ......... ............. ..... .. .... ... ... ............ . 
LAST MENSTRUAL PERIOD .... .. ... .......... ............. ... ... ....... ........ .. 
AVERAGE LENGTH OF CYCLES ...................................................... . 
NUMBER OF PERIODS IN LAST YEAR .............. .. ...................................... . 
SHORTEST CYCLE IN LAST YEAR ................ ... ........ ...... .. ....... ... ......... . 
LONGEST CYCLE IN LAST YEAR .... .................. .. .. ............................ . 
VARIABILITY ... ... .... .... ..... ... .. ...... ... ........ ............. . 
DURATION OF ABNORMAL PERIODS .. .. ............ ..... .... .... ........................ .. 
SMOKING YES/NO (If yes, how many a day? .............. ) 
ALCOHOL YES/NO (If yes how many units a week? ........ ) 
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FERRIMAN-GALLWEY SCORE 
A 
B 
c 
D 
E 
F 
G 
H 
I 
TOTAL 
MEDICAL HISTORY 
CONDITION 
IDDM 
NIDDM 
GESTATlONAL DIABETES 
THROMBOSIS 
STROKE 
MYOCARDIAL 
INFARCTION 
HYPERTENSION 
INFERTILITY 
PCOS 
LIVER DISEASE 
OTHER HAEMATOLOGY 
DX 
OTHER 
OPERATIONS 
DATE OF LAST OPERATION 
FAMILY HISTORY 
CONDITION 
IDDM 
NIDDM 
GESTATIONAL DIABETES 
THROMBOSIS 
STROKE 
MYOCARDIAL 
INFARCTION 
HYPERTENSION 
INFERTILITY 
PCOS 
YES/NO DETAILS 
YES/NO DETAILS (who) 
OTHER: .......... .. .................. ........ ...... ... ... ..... .. .. ......... ... .. .... ... ........... ........ .. .......... ....... . 
HEIGHT (cm) ............. WEIGHT (kg)................ BMI .............. .. 
WAIST CIRCUMFERENCE (cm)............. HIP CIRCUMFERENCE(cm) .............. . 
WAIST/IIIP RATIO....................... 0/o BODY FAT ..................................... .. 
BLOOD PRESSURE I MAC (cm).. .... .. .. .. CUFF SIZE Normal I Large 
POSITION Sitting/Standing/Supine 
KOROTKOFF PHAS E: .......... .. 
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ULTRASOUND FINDINGS 
ABDOMINAL I TRANSVAGINAL 
Right Ovary Left Ovary 
Was The Ovary Seen Yes/No Yes/No 
Number Of Follicles 
Diameter of smallest Follicle (mm) 
Diameter of largest Follicle (mm) 
Distribution of Follicles Periphery I All over Periphery I All over 
Stromal Echogenicity Low/ Normal/ High Low/ Normal/ High 
Maximum Stromal Width (mm) 
Ovarian Size (length X width X X X X X 
--
-- -- -- -- --
thickness in ems) 
Maximum Endometrial Thickness (mm) 
OTHER COMMENTS ............................................................................................... . 
BIOCHEMISTRY 
TEST RESULT & DATE 
TESTOSTERONE 
SHBG 
FAI 
PROLACTIN 
LH 
FSH 
17 OH - PROGESTERONE 
CONCLUSION 
SUBJECT I CONTROL I EXCLUDED ( give reason) 
Follow Up 
Other Comments 
Amount claimed 
Signature and Date 
Name 
TRANSPORT 
£ ............... . 
174 
STUDY CODE 
INFORMATION SHEET? 
CONSENT? 
NAME 
DATE OF BIRTH 
LMP 
DATE AND TIME 
Last Meal 
Last Cigarette 
IS Minute Rest Period 
Time Of Pre Occlusion Sampling 
Time Of Post Occlusion Sampling 
YES NO 
D D 
D D 
----------------------------------------------------------------------------------------------------
ASSAYS 
TEST Pre Occlusion Result Post Occlusion Result 
FIBRINOGEN 
PLASMINOGEN 
PAI-l 
tPA 
a-2 ANTJPLASMIN 
INSULIN 
GLUCOSE 
TRIGLYCERIDES 
HDL 
LDL 
CHOLESTEROL 
OTHER ....................................................................................................................... . 
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... . , ...... I UoiWWk IPG I~ 
)I No !No !No No_ No No ... No NO NO No 
31 No IN• No :No !No No No No 
No No No 
I 
I 
<JS 
No 
'" ,. Vn IN• ... 
lO .. ·~ No !No .. ... 
No IN• 
0 .. 
:os 
"" 1)8 
'"" 
., 
'OS 
4] os 10 
' 36 
lO cos No 
14 No ... Vn 
No No No v .. No 
,., .. No_ No . .. 
'" No 
I 
J3 
38 I 
coo o. No ... 
···-
"'' " '"" 
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BM Wah4Circ(t•)lll C\r't ta WUR •y..t•lk•r 41ont•Uc:. IISSre"t. R evNO llevDSF c:ao~ R • vUU'eolh trrooU.arl •• atr• .. Jt •.,.,. v•IRn at~ ETLevNO L • vDSI' c• LevD(.J'c•4hii'(•U•l• ll•v cLn••L• 
, 21 14.S tl O.U 1•0 ID V iaaJ ll O.t f .l All av•r Non:nal 11. 1 ' 11 l .tt S Allvv•r N S'7tt J.t 
No No No 
1
•
7
u 10 16 uj lDS o,t4 120 70 ~ 1 U 4·1 All~v~"t===~~N~.....,~==E==~'~·'E'~=~·~==~·~=~'i'·~l~A~II~•~·"~==l";onoal~~=l==5'·i"~====:i"~' No No No J .. )(l SI 24 71.l IJ O.Pl 110 70 Y~nW I J 'l1 All o••r NonntJ • 11 7 7 0 t ~: ~: ~: ':.!! :; ~~ ~~:r---:;:;:;':lr.!.:!--:~~·---Toi~= ! l.~ 7.i~:::::~  ~:!: ·: l~ 2.! 'i.!~:::: N= :·.~: 1·: 
Y•• No Yu J.7S 60 20 71 71 0 94 11! "  7 l .t 1ii Allov•r Bri.W 20.1 t 7 S.1 U .l All over N--.1 4.79 0.9 
111/JDCUB llUalutWIX 111/rCOS II•_IPH~_{ W•l 
~ ~ ~ ·~ 
••lL•• c•T•d•d..--• -•IlL 
~:• N: N: I .~,~ : !: :: IOl 0 U 110 · 70 V-..in•l l 2,;1) ------;,,..: ·~.~ ~~ ::: ::::: ~:.~ ; I! ~: 1~:! ~:: ::: == ·:·: U 
No Vu Vu U7J t2 37 109 .:~ :::~ :!: !: ~__.!j !.: 7 All ov.c' Nonn&l t .U 4 11 1.7 l S • ri ~.,.., Ntn!UIJ S.:U 2.2 
Vu No o 1.nJ 101 ll tlO Ul 016 UO lDS Ab~inU J 1.7 :u AIIO\'"' Non..J , ,1l 2 11 2 ] .) Allovtt Normal 10.1 4 
No Na Vu Ul J7 20 n 17 0.9 110 ID ~ ' 2.7 1 All ovc,. 'NonnU 7.ll 1 11 l .J ' -' JMriP~•f'.l Bri&hl I'U t .l ,~ ;:: No l ." 107 lJ 112f---1~2~1 O.flr--m ID~ I 29 '' P..-tf"pl i:'u,.,':::-,.-----ilfw;::onoal::=,---i--t-----f.,ofi.,cf-a<l---il:i-lt---~,.71sf---',ii,1'.,"-.,,'i"f ...,onl=.- -r.Bri::ii~IIO--+----+,?,.I;+-------?..,:I 
~= ~=. ~: ·:;;: ·:: ~~ '£ ·~ m :~~ ~ ==11 q s;; ;~~:" ~~~ :::! -: :: H H :~::::~ ~~ .::: ~ 
Vu Vu Ne 1.'1 " 17 91 t1 OSJ4 IlD 10 V iaal 11 lf ,, l'cri t Bri 11.1 4 11 l .l l .6 eri e....t Uti JO.t ) .4 
No No No U2 " U 10 12 0 91 120 70 V iAAI 11 1., )4 All avrr Bti 4 12 . .U l ll 2., , ,] ptri~AI Bri l4.U 1.1 
No No No Ul 77 17 fl f7 0 '' 110 7J Y!IJ.iaal ll 2 l .l P~~"l' 8ri 10. 0~ I 11 3.3 ll •r'~nl Dri 10.1 1.1 
Vu No 1.7J U 21 tl Ill 0 l l 12l ID V1,1la.t 11 1.7 'Puiphuy Bri 1.41 4 11 2..2 6.9lp~ Bti 7.J1 O.t 
~:· ~: ~: \~~ ~: !! ~ :~ :.:~~~ ;! ~:;:~ 1~r----;!c;:!C~-----+!:'=~I;:C':.;t::=:;:;~·:::L..~---r.~;:~;..:;:;:,'--+----:1_,=1· ~ :: ~·! ~~ ~i b.~ ~ t~:; !:~ 
Yu No Yn 1 6 70 27 17.J U 0 91 UO fD v.._i...J 11 2,.t '' Allovrr Bti&hl 12.7 7 1 U n ri lll•....t Bri U .ll 1 1 
Yu 'No N• J.t7J 74 Z' 92 101 0.91 110 70 V~o£iNII 11 .t 7.1 P1nphlt)' Bri&hr 11.96 I 10 l .l ' -7 ri .,..., Ne1B1aJ 111 2) 
N'o No a 1,'71) lll 40 lOt tU 0.11 110 ID Vqi'*' 7 ll 2.1 lt Altov.r Bri • 14.2 1.' 
No No No UJ C .J U t2 tJ O.SIJ 120 10 Vlf.i-J 11 2.1 ' ..l Ptriphur Br-i&hf l .t-& 7 ll 1..1 J.1 nJ Bri IU t l 
Ne Na Ne 1.7U 121 l9 127 Il l 0.97 110 90 Vllf.lnal 11 l.l ' ·s All ovl't Bri&ht t 2-4 l ll 1.1 1.1 m Bri • IU 1. 1 
Ne No No J.SJ fl 19 97 1 U 0 l.t 120 PO Vqiaal lt 2 .t S.7 Prriphuy Bri .. lll J'l.t ' 1l L9 ( t 2!,ri •nl Bri U.S J.1 
Y" N'• Ne US " H 71 90 0.11 110 70 VaaiDAI 7 2.2 4,1 All over NOftllaJ , .47 S 11 2 S '4 t1i Bri { 01 t.4 
Vu Vu Yu '" 16 12 109 l ll 096 120 IOV ... lnel l ll----;'c;·Scf----=-:'7Pui•• Ncnul 1104: l 11.06 4) ~:: ~= :: .. ,~! :~ ~: '!~ :~~ ~.:~ :~: =~~ -n ~.~t----;~,..,_!' :~!i;~~ ::a:.. ~~~ : :: ;_~ ;:  ftrl ... ~~ :;: .:·;: !:: 
No No o U4 79.J ]0 120 70 ~nal ll 1.J 4' Puiph•ty Bf'ia,ht 11.3 4 J1 1.2 4.J All uvct Bri lU ) , I 
No No No 1.7 77 l7 IS tt 0,16 110 10 AbdominaJ 11 l .J l .l Ptri~uy Nonaal 7.41 1l 11 2., U f!ri nJ Bri 1,41 1.2 
Yu Yn Ne U " 2l 7f tJ D.ll 120 ID V11,1inal 11 J I 7.1 Puiph Bri l2.1 I 11 2.2 ' ' •ri ral 8ti U .U 1.2 
No No e 1.77J 9] ]0 1a.. ID' 0 91 100 60 YA&in.J 11 I 7 4 I Per! h Bri 11.41 '1 11 2 J ' · ' t!."i ,., ~ 11.11 1.6 
}fe Vu Vd l .J2 Jl 21 72 91 0 79 100 '0 AbdotuianJ 7 11 l .1 S All Gvtt U t I 
Y" No No l .U 14 10 19 107 0.11 110 90 ~ 11 1.11 H Peripl1uy Nonual ' ' · ' J 11 J.J ] .1 •ri ll.J l 
Vu No o 1.77 " 12 " IJ 0 92 120 10  11 I I l J Pcriph,ry 8ri 60 4 11 11 ' f'i l'al II.JJ J.4 
Yu No Ne I.U n .tO 120 12-4 .. ~ IG01-!D~ ll f-- --''0:"1;1 7'Pulpbuy & i 11 C 11 '12 !~ ri ~ '8ri IU 1.C 
~:: v:· :: •. ·;~ !: ~:-er----.::~"'1 ::: :~~~::;= :: 2.! ,'.!~~;~:~~ry ~= ·~1~~ ~ :: ~:! ,, tnh.nJ ~= ·~: ·; 
Yu Yu No UJ Jl 24 ID U Ol<ti-J)of-~ol cy,:<;:'li;a::;oJ-1--f;ll 29 'P•ri~huy NIHWI-I 11.%2. 7 11 1.4 '' Nona~ IJ.J I.J 
He Y•• o Ul 100 lJ 110 119 0.91 110 100 Vlllinal t I i 4.9 Allo••r Nonnal J.ll 4 11 1.6 ' ti lw.raJ N..,..J I 16 
Yu No ~ . ' IC 11 14 101 IDI I 110 J0 V-ai.W ll 16 l .l Allov•,. Nonu.l llO.l I 11 U l l ri N.,...J 11.C 1.4 
y.. Ne No 1.7J 101 11 101 120 D.t 1-40 ID y~ 11 I l 44 Pcriphtry Norma.! 1.04 4 tl 1.1 l' rat Bri ' ·" 1.J 
Ne No Ne 1.71 9C 11 tOO lDS O.t_! 110 ID V~ 11 1 ll P.tipl•trl' Norm.- ' ' ' 11 1.2 '' •t lllwnJ Non'l\.1 Ul JS 
!=:----." :.•.• Ne l.J.4 U 21 11 tJ 01! IlD 70A~U'alf---'-',;,'Jf----7,'!,_JI)f.pre'',' i'li ... :;::, ,'."-"-''-. --I:Nnn7,::C.~_,.---f ll.ll--=
2
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PRO_FeRMA FGR;S:('NDYGR~N~~3 
Name: 
Path Number: 
.Hospital N'umber: Age; 
ID lite Qf Opt:ration: • 
Operation: 
Notes: 
Hist()iy:-
Examination: 
tiDrugs: 
Weight: 
Height: 
, 0pdindlngs: 
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PROTOCOLS USED IN IMMUNOHISTOCHEMISTRY 
I initially tried to detect PAI-l using a polyclonal antibody, but unfortunately there was a 
problem with significant background staining in all the slides and it was therefore felt that 
it was best to switch primary antibodies to a monoclonal antibody to PAI-l to resolve this 
problem which was successful. 
REAGENTS 
Solution for blocking endogenous peroxidase 
9mls of lOO-volume hydrogen peroxide in 300mls of methanol. 
Trypsin Preparation (pH 7.80) 
0.1 g of calcium chloride was added to 0.1 g of trypsin and dissolved in 1 OOmls of distilled 
water for 30 minutes. The trypsin temperature was checked 0.01% Sodium hydroxide 
added in drops to bring the pH of the trypsin up to 7.80. The trypsin was then transferred 
to a Grant water bath and allowed to warm up at 37 degrees centigrade for 30 minutes. 
Primary antibody 
Sheep anti-PAI-l polyclonal antibody, - chemicon international inc AB778. Dilution's 
made up as follows; I: I 00 = I 0 J.lL of antibody + I 000 J.lL of Tris, 1: I 000 = I J.lL of 
antibody + I 000 J.lL of Tris & 1: 10000 = 0.5 I J.lL of antibody + 5000 J.lL of Tris. The 
minimum volume of solution required for the 6 slides on which each antibody was to be 
tested was 900 J.lL. 
Secondary Antibody 
Rabbit anti-sheep IgG (H&L) affinity purified antibody (chemicon international inc 
AP147). Dilution's made up as follows; 1: 50= 20 J.lL of antibody and 1000 J.lL ofTris. 
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1: 100 == 10 J.1L of antibody and 1000 J.1L of Tris. 1 : 200 == 5 J.1L of antibody and I 000 IlL 
ofTris. 
Tertiary Antibody 
Biotinylated goat anti mouse I rabbit immunoglobulin (DAKO K0492) Prepared as follow; 
10 J.1Liml required. Total number of slides in the run was 20, which meant that 3000 J.1L of 
volume was required. To make up this dilution, 30 J.1L of the tertiary antibody was added 
to 3 mls ofTris. 
Streptavidin-biotinylated horseradish peroxidase complex (Dako K0492) 
30 J.1L of biotinylated peroxidase, 30 J.1L of steptavidin and 3000 J.1L of Tris 
DAB Solution 
Sigma tablet set - I tablet of DAB added to I tablet of urea and made up to 15 mls with 
distilled water. Allowed to dissolve and filtered into a small 50ml beaker. 
Bleach Solution Prepared For Disposal Of DAB Contaminated Equipment 
10 tablets of actichlor 0.5gms and tap water. 
IMMUNOHISTOCHEMISTRY USING A POLYCLONAL ANTIBODY TO PAI-l 
The steptavidin biotin method was used. Inflamed appendix was used as the positive 
control tissue (Whawell et al 1993). The primary antibody used was sheep anti-PAl- I 
polyclonal antibody, - chemicon international inc AB778. The secondary (link) antibody 
used was rabbit anti-sheep IgG (H&L) affinity purified antibody (chemicon international 
inc AP147), and the third antibody was biotinylated goat anti-mouse/ rabbit 
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immunoglobulin (Dako Denmark, K0492). A checker board titration was used. The 
dilutions of the primary antibody tested were I: 100, l: 1000 and l: l 0,000. The dilution's 
of the secondary antibody were 1 :50, l: l 00 and 1 :200. One negative control slide was 
included. Slides were stained in pairs to determine whether pre-treatment with I 0 minutes 
of trypsinisation or no pre-treatment was required for antigen retrieval. 19 slides in total 
were available for this run. 
1. 4 Jlm sections were cut, mounted on si lane-coated slides and left in a 3 7°C incubator 
overnight. 
2. The slides were transferred to a 60°C incubator for a maximum of 2 hours the next 
mommg. 
3. The slides were dewaxed as follows. 2 minutes in Xylene, 2 minutes in Xylene, 2 
minutes in Alcohol and 2 minutes in alcohol. 
4. Endogenous peroxidase was blocked with 9mls of I 00-volume hydrogen peroxide in 
300mls of methanol for I 0 minutes. 
5. Slides were washed in running water for 5 minutes. 
6. Slides requiring no pre-treatment were left in a Tris bath, while the slides for 
trypsinisation were transferred into a grant water bath set at 3 7 degrees centigrade. 
7. Trypsin was prepared and buffered to a pH of7.80. 
8. Tris in slides for pre-treatment replaced with trypsin for I 0 minutes. 
9. After trypsinisation both set of slides (trypsinised and no pre-treatment) were drained 
onto a blotter, washed well in water marked with a Papain pen, and placed in Tris buffer 
for 2 minutes. 
I 0. The slides were placed in a humid incubation chamber and incubated with the primary 
antibody (three drops of the primary antibody were added to each slide) for 30 minutes 
taking care to put plain Tris on the negative control. 
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13. After incubation, slides were drained and placed in a Tris bath. The bath was emptied 
and replaced with fresh Tris for 5 minutes. 
14. Slides incubated in secondary antibody for 30 minutes. 
15. Same as step 13 
16. Slides incubated with the tertiary antibody for 30 minutes. 
17. Same as step 13 
18. Slides incubated with Streptavidin-biotinylated horseradish peroxidase complex for 30 
minutes. 
19 Same as for step 13, and placed over metal racks over sink. 
20. Incubated for I 0 minutes in 2-3 drops of DAB. 
21. Slides drained off into bleach solution, placed in slide tray and washed well with 
water. 
22. Stained with DAB enhancer for 2 minutes. 
23. Washed well in water 
24. Stained with hematoxylin for 2 minutes. 
25. hematoxylin washed off well in water. 
26. Dipped in acid alcohol I 0 times to remove hematoxylin. 
27. Washed well in water. 
28. Dehydrated in Alcohol, Alcohol, Alcohol, Xylene, Xylene, and Xylene for I minute 
each. 
29 Slides Mounted and viewed. 
Outcome There was a positive stain for PAI-l at all dilution's of the primary antibody in 
the endothelial cells, serosal cells and inflammatory cells in the sections pre-treated with 
trypsin and minimal staining in those that were not pre-treated. However there was also a 
significant amount of background staining in the sections. 
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To resolve this problem, the experiment was repeated replacing the tertiary antibody with 
biotinylated swine anti-rabbit immunoglobulin (Dako E0353) at a dilution of I :200 made 
up as l5J.LL of antibody in 3000 J.LL of Tris. Placental tissue in addition to inflamed 
appendix was used as positive controls, and all the sections were trypsinised. The 
dilutions used for the primary and secondary antibodies were as in the first experiment. 
There was still a problem with non-specific background staining after this experiment and 
the negative control slide had stained positive invalidating the whole batch. 
To resolve these problems, I repeated the experiment usmg weaker dilution's of the 
primary antibody (I: 1000, I: 10000, and I :50000), and secondary antibody (I :200, I :400 
and I :800). In addition, prior to incubating the sections with the primary antibody, they 
were incubated with 20% normal rabbit serum for ten minutes, and the primary antibody 
was diluted in 4% normal rabbit serum. 
Unfortunately, there was still a problem with significant background staining in all the 
slides. It was therefore felt that it was best to switch primary antibodies to a monoclonal 
antibody to PAI-l to resolve this problem. 
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REAGENTS USED FOR IMMUNOHISTOCHEMISTRY USING A 
MONOCLONAL ANTIBODY TO PAI-l 
The following solutions were made up as described for use with the polyclonal antibody; 
Blocking solution for endogenous peroxidase, Trypsin, Biotinylated goat anti mouse/ 
rabbit lgG, Streptavidin-biotinylated horseradish peroxidase complex, DAB Solution and 
Bleach Solution for Disposal Of DAB Contaminated Equipment. The volumes made up 
depended on the number of slides being tested. 
Primary antibody Murine monoclonal antibody (American Diagnostica Inc product 
number 3785). Dilution's made up as follows for testing on appendix (positive control) I: 
25 = 12 IlL of antibody+ 300f1L of 5% nonnal goat serum in Tris and tween (NGS), I :50 
= 150 IlL of I: 25 antibody + 150f1L of 5% NGS, I: 100 = 150!-lL of I :50 antibody + 150 
1-1L of 5 % NGS, I :200 = 150!-lL of I: 100 antibody + !50 IlL of 5 % NGS, I :400 = 150!-lL 
of I :200 antibody + 150 IlL of 5 % NGS, 1 :800 = 150f1L of 1 :400 antibody+ 150 flL of 5 
% NGS, The minimum volume of solution required for each slide on which each 
concentration of antibody was tested was 150 1-1L. For the ovarian sections, the dilution's 
were made up as follows; I :25 = 801-1L of primary antibody and 2000f1L of 5% NGS, and 
I :50= 40!-lL of primary antibody and 2000!-lL of 5% NGS. 
PROCEDURE 
Same as used with the polyclonal antibody to PAl-l, except that the primary antibody was 
incubated for I hour, no secondary (link) antibody was required, and the slides were 
incubated with 20% NGS before incubation with the primary antibody to reduce non-
specific binding. 
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REAGENTS FOR IN-SITU HYBRIDISATION 
Blocking solution to block non-specific binding prior to adding antibody during ISH. 
Dissolve 3g of bovine serum albumin in lOOm! ofTBS and add 100 Ill ofTriton X. Filter 
through Whatman filter paper and store at 40C until use. 
BCIP solution for detection of alkaline phosphatase 
I. Weigh 12.5 mg of 5-bromo-4-chloro-3-indolyl phosphate into a bijoux. 
2. Add 500 Ill of dimethyl formamide in a fume cupboard. 
3. Dissolve and store in the dark at 40C. 
Buffer 3 for the detection of alkaline phosphatase. 
Add: 10 ml I M Tris Cl, pH 9.5, 2 ml 5M NaCl and 5 ml I M MgCl2 to 83 ml of sterile 
ultrapure water. 
Dextran sulphate (50%) 
I. Dissolve I 0 g dextran sulphate (Sigma D600 I) in 17 ml of DEPC treated water, at 600C, 
using RNase free glassware. 
2. Store at 40C. 
DEPC water 
1. Fill empty clean 2 litre bottle with ultrapure water. 
2. Add 2 ml of diethyl pyrocarbonate (Sigma D.5758) in a fume cupboard. 
3. Mix vigorously until DEPC globules disappear. 
4. Leave to stand for at least I hour. 
5. Autoclave. 
6. Store at room temperature. 
Levamisole (1 M) 
1. Dissolve 120 mg levamisole (Sigma, L9756) with 500J.1L sterile ultrapure water in a 
bijoux. 
2. Aliquot and store in 20 IlL aliquots at -2ooc. 
MgCI{!_M) 
1. Dissolve 20.33 g of MgCI2 (Sigma) into final volume of 100 ml of sterile ultrapure water. 
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2. Autoclave and store at room temperature. 
NaCI(S Ml 
I. Add 29.2 g (5 M) NaCI (Sigma) to I 00 ml (final volume) DEPC treated water. 
2. Autoclave and store at room temperature. 
NBT solution for detection of alkaline phosphatase 
I. Weigh 18.5 mg of nitroblue tetrazolium into a bijoux bottle. 
2. Add 350 Jll of dimethyl formamide in a fume cupboard and 150 Jll of sterile water. 
3. Dissolve and store in the dark at 4oc. 
Phosphate buffered saline (PBS) 
I. 5 tablets of PBS (Sigma) dissolved in I Litre of ultrapure water. I tablet in 200mls of water 
gives 0.01 M phosphate buffer, 0.0027M potassium chloride and 0.13 7 M sodium chloride. 
2. Make up to I litre with further water. 
3. Autoclave and store at room temperature. 
PE, modified for ISH (10 X) 
1. Add 6.058 g Tris (hydroxymethyl) methylamine and 1.862 g EDT A to 70 ml DEPC treated 
water in fume cupboard. 
2. Adjust pH to 7.5 with concentrated HCI. 
3. Add: 
I g tetra sodium pyrophosphate (Sigma) 
2 g poly vinyl pyrrolidone (Sigma) 
2 g Ficoll (Sigma) 
4. Dissolved. 
5. Add further DEPC treated water to make final volume 100 ml. 
6., Store at room temperature. 
Proteinase K (lmg/ml) 
I. Weigh out 5 mg proteinase k (Boehringer/P4914) into an RNase free bijoux bottle. 
2. Add 5 ml ultrapure water 
3. Split into 150 Jll aliquots in sterile 0.5 ml eppendorfs. 
4. Store -2ooc. 
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Salmon sperm DNA (10 mg/ml) 
I. Using forceps add 0.1 g deoxyribonucleic acid from salmon testes to a 50 ml beaker 
(RNase free). 
2. Add DEPC treated water to the 20 ml line. 
3. Add small flea and seal with nescofilm. Dissolve overnight on the spinmix at 40C. 
4. Passed through a fine bore needle several times to break up. 
5. Dispense into 1 ml aliquots in eppendorfs. 
6. Pierce lids with sterile needle and boil for 10 minutes to denature. 
7. Cool and store at -200C. 
SDS (10%) 
I. Add I 0 g sodium dodecyl sulphate (launyl sulphate) to a 250ml jar (RNase free) in the 
fume cupboard. 
2. Add DEPC treated water to I 00 ml level. 
3. Cover with nescofilm over the top and dissolve using a spinmix. 
4. Store at room temperature. 
SSC (20X) 
I. Dissolve 87.7 g NaCI (analar) and 44.1 g trisodium citrate dihydrate (analar) in 400mls 
DEPC treated water. 
2. Adjust pH to 7 with a small amount of 0.1 M HCI. 
3. Add further DEPC treated water to make up to 500mls 
4. Filter, autoclave and store at room temperature. 
Tris buffered saline (TBS) 
I. Dissolve 6.06 g Tris (hydroxymethyl) methylamine (BDH) and 8.76 g NaCI in 500 ml 
sterile ultrapure water in the fume cupboard. 
2. Adjust the pH to 7.65 with concentrated HCI. 
3. Make up to a final volume of I 000 ml with sterile ultra pure water. 
Tris-HCI (1 M) CDEPC) 
1. Dissolve 12.1 g ofTris (hydroxymethyl) methylamine in 50 ml of DEPC treated water. 
2. Adjust pH to 7.65 with concentrated HCI. 
3. Volume made up to 100mls with DEPC treated water 
4. Autoclaved and stored at room temperature 
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In situ hybridisation using digoxigenin labelled synthetic oligonucleotides 
I. Dewax sections (4J.Ull on silane coated slides) with xylene/graded alcohols. 
2. Rinse (DEPC treated water). 
3. 2x SSC, 700C for 10 minutes. 
4. Rinse (DEPC treated water). 
5. Proteinase K (2-5 f.1g/ml in O.OSM Tris) for I hr at 370C. 
6. Rinse (DEPC treated water). 
7. 0.4% paraformaldehyde in I X PBS for 20 minutes at 40C. 
8. Rinse (DEPC treated water). 
9. Prehybridisation solution, ISO fll/section, 30mins at 370C (30% formamide, 600mM NaCI, 
I X PE, I 0% dextran sulphate, 150f.1l/ml SSDNA). 
e.g. for 4m I: I 060fll water 
480f.1l SM NaCI 
400fll IO X PE 
800fll 50% dextran sulphate 
60fll IOmg/ml SSDNA (boil 5 minutes, chill on ice for 5 mins) 
I200f.1l I 00% formamide in a fume hood 
10. Hybridisation solution (lml ofprehybridisation solution+ IOOng of probe), 60fll /section, 
overnight with coverslip at 37°C (add probe to the prehybridisation solution to make it at 0.1 
ng/f.ll). 
N.B. all glassware and solutions up to this stage are treated with diethyl pyrocarbonate 
(sigma)-add 1 ml to I litre of solution, leave overnight, then autoclave). 
II.2 X SSC/30% formamide 370C, 3 X 5 minutes washes. 
12. Rinse (ultrapure water) x 4 
13. Block at Room Temperature for 10 minutes (IOOml TBS, 3g BSA (Bovine Serum 
Albumin), IOOfll triton X). 
14. Antidigoxigenin alkaline phosphatase (Boehringer Mannheim) at I :600 11 :300 in blocking 
solution, 30 minutes on rocker. 
IS. Rinse TBS x 2 
16. Rinse Ultra pure water. 
17. Buffer 3, 5 minutes (I Oml I M Tris Cl pH 9.5, SmllM MgCI2, 2ml SM NaCI, 83ml UP 
water). 
18. Substrate (5ml buffer 3, 5 Ill I M levamisole. 22 fll NBT, I6.5 Ill BCIP), 200 Ill/section, 
coverslip and leave in dark for 1-16 hrs. 
19. Rinse and counterstain with hematoxylin. 
20. Mount in Apathy's. 
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3' end labelling of Mitochondrial ribosomal RNA oligonucleotide probes with 
Digoxygenin 
Add the following in an eppendorf tube: 
l. Sterile ultrapure water - 63 Jll 
2. Oligonucleotide ( 40ng/Jll) - 2 J.!l 
3. CoCI2- 10 Ill 
4. 5 x reaction buffer - 20 Ill 
5. I mM digoxigenin-1 I -dUTP - 2.0 Ill 
6. I mM dATP (spacer)- 3.3 Ill 
7. Terminal Tranferase - 4 Ill 
Mix and incubate at 3 70C for I hour then separate. 
3' end labelling of PAI-l mRNA oligonucleotide probes with Digoxygenin 
Add the following in an eppendorftube: 
I. Sterile ultrapure water - 63 J.!l 
2. Oligonucleotide (I OOOng/lll) - 2 J.!l 
3. CoC12- 6 J.!l 
4. 5 x reaction buffer - 20 Ill 
5. !mM digoxigenin-11-dUTP- 2.0 Ill 
6. 1 mM dATP (spacer)- 3.3 J.!l 
7. Terminal Transferase- 4 Ill 
Mix and incubate at 37°C for 1 hour then separate. 
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17-0HP 
A 
A.2.aP 
ACTH 
AEC 
ANOVA 
APC 
APTT 
Au 
BCIP 
BMI 
BP 
c 
CAH 
CCD 
CVA 
cDNA 
Cm 
DAB 
DEPC 
DHEAS 
Diabe 
Distr 
DLF 
DNA 
ABBREVIATIONS 
17 Hydroxyprogesterone 
Adenine 
Alpha-two antiplasmin 
Adrenocorticotrophic Hormone 
Aminoethylcarbazole 
Analysis Of Variance 
Activated Protein C 
Activated partial thromboplastin time 
Arbitrary Units 
5-bromo-4-chloro-3-indolyl phosphate 
Body Mass Index 
Blood Pressure 
Cytidine 
Congenital Adrenal Hyperplasia 
Cathode Couple Device 
Cerebrovascular accident 
Complimentary deoxyribose nucleic acid 
Centimetres 
3,3 "-diaminobenzidene 
Diethypyrocarbonate 
Dehydroepiandrosterone Sulphate 
Diabetes 
Distribution 
Diameter of largest follicle 
Deoxyribose nucleic acid 
193 
DSF Diameter of smallest follicle 
DVT Deep vein thrombosis 
Dx Disease 
ECL T Euglobulin Clot Lysis Time 
EDT A Ethylenediamine tetra-acetic acid 
ELISA Enzyme Linked Immunoassay 
EMBL European Molecular Biology Laboratory 
ET Endometrial thickness 
F AI Free Androgen Index 
FG Ferriman Gallwey 
FH Family history 
FSH Follicle Stimulating Hormone 
G Guanine 
OD Gestational Diabetes 
GnRH Gonadotrophin Releasing Hormone 
HDL High Density Lipoprotein 
HGMP-RC Human Genome Mapping Project- Resource Centre 
HOMA Homeostasis Model Assessment 
IDDM Insulin dependent diabetes mellitus 
IGF Insulin Like Growth Factor 
IgG Immunoglobulin 
ISH Insitu-Hybridisation 
IU International Units 
Kg Kilograms 
L Litre 
LDL Low Density Lipoprotein 
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LH Lutenising Hormone 
LHRH Lutenising Hormone Releasing Hormone 
mAB Monoclonal Antibody 
MAC Mid ann circumference 
mg Milligrams 
MHz MegaHertz 
Ml Myocardial infarction 
MPB Male Premature Balding 
mRNA Messenger Ribose nucleic Acid 
n Nano 
NBT Nitroblue tetrazolium 
ng Nanograms 
NOS Normal Goat Serum 
NIDDM Non Insulin Dependent Diabetes Mellitus 
nm Nanometres 
nmol Nanomoles 
OD Optical density 
p Pico 
PAI-l Plasminogen Activator Inhibitor-! 
PAS Plasminogen Activator System 
PBS Phosphate buffered saline 
PCO Polycystic Ovary 
PCOS Polycystic Ovary Syndrome 
PE Phosphate ethylenediamine tetra-acetic acid 
Plas Plasminogen 
PMH Past medical history 
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pmol Picomoles 
r Regression coefficient 
RNA Ribose nucleic acid 
RNase Ribonuclease 
RJL ov NO Number of follicles in right or left ovary 
SD Standard Deviation 
SOS Sodium dodecyl sulphate 
SHBG Sex Hormone Binding Globulin 
SSC Standard citrate saline 
SSDNA Salmon sperm deoxyribose nucleic acid 
ssDNA Single stranded deoxyribose nucleic acid 
T Thymine 
TdT Terminal deoxynucleotidyl transferase 
Thro Thrombosis 
Tm Melt temperature 
U Uracil 
UP Ultrapure 
USS Ultrasound 
VLDL Very Low Density Lipoprotein 
VO Venous Occlusion 
a Alpha 
P Beta 
8 Delta 
a Gamma 
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The plasminogen activator system in 
women with polycystic ovary syndrome 
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Oeoartmenc o; Obsrerrics and Gynaecology and Oeparrmenr of Haematology. Derriford Hospital, Plymouth, 
Umtea Kingaom 
Objective: To ~valuate th~ pla.sm1nogen acuva10r system on women wuh polycystu: ov:u-y syndrome CPCOS). 
Design: Casc..:ontrol study. 
Setting: A discm:c geneml hospu:ll in che United Kin~dom. 
P:llientlsl: Eleven women with PCOS ~nd 12 controls. 
lntervencion{s): Vempunctures for assays of the plasminogen activator system. 
Main Outcome Measure(sl: Euglobul in clot lySIS times. plasminogen activator inhibitor I (PAI·I) activity, fibrino2en. 
plasm1nogen. and llpha-Z l ntiplasmtn concencr.111ons in plasma. -
RcsuJUsl: Women wrth PCOS had·a significantly longer ~uglobulin clot lysis time (me:lll ::: SO. 389 ::: 164 minute.s vs. 
~20 ::: 110 mtnutes). ~higher PAl-l acuvicy lme:m =SO. 19.i::: 12 arbitr:u-y unus (AU) per !]1L vs. 10.9::: /.9 AlJ/mLl. 
Jnd a higher ribnnogen level (m= ::: SO. 4.02 ::: 0.64 g.tl vs. 3. 15 = 0.6 g/l.) compared eo controls. 
Condusion(s): Women with the PCOS may have an imbalanc: in the plasminogen activacor system that is tilted coward 
1 rcduc:d producuon o! the protC1Jiyuc ~nzyme plasmtn. Syste:mcally. thcs may mc:-easc the1r risk of clrdiovnscuiar disc=. 
but at .:ellular level in che ovaries. ot may resuit in impa1red follic:.tiar rupture and l novulation. ( Fe~li Steril~ 1998:69: 
236 - .!1. :0 1998 by .;mencan Soc1etv (or Reproductive Medictne.) 
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Polycystic ovaries are the most common 
fi ndings in women wi th anovulatory infertil-
ity ( I), ol igomenorrhea (2). and recurren t 
misc:miage (3). Tne origin of anovula[Qry 
infertility in these women is unknown. Until 
recently, attention has been focused on ~Q­
docrine abnormalities and LH hypersecretion 
( 4 ), abnormal follicle stimulating hormone 
dynamics (5). androgen effects on the follicle 
( 6). and disturbances in intraovarian growth 
factors (5) have been put forward as possible 
mechanisms oi anovulatory infertility. How-
~ver, there may be a relation between abnor-
malities of the ~ndocrine and coagulation 
systems involved in the etiology. 
Insulin resistance is also found in these 
women independent of body mass index (7), 
and in diabetes. insulin resistance correlates 
positively with plasma levels of plasminogen 
activator inhibitor- ! (PAl-l) (8. 9). Plasmino-
gen activation produces plasmin .. a proteolytic 
240 
enzyme ( I 0) that is important in clot lysis. 
ovulation ( 11-IJ). and implancation (14). Plas-
minogen activator inhibitor I ·is the main reg-
ulator of the plasminogen activator system. 
ComponentS of the plasminogen acrivator sys-
tem have been found in ·t:he foll icular ftu id ( 15) 
and granulosa cells of human ovaries ( ll ), and 
plasmin has been shown to weaken the follic· 
ular wall in vtcro ( 12). le aiso activates the 
conversion of procollagenase to collagenase 
(13). which is required for the breakdown 
of type IV collagen present in the basement 
membrane around the graifian fo llicles at ovu-
lation (13). 
It is interesting to speculate whe ther in the 
polycystic ovary syndrome. an insulin-driven 
overproducuon of PAI- l leads to distortions 
in the incraovarian plasminogen-plasmin 
pathway and anovulation. Before initiating 
this srudy, we identified only two studies on 
the plasminogen activator system in women 
Clinical variables for patients with polycystic ovary syndrome versus controls. 
ClinicJI variable Polycystic ovary syndrome (11 = 111 Controls (n = 12) P value 
:'>o1c:1n age :: SO Cy) !7 ::: J.6 31.8 = 7.J 0.06 
Mean BM! = SO (kg/m:) -31 = j.J !5.9 = 2.6 0.003 
8 (1-221 1 (0-8) 0.003• Medi;~.n !lirsutism score (range) 
Median cycle lcnglh in weeKs (range) 
No. w11h hisLOry of subJcru1ity (%) 
.~o. or" nulliparas (<;to) 
!0.75 (7.5-104) .~~ (3.7-5.0) 0.00007• 
~o. with previous misc:uriage (%) 
No. oi smokers (%1 
No. oi ~conol uniu p.:r •.ote:k (range! 
Me:1n ;ystolic blood pressure = SO (mm Hg) 
Mean dia.sto1ic bloo9 pressure ::: SO (mm HgJ 
Nor~. aMI = body ma.ss index. 
• Determined b~ the Mann-Whime~ U test. 
wi th the polycystic ovary syndrome (PCOS). The first 
scudy (16) showed char PAI-l levels were about rh·e same 
in 28 women with PCOS and 56 age- and weight-matched 
controls . However. in the second srudy ( 17), there were 
high PAr-l levels in nine obese patients wich PCOS. and 
these levels were reduced by dietary in tervention in the 
six pa(lencs who completed the study. This reduction in 
PAI- l level was associated wich che rerum or· regular 
menstruation and successrul pregnancy. Therefore. chis 
study evaluates further che plasminogen accivamr system 
in women wirh PCOS. 
MATERJALS A.t'ID ~THODS 
The srudy was carried ouc in 1996.at Derriford Hospi tal 
(Plymouth. United Kingdom). [nsmucional review board 
approval fo r che srudy was obtained from the loc:1l re-
search ethics committee. The hospital records of patients 
suspected eo have PCOS were reviewed by one of che 
authors (W. U. A. ) and recruited into che study group if 
they had an ultrasound (US) report suggestive of polycys-
tiC ovaries and a history of oligomenorrhea or amenorrhea 
with or wi thout a history of hirsutism. The US cnceria 
used were the presence of 10 or more 2- ro 8-mm roilic les 
dis tributed around the periphery or all over the ovary 
associated with the presence of a bnghr ovarian stroma 
( 18). Women were recruited as controls 1f they had regular 
menstrual cycles and US scans char were negau ve fo r 
polycystic ovaries. Women wirh any of the fol lowi ng 
were excluded from the study: current pregnancy. delivery 
or miscarriage occurring within the preceding 3 months. 
recent surgery (wichm 3 months), recent myocardial in-
farction. use of asptrin or heparin wichtn 15 days of lhe 
rest. sex steroid therapy . and a history of hemarolog1c 
dise:J.Se, malignancy. or liver dise:J.Se. 
FERTILITY & STERILITY~ 
7 (64) <I (33) 0.22 
7(~) 7 (58) l.O 
2 ( 18) J (25) l.O 
J !361 ~ (331 l.O 
2 (0-;J1 3 (0-14) 0A9" 
123 = 14 114 = 15 0.14 
82.7 = 6 72.7 = 9.9 0.008 
Before our scudy, the only c:J..Se-control srudy of the 
plasminogen activator system in women with PCOS had 
shown no difference in P A.I-1 levels between women with 
PCOS and controls (16). Therefore. ir was difficult ro deter-
mine what difference in PAI-l levels was likely to bP. :lSSo-
ciared with a clirucal finding of oligomenorrhea and to then 
calculate a sample size. We arbitrariiy agreed eo test 10-1) 
women with PCOS and a similar number of controls as a 
piloc. Eleven women with PCOS were recruited from sub-
fertili ty and gynecology clinics, and 12 controls of a similar 
age were recruited from among the female sraif members at 
the hospual and the infertility clime. Tables l and 2 show rhe 
clinical and hormonal prociles in subjects and controls: these 
profiles provide biochemical confirmation chat the recruned 
subjects has PCOS. 
All the tests were earned out berween 8 A •• '-i. and 10 ..... ~1. 
because of the diurnal variauon in PAI-l ( 19), and particl-
pants were asked to fast overnight and refrain from smoking 
beginning ar midnighr. 
On amval at the hospital. the subjects· weights and 
hetghts were recorded. Partictpants were then asked to m 
upright or in a supine posiuon for 15 mmuces. during which 
clintcal deraiis Cage and menstrual. obstetric. medical. fam-
icy, and social his rones) were obtained and they were given 
a Femman-Gallwey chart (20) to score their perceived htr-
surism. 
A blood sample ( 18-20 mL) was then taken from an 
antecubital vem on the left forearm wi th minimal or no 
venous occlusion into four ro five cirrare tubes tor assays of 
the plasminogen activaror system (prolonged venous occlu-
sion can stimulate the producuon of tissue plasminogen 
activator and plasminogen activator inhibitor from the endo-
thelial cells, hence rhe need for minimal or no venous oc-
clusion for srandardizntion). Five millilirers of blood were 
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ormonal vanables ior patients with polycystic ovary syndrome versus controls. 
Cnnr.ml~ 111 = 121 P value 
l~an FAI = SO 
kan SHBG = SO ln~/Ll 
lean tcsubtcronc = SO lng/Ll 
~can OHE.\S = SO tml!flllO mll 
kui~n ~~tr.tuiol lp~mLJ ~range! 
kuian FSH IU/LJ l l"lng~l 
lUl l= :1)1 
X. i .= .q; 
ll.7=tUI 
:1)7 = 11>5 
! .::! = 0.9 
15.7 = i .S 
1),) = 0.2 
~71 =~ 
O.IM'I:'j 
0.0~ 
0.110 1 
0.~ 
0.93~ 
0.<14• 
O.!J .. 
0.03 
22.3 ( 12.5- 1 :!6.1) 
HI I 1.:1-5.21 
:6.9.(5.44-~6\ 
-U5 (:!.9-13.11 
.!.05 ( 1.6-36.J.\ 'leui:m LH 1 U/Ll 1 range 1 7 ()11.1-:.;_j) 
·le ~n LHIFSH l"lllo = SO 1.; = 0.~ I = 0.4} 
'olt!. FAI - Free .>ndrog~n tm.lc., ltcscostc:-on<!ISHBG X IO<ll: 5HBG - "::;( hurmonc:: ·btnding g!obu1in. 
Octcrmtttc::d b~ tne _;\ lann-Whimcv U test. 
·oilected mto a separace cube tor hormonal assays. The blood 
1ressure was then checked .on che righc arm. and the sphyg-
nomanometer cuff was inftated midway between systali<.: 
.nd diascolic pressures for 10 minutes. After this test. an-
Jther 18-20 mL or blood were collected from be!ow the cuff 
or posrvenous occlusion samples. 
The samples fo r :he plasminogen activacor system assays 
.vere immediately placed on ice and centrifuged wHhtn .30 
n1nuces or collecuon at 2.000 X g for 15 minutes :u 4°C. 
-iormonal assays were performed in the hospital diagnosw: 
aborawry. 
\ssays 
The assays pe:-r"ormed eo <!valuace the plasminogen acti-
lator system were euglobulin clot lysis umes. fi bnnogen. 
Jlasminogen. alpha- 2 ann plasmin concentrations. and PAl-l 
tcri vHy . The hormonal assays perio~eJ were testosterone. 
;ex hormone-bindinggiobuiin. luteinizing hormone. rol lic!e· 
;<imulating hormone. E;. and DHEAS. Plasma was frozen at 
-'i0°C and tested wtthm 3 months for PAI-l acnvity. al-
?ha-2 antiplasmtn. and plasminogen concentrauons .. -\11 
Jther coagulation ;escs were done immediacely on fresh 
plasma. 
Euglobulin cloc lysis time was determined as previously 
descnbed (::! l ). In th1s assay plasma is diluted and acidified. 
fo rming a precipitate (euglobulin) that comains plasmtnogen 
:1cuvator. plasminogen. and fibrin. The precipitate is redis-
solved. the ribnnogen cloned wich thrombin. and the time for 
clot lysis m~ured. The normal time range for this assay IS 
90-240 minutes. 
Plasminogen activator inhibitor l activity was tested us-
ing a commercially avai lable chromogenic assay (Chro-
mogenix. Molndal. Sweden). In this assay a tixed amount of 
tissue plasmtnogen activator is added to undiluted plasma. 
where part of it forms an inactive complex with PAI- l. !n the 
presence of a stimulator. the residual tissue plasminogen 
activator activates plasminogen to plasmin. The plasm1n 
2J8 Atiomo et al. The: plasmin pathway amJ polycystic uvaric:s 
formed ts inversely proportional to the PAI-l activity in the 
sample. The amounc of plasmin is measured from its amido-
lytic activity on a chromogenic subsrrate. The normal range 
is less than 15 arbitrary umts per mL (AU/mL). 
Plasminogen and alpha-2 antiplasrnin levels were also 
tested using chromogenic assays (Instrumentation Labora-
tory. Milan. !taly). In the plasnunogen assay an excess of 
streptokinase is added to diluted plasma. The plasmmogen 
pres<!nt wii\ complex with streptokinase. forming a complex 
wHh plasmin-like activiry. This acts on a chromogenic sub-
scrate. reieasing paranitroamline in amounts directly propor-
tional eo the plasminogen level. The normal range for this 
assay is 80%-110%. 
. In the alpha-2 antiplasmin assay, diluted plasma sam-
ples are incubated with an excess of plasminogen. AI· 
pha-2 anuplasmin has a poweriul and rap id plasmin· 
inhibicory potencial. and the residual plasmin is measured 
by ItS accivi ty on a chromogenic substrate. The amount or' 
the parani troanaline released is inversely proportional eo 
the alpha-2 an tipiasmin !e•1el. The normal range of this 
assay is 80%-!20%. Fibrinogen concentration was cesced 
using an auromaced coagulation laboratory analyzer (In-
strumentation Laboratory). This is a nephelometric anal· 
ysis measuring the intensity of light scanered by a plasma 
sample before. during, and after clot formacion . The lighc 
5Gatter reached is proportional to the fibrin concentration. 
and. therefo re. the coca! clouable fibrinogen. The normai 
range is 2-6 g/L. 
Follicle-stimulating hormone and LH concentraoons were 
tested using the Amerfite-enhanced lurninesence method 
(Johnson and Johnson. New Brunswick:. NJ). Serum 
DHEAS. serum testosterone. E;. and sex hormone-binding 
globulin: levels were tested using RlA kits (Johnson anu 
Johnson; Medgenix. Chevrus. Belgium: Sarin Diagnostics. 
Salluggia.. Vercelli. Italy; and Farmos Diagnostics. Espoo. 
Finland. respectively). Free androgen index was c:llculaced 
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Results of assays of the plasminogen activator system for patients with the polycystic ovary syndrome versus controls. 
Group 
Assay parameter Polycysuc uvary syndrome In = 11) Cumrols (11 = 121 P ,·alue 
Median b:ISal ECLT (11111ge) (min) 
Median post VO ECL T (range (mini 
MeJn ba.~al fibrinogen concenmuion :: SO (giLl 
Mc:an post VO tibnnogen concenlr.luon :: SO (g/Ll 
MeJn basal PAl-l activity :: SO (AU/mll 
Mean post VO PAl-l acuvicy :: SO (range ) (AU/mll 
Mean b:ISal plasmmogen level :: SO (%) 
.VIean basal Jlph·a-l antlpi:ISmin level :: SD (%1 
~I ~.5 (I :!0-5711 
150 (45-562.5) 
~.02 :: 0.6<! 
~.66 :: O.i 
19.7:: I~ 
(6 (4-j7.51 
Y6:: 21 
103 = 6./'l-
187.5 (105-HO) 
82.5 (45~5) 
3.1 8 = 0.6 
3.8 = O.o 
10.9 = 7.9 
8 ( 1.5-161 
95 = 3 
100 = 8.8% 
0.016• 
0.055• 
0.()()4 
0.007 
0.049 
0.! 16• 
0.095 
0.38 
.Vou. ECL T - euglobulin dot lySIS time: PAl- l - pi:ISminogen activator inntbiiOr·l: and VO = venous occlusion. 
• Determined by the Mann-Whitney U test. 
using the following formula: (te,stosterone/sex hormone-
binding globulin levels X 100). The incerassay and in traas-
say coefficient of variation for all these assays were <9%. 
The sensitivities for testosterone . . DHEAS. sex hormone-
binding globulin, ~- LH. and follicle -stimulating hormone 
were 0.05 mg!L, 14.7 mg/100 mL. 2.30 ngJl.. ~.5 ::::: 0.55 
pglmL. 0.2 IU/L, and 0.5 IUIL. respectively. 
Statistical Analysis 
Means and standard deviations were calculated for the 
clinical and biochemical variables and for the assays of the 
plasminogen activator system (Tables l to 3). The analys1s 
used to compare the rwo groups depended on the distribution 
of the variables. For those variables where normal probabil-
ity plots indicated a normal distribution. a Student's Hest 
was used. to compare the means. Two other variables. E:! and 
LH (U/L), were ·'normalized" by the removal of an ourlier. 
Where appropriate. r-tests took account of any differences in 
standard deviat ions between the two groups. For variables 
that were dearly not normally distributed according to a 
normal probability plot (hirsutism score. cycle lenglh. alco-
hol incake. E:!. follicle-stimulaong hormone levels. LH. basal 
<!uglobulin clot lysis time. postvenous occlusion euglobulin 
d ot lysis time. and postvenous occlusion PAl-l activity!. a 
M ann-Whitney U test was appropriate for companng the two 
:6roups. 
Some of the measured variables had a limited range or' 
values. and for these neither a r-test nor a Mann-Whitney tesr 
was appropriate . ln these cases. Fisher's exacr test was used 
ro compare the proponions of "high" values for the two 
~mups . A P value of < 0.05 was defined as statisticJlly 
Stgnrticant. 
RESULTS 
Table 3 shows the results of assays of the plasminogen 
activator system. The mean basal PAl-l acuvity and the 
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mean basal fibrinogen concentrations were significantly 
higher in women wich PCOS than in controls (P = 0.049 and 
0.004. respectively). The mean prevenous occlusion euglob-
ulin clot lysis time was longer in women with PCOS lP 
= 0.016). 
Forty-five percent of the women with PCOS had a blun t 
response to the venous occlusion test as compared w 9% 
in the control group (P = 0.06). A blunt response to the 
venous occlusion test was defined as <'28% reduction in 
the euglobulin clot lysis time. This was based on data 
from a previous study (22), in which a control population 
of 90 apparently healthy women was used to defi ne a 
normal response to the venous occlusion test. A reduction 
in euglobulin clot lysis time of <28% was below the rirst 
percentile. 
The mean PAI- l levels were higher in the four women 
w(rh PCOS who had a normal body mass index { <27) 
compared with the eight controls who had a normal body 
mass index, although this difference did not reach sransricJl 
>ignincance (mean ~ SD. 18.6 = 16 vs. 12.5 = 9 .-\L:/mL. 
p = 0.4). 
DISCUSSION 
Our results show that women with PCOS have a pro-
longed euglobul in clot lysis time and high PAl-l act ivity. 
These tindings may be explained by the greater body mass 
1ndex in our PCOS group. as it influences PAl-l levels 
r23). However. an article published after the compleuon 
of our study (24) showed that PAI-l levels were elevated 
1n 14 nonobese women with PCOS and extreme menstrua l 
disturbance compared with I 0 matched controls with reg-
ular menstrual cyc les. We fou nd a similar trend in the 
nonobese women in our study. but because of the small 
numbers. the difference was not statistically significant. 
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.Jrrencly, we: are addressing thi~ issue: in an ongoing 
.arger study. 
The: signific:uu:t: uf our tindings i~ unknown Jt the: pre~c:nt 
cimc:. buc ic is intc:rc:scing tu speculace whc::her J discurbt:d 
incraovarian pht.-;minugc:n-plasmin pachway plays a signifi-
cant role: in ano\'ulacory inlt:rulity in womc:n with PCOS. An-
tncreast:d syscemtc level ut' PAl-l does noc nec:!~sarily imply 
high local ovadan levc:ls and we know of no correlation 
betwe:::n follicular Ruid and plasma PAI-l b·els. We: are 
now evaluating e.xpression of PAl-l mRNA anJ protein in 
uvarian biopsit:S from womt:n with PCOS. 
Another speculative implication of our findings is that 
women with P-C OS may be at incre:J.Sed risk of thromboembolic 
disease. This is because elevated PAI-l levels impalf tibnno-
lysis by limHing plasmin formation, and impaired tibnnoiysts is 
a significant risk factor in the development of fatal tschemic 
hem disease in women (25) . Although there is no direct evi-
dence of an increased risk of thromboembolic disease in these 
women, indirect evidence suggests that this may be the case. as 
women with clinical signs of androgen excess ot'ten have ab-
normal coronary angiograms (26). More srudies should be 
periormed to determine whether women with PCOS are indeed 
at inc~ed risk or' ischemic hem disease. 
Higtr-PAI-1 levels are one mechanism that may explain 
the previously unexplained link between the finding ·of poly-
cystic ovaries and recurrent rrusc:u-riage. but this is entirely 
speculative. The finding or' htgh PAI-l levels in many 
women with recurrent misc:u-riage (22. 27) and the important 
role played by plasmin in animal implantation ( I.:J.) justify 
further studies eo evaluate the link between abnormalicic:s or' 
the plasminogen activator system and the outcome or' preg-
nancies in women with polycystic ovaries. 
To dare . purely endocrine explanations of the patho-
physiology behind this syndrome remains controversial 
and unproved. For example. hypersecreuon of LH has 
been suggested as a cause (4), but a recent attempt at 
lowering LH le·,els in women with recurrent miscar-
riage did not improve the pregnancy rates (28). Our 
study suggests an alternative explanation. with the bal-
ance in the plasminogen activato r system in women wnh 
PCOS probably ttlted tOward a reduced production of the 
proteo lyuc enzyme plasmin. Systemically this may in-
crease thei r risk of c:~rdiovnscular disease. but ac the 
cellular level. it may resu lt in impaired follicular rupture. 
anovulation. failed implantation. and misc:~rriage. More 
research is requtred to test these two hypotheses. wh1ch 
may lead to trials of interventions thac encourage plasmtn 
production to improve the reproductive outcome in these 
women. 
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"So do not worry, saying, "What shall we eat?" 
or "What shall we wear?" For tire pagans nm 
after all these things, and your heavenly Father 
knows that you need them. 
But seek first his kingdom and his righteousness, 
and all tlrese tlrilrgs will be given to you as well. 
Therefore do not worry about tomorrow, 
for tomorrow will worry about itself. 
Each day has enough trouble of its own". 
-Matthew 6:31-34. 
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